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ABSTRACT 
Data quality is foundational to clinical research and each process through which the 
data passes must be documented such that the published tables and listings can be traced back 
to the original, raw data (Nahm, 2012). In regulated clinical research, traceability is a 
requirement and indicates that the content of the clinical study report can be traced back to the 
original source data. Today’s clinical research solutions have significant traceability 
limitations. This design science research (DSR) project creates a traceability framework for 
clinical research that builds on the existing industry data standards and improves a reviewer’s 
understanding of the data for data quality and regulatory compliance purposes. The 
framework consists of 3 layers: (1) the Information Product Map (IP-Map) model: a high-
level view of the manufacturing process for creating an information product (IP); (2) the 
CDISC standards metadata: metadata describing the IPs, data elements, and computations at a 
detailed level of granularity; and (3) a graph model: traceability throughout the clinical 
research data lifecycle that supports traceability visualization, validation, and queries. The 
primary benefits of the Trace-XML Framework are (1) to identify and resolve traceability 
gaps in clinical study metadata, (2) validate metadata traceability in a clinical study, and (3) 
query and visualize traceability metadata. The Trace-XML Framework maximizes the use of 
the existing standards models and technology to minimize barriers to implementation. This 
framework contributes a new extension to the industry standard metadata that addresses 
traceability gaps uncovered during the development of the Trace-XML software. The Trace-
XML software contributes the algorithms needed to remedy and validate traceability in the 
Trace-XML graphs, in addition to adding support for traceability queries. 
 
 v 
DECLARATION 
I hereby certify that this dissertation constitutes my own product, that where the 
language of others is set forth, quotation marks so indicate, and that appropriate credit is given 
where I have used the language, ideas, expressions or writings of another. 
I declare that the dissertation describes original work that has not previously been 
presented for the award of any other degree of any institution. 
 
 
Signed,  
 
 
Samuel Hume 
 vi 
TABLE OF CONTENTS 
DISSERTATION APPROVAL FORM ................................................................................................II 
ACKNOWLEDGMENT ...................................................................................................................... III 
ABSTRACT .......................................................................................................................................... IV 
DECLARATION .................................................................................................................................... V 
TABLE OF CONTENTS ..................................................................................................................... VI 
LIST OF TABLES ................................................................................................................................ IX 
LIST OF FIGURES ................................................................................................................................ X 
INTRODUCTION ................................................................................................................................... 1 
GENERAL BACKGROUND ON CLINICAL RESEARCH ................................................................................ 1 
BACKGROUND ON CLINICAL RESEARCH DATA ...................................................................................... 2 
THE TRACEABILITY PROBLEM: LIMITED COMPUTABLE TRACEABILITY IN CLINICAL RESEARCH .......... 5 
RESEARCH OBJECTIVES OF THE PROJECT ................................................................................................ 9 
LITERATURE REVIEW ..................................................................................................................... 10 
HEALTH INFORMATION TECHNOLOGY STANDARDS GENERAL TO CDISC ........................................... 10 
XML IN HEALTHCARE DATA STANDARDS .......................................................................................... 13 
INTRODUCTION TO THE CDISC STANDARDS FOR CLINICAL RESEARCH .............................................. 14 
OVERVIEW OF THE CDISC FOUNDATIONAL STANDARDS .................................................................... 16 
TRACEABILITY WITHIN CLINICAL RESEARCH DATA ............................................................................ 20 
TRACEABILITY WITHIN INFORMATION PRODUCT MAPS ....................................................................... 23 
TRACEABILITY AS DIMENSION OF PROVENANCE ................................................................................. 27 
PROVENANCE REQUIREMENTS IN HEALTHCARE SYSTEMS .................................................................. 41 
COGNITIVE LOAD AND VISUALIZING TRACEABILITY INFORMATION ................................................... 45 
RESEARCH METHODOLOGY ......................................................................................................... 47 
TRACEABILITY FRAMEWORK HIGH-LEVEL REQUIREMENTS ................................................................ 49 
ARTIFACT DESIGN TABLE .................................................................................................................... 50 
TRACE-XML DEVELOPMENT .............................................................................................................. 52 
TRACE-XML LAYERED FRAMEWORK IMPLEMENTATION .................................................................... 52 
TRACE-XML ACCESSIBILITY AND LICENSE ........................................................................................ 53 
EVALUATION ....................................................................................................................................... 53 
ANALYTICAL EVALUATION ................................................................................................................. 54 
 vii 
OBSERVATIONAL EVALUATION ........................................................................................................... 54 
THE TRACE-XML FRAMEWORK................................................................................................... 56 
DESIGN SCIENCE RESEARCH ARTIFACTS ............................................................................................. 56 
TRACEABILITY FRAMEWORK OVERVIEW ............................................................................................ 56 
TRACE-XML: AN INTEGRATED FRAMEWORK ..................................................................................... 65 
ESTABLISHING TRACEABILITY USING TRACE-XML ............................................................................ 71 
VISUAL ASSESSMENT OF TRACEABILITY USING GRAPH VISUALIZATIONS ........................................... 75 
SUMMARY OF THE TRACE-XML TRACEABILITY RULES ...................................................................... 76 
TECHNOLOGIES USED IN THE PROTOTYPE IMPLEMENTATION .............................................................. 80 
THE ANALYTICAL EVALUATION OF TRACE-XML ................................................................. 85 
CREATING A SIMPLE IP-MAP TO EVALUATE TRACE-XML .................................................................. 85 
TESTING TRACEABILITY IN TRACE-XML ............................................................................................ 87 
CREATING THE ATTRIBUTE-LEVEL GRAPH .......................................................................................... 88 
TESTING FOR REACHABILITY IN THE ATTRIBUTE-LEVEL GRAPH ......................................................... 89 
IDENTIFYING THE REACHABILITY GAPS .............................................................................................. 90 
RESOLVING THE TRACEABILITY GAPS IN THE CDISC STANDARDS METADATA .................................. 92 
RESOLVING REACHABILITY GAPS USING TRACEABILITY..................................................................... 94 
RE-TESTING FOR REACHABILITY AND TRACEABILITY IN THE ATTRIBUTE-LEVEL GRAPH .................... 95 
TESTING THE ATTRIBUTE-LEVEL GRAPH FOR COMPLETENESS ............................................................ 96 
THE QUALITATIVE EVALUATION OF TRACE-XML ............................................................... 98 
RESEARCH QUESTIONS ........................................................................................................................ 98 
RESEARCH DESIGN .............................................................................................................................. 99 
Research method ............................................................................................................................ 99 
Data collection technique .............................................................................................................. 99 
Data analysis approach ............................................................................................................... 100 
Written record .............................................................................................................................. 100 
SAMPLING AND SAMPLE SIZE ............................................................................................................ 100 
IRB APPROVAL AND CONSENT .......................................................................................................... 101 
THE INTERVIEW DEMONSTRATION AND QUESTIONS ......................................................................... 102 
Traceability Definitions and Background .................................................................................... 102 
Trace-XML Demonstration .......................................................................................................... 102 
Questions on Trace-XML as an End-to-end Traceability Solution .............................................. 103 
ANALYSIS .......................................................................................................................................... 105 
Methods ........................................................................................................................................ 105 
Results .......................................................................................................................................... 106 
 viii 
DISCUSSION AND CONCLUSION ................................................................................................. 114 
PRIMARY BENEFITS OF TRACE-XML ................................................................................................ 114 
IMPLEMENTATION FEASIBILITY ......................................................................................................... 115 
TRACE-XML AS A VALIDATION TOOL .............................................................................................. 117 
TRACE-XML AS A TOOL TO ENHANCE DATA QUALITY .................................................................... 119 
TRACE-XML AS A VISUALIZATION TOOL .......................................................................................... 120 
TRACE-XML FRAMEWORK UTILITY ................................................................................................. 121 
IMPACT ON REGULATORY SUBMISSIONS ........................................................................................... 126 
FUTURE WORK .................................................................................................................................. 127 
RESEARCH CONTRIBUTIONS .............................................................................................................. 130 
CONCLUSION ..................................................................................................................................... 130 
APPENDIX A: GLOSSARY OF TERMS ......................................................................................... 132 
APPENDIX B: TRACE-XML USER DOCUMENTATION ........................................................... 135 
TRACE-XML ..................................................................................................................................... 135 
RUNNING A JAVA PROGRAM .............................................................................................................. 135 
INSTALLING TRACE-XML ................................................................................................................. 135 
CONFIGURATION FILE ........................................................................................................................ 135 
RUNNING TRACE-XML ..................................................................................................................... 137 
TRACE-QUERY .................................................................................................................................. 138 
RUNNING TRACE-QUERY................................................................................................................... 139 
APPENDIX C: TRACE-XML DEFINE-XML EXTENSION ......................................................... 140 
APPENDIX D: TRACE-XML SOURCE CODE DOCUMENTATION ........................................ 144 
APPENDIX E: TRACE-XML QUALITATIVE ASSESSMENT INFORMED CONSENT ........ 145 
APPENDIX F: TRACE-XML QUALITATIVE ASSESSMENT IRB APPROVAL LETTER .... 147 
REFERENCES .................................................................................................................................... 149 
 
 ix 
LIST OF TABLES 
Table 1. Example healthcare data standards ................................................................ 11 
Table 2. Define-XML v2.0 def:Origin types taken from (CDISC, 2013a).................. 22 
Table 3. Define-XML v2.0 traceability rules taken from (CDISC, 2013a) ................. 23 
Table 4. IP-Map block types ........................................................................................ 25 
Table 5. Clinical study metadata types or sources from (Zozus & Bonner, 2017) ...... 42 
Table 6. Interoperable provenance recommendations from (Curcin et al., 2014) ....... 42 
Table 7. Based on Hevner et al. (2004) design science research guidelines (P. 83) .... 47 
Table 8. Traceability framework high-level requirements ........................................... 49 
Table 9. DSR artifact design table ............................................................................... 50 
Table 10. Trace-XML Framework layers .................................................................... 58 
Table 11. Main Trace-XML Framework software applications .................................. 65 
Table 12. Example Trace-XML query results for the Pooled Site Group 1 variable... 72 
Table 13. Summary of Trace-XML specific traceability rules .................................... 77 
Table 14. Summary of Trace-Query display rules ....................................................... 80 
Table 15.  Prototype implementation source code inventory ....................................... 81 
Table 16. Clinical data expert subject counts by category ......................................... 101 
Table 17. Number of Categories and Codes .............................................................. 105 
Table 18. Coding Frequency Analysis ....................................................................... 107 
Table 19. Salient themes for each research question ................................................. 109 
Table 20. Glossary of Terms / Acronyms .................................................................. 132 
 
  
 x 
LIST OF FIGURES 
Figure 1. Clinical research data lifecycle ....................................................................... 3 
Figure 2. Example clinical trial data flow (Iberson-Hurst, 2008) .................................. 5 
Figure 3. Clinical research data lifecycle example ........................................................ 6 
Figure 4. Metadata definitions for datasets include Origin for traceability ................... 7 
Figure 5. Variable traceability through a PDF-based annotated CRF ........................... 8 
Figure 6. CDISC foundational standards ..................................................................... 16 
Figure 7. The ODM metadata and data hierarchies ..................................................... 18 
Figure 8. Provenance taxonomy (Simmhan et al., 2005a) ........................................... 28 
Figure 9. CDISC ODM audit trail support (CDISC, 2008) ......................................... 30 
Figure 10. Design science research cycles (Hevner, 2007) ......................................... 49 
Figure 11. Trace-XML adds cross-lifecycle, study-level metadata traceability .......... 57 
Figure 12. 3-layered Trace-XML Framework conceptual diagram ............................. 58 
Figure 13. Example layer 1 partial IP-Map for ADSL................................................. 60 
Figure 14. Using Alias to link a Define-XML domain to an IP-Map block ................ 61 
Figure 15. Full lifecycle Trace-XML graph using the tree layout ............................... 63 
Figure 16. Trace-XML Unreachable Nodes report fragment ....................................... 63 
Figure 17. Example Trace-Query output for the ADSL SEX variable ........................ 64 
Figure 18. Trace-XML predecessor traceability graph generated using yEd .............. 66 
Figure 19. Trace-XML Framework creates new dimensions of traceability ............... 67 
Figure 20. Example Trace-XML extension shown with the trc namespace prefix ...... 68 
Figure 21. Full lifecycle Trace-XML graph fragment in a hierarchical layout ........... 69 
Figure 22. A predecessor graph showing the metadata details for a node ................... 70 
Figure 23. Trace-XML edges added to Define-XML using SHARE content ............. 70 
Figure 24. Links to trace queries added to the Define-XML Source column .............. 73 
Figure 25. Report showing unexpectedly unreachable nodes in a Trace-XML graph. 74 
Figure 26. Full lifecycle Trace-XML graph in a directed tree layout .......................... 74 
Figure 27. Using graph visualization to identify traceability gaps .............................. 76 
Figure 28. Simplified IP-MAP for creating a submission-ready dataset ..................... 86 
Figure 29. DFS marks reachable nodes in the first 3 stages of IP-Mapa...................... 90 
 xi 
Figure 30. Identifying the metadata missing from the attribute graph ......................... 91 
Figure 31. Algorithm to create the missing metadata in the attribute graph ................ 92 
Figure 32. Example of the Trace-XML Define-XML extension ................................. 94 
Figure 33. Re-testing for reachability from DS1 to P1 using the updated graph .......... 95 
Figure 34. Testing shows reachability from DS1 and DS2 to P1 in the updated graph. 96 
Figure 35. The Trace-XML thematic hierarchy ......................................................... 108 
Figure 36. Code category frequency percentage totals .............................................. 111 
 
1 
CHAPTER 1 
INTRODUCTION 
General Background on Clinical Research 
Clinical trials test the safety and efficacy of new medical treatments for human use. 
The medical field uses clinical research to determine if a new therapy provides the expected 
benefits to patients based on its ability to treat the disease and improve the patient’s overall 
quality of life. The Code of Federal Regulations (CFR) defines a clinical trial as a clinical 
investigation in which a drug is administered, dispensed to, or used by one or more human 
subjects (21 CFR 312.3). As a form of scientific research, clinical trials follow exacting 
scientific standards to ensure reliable and repeatable results.  
Federal regulations apply to clinical trials involving the investigation of a new drug, 
device, biologic, or cases where an existing therapy is used for a new indication. Industry 
often sponsors such trials to gain the regulatory approval needed to market the therapy for the 
specified indication. In 2013 the biopharmaceutical industry sponsored 6,199 clinical trials of 
medicines in the United States (US) involving 1.1 million subjects (Battelle, 2015). The 
clinical trials used to generate medical evidence in support of new therapies have grown 
increasingly lengthy, expensive, and risky (English, Yeonwoo, & Griffin, 2010). The high 
cost of prescription drugs in the US has become a point of national concern. Prescription 
drugs now account for 10% of all healthcare spending in the US and remain the fastest 
growing segment of healthcare costs increasing at a rate of 12.2% in 2014.  The average 
development time for a new medicine now exceeds ten years at a total cost of $2.6 billion, 
including the cost of capital and failed R&D projects (DiMasi, Grabowski, & Hansen, 2014). 
The costs of a single large, multi-center trial can range from $300 - $600 million, depending 
on factors such as the duration, number of subjects, and the number and location of the 
research sites (English et al., 2010).   
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Although total spending on biopharmaceutical research and development (R&D) has 
continued to increase annually, rising costs, complexity, risk, and process inefficiencies have 
limited corresponding increases in productivity (Lamberti & Getz, 2015). Success rates for 
commercializing medicines have been dropping with only 11.3% of those medicines that enter 
human trials making it through to Food and Drug Administration (FDA) approval (DiMasi et 
al., 2014). The length of the clinical trials phase of drug development has increased 15% over 
the last ten years to 6.8 years. The complexity of the clinical trials has also been increasing 
with more sophisticated study designs involving more study sites and countries. The lengthy 
timelines to complete the clinical trials needed to gain regulatory approval both increase cost 
and reduce revenue due to the limited patent life granted to new compounds. “Improving the 
efficiency and effectiveness of medical product development is a national priority,” according 
to the US FDA (FDA, 2013a). 
The expanding complexity and scope of clinical research coupled with the 
pervasiveness of technology has yielded a corresponding increase in associated data volumes 
(Hume, Aerts, Sarnikar, & Huser, 2016). From 2002 to 2012, the number of endpoints in a 
typical phase III clinical trial increased by 86%, the number of procedures by 58%, and the 
number of data points collected per patient to 929,203. FDA submissions from the top 10 
pharmaceutical companies over the period from 1997 to 2005 increased in sized from an 
average of 70,000 to 222,000 pages. From 2005 to 2012 FDA submission sizes increased 
1,423% to 3.4 million pages (Getz, 2013). At this scale, operational inefficiencies add 
considerable time and expense to the clinical development cycle time. A lack of supporting 
clinical trials infrastructure in the US has been identified as a contributing cause of the 
inefficiencies (English et al., 2010). The Center for Information Technology Leadership 
estimated that the implementation of the national standards for interoperability for the 
exchange of health information would save the US approximately $77 billion annually. 
Innovative new tools and processes are needed to improve the efficiency of clinical research 
to reduce the cost of new medicines while maintaining high quality.  
Background on Clinical Research Data 
“The validity of clinical research rests on a foundation of data,” (Nahm, 2012).  
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Clinical research data can be expressed as a lifecycle where data and information are 
created and transformed through the various phases of the clinical research process based on a 
variety of planning documents including the study protocol, statistical analysis plan, and data 
management plan. Regulated clinical trials include additional requirements mandated by 
federal regulations, or strongly recommended by FDA guidance. Figure 1 shows a 
representation of a regulated clinical research data lifecycle that generates a submission to a 
regulatory agency such as the FDA. The lifecycle displayed in Figure 1 represents a clinical 
data perspective at a level of granularity that suits the needs of this research project, but many 
valid alternative representations exist. Acronyms used in the diagram and throughout this 
document are defined in the Glossary in Appendix A. 
 
Figure 1. Clinical research data lifecycle 
The lifecycle shown in Figure 1 highlights the states of the clinical data throughout a 
trial including: EHR electronic source data, data collection, standardized data tabulations, 
analysis datasets, analysis results, and data archival. Data transformations throughout the 
lifecycle transition the data from state-to-state. Data transformation has remained largely a 
manual development effort despite the availability of more modern alternatives. The current 
processes for clinical research data transformation are error prone, inefficient, lack 
traceability, and are not portable. While partially interoperable data standards exist for 
protocol through data analysis, there are no standard mechanisms for capturing and executing 
the transformations that convert data from state-to-state in the clinical research data lifecycle. 
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A typical data transformation implementation in a biopharmaceutical organization involves 
manually crafting SAS macros to transform SAS datasets from one state to the next, possibly 
using metadata captured in spreadsheets. These bespoke data transformation applications 
make maintainability and traceability difficult, especially when the clinical data lifespan is 
often 50 years or longer. This process is particularly time consuming and costly due to the 
software validation requirements imposed by federal regulations. 
The clinical trial data lifecycle maximizes the use of structured data. Alternatively, in 
routine healthcare the diversity of diseases and conditions has necessitated a higher level of 
narrative text. In clinical research, subjects are pre-screened for specific clinical conditions 
and treatment follows a pre-specified protocol allowing for more structured data during 
collection (Nadkarni, Marenco, & Brandt, 2012). Unstructured narrative text presents 
significant challenges during data analysis. Clinical trial data collection instruments seek to 
leverage structured data and controlled terminologies to improve the ability to accurately 
analyze the data. The use of data standards, including standard terminologies, further benefit 
clinical research by improving data quality, easing data integration, facilitating data exchange 
between organizations, facilitating regulatory reviews, and enabling the development of 
software tools that work with the data (Downey & Olson, 2013).  
A typical clinical trial sponsored by industry involves a growing number of 
participating organizations and is increasingly conducted in network structures where 
seamless data exchange is essential to operational efficiency (Hume et al., 2016). Figure 2 
shows a simplified data flow for a regulated clinical trial. It highlights the type of participants 
that generate and process data, as well as the data interchange scenarios necessary to support 
data collection during the trial. Over the last decade the total number and diversity of data 
sources used in all clinical research has increased ten-fold (Zozus et al., 2017). As clinical 
trials continue to grow in complexity, the network of participants contributing to the 
collection, processing, analysis, and integration of clinical data across systems and 
organizational boundaries has grown (Hume et al., 2016).  The progression of 
biopharmaceutical in-licensing and partnerships have made common place new data sharing 
scenarios that add to the challenge of maintaining a sound chain of custody. 
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Figure 2. Example clinical trial data flow (Iberson-Hurst, 2008) 
 
The data flows in Figure 2 highlight the need for efficient data exchange. Most 
systems that support data interchange during a clinical trial do so via a file export and import 
mechanism (CDISC, 2017; Jiang, Solbrig, Iberson-Hurst, Kush, & Chute, 2010; Wolfgang 
Kuchinke, Wiegelmann, Verplancke, & Ohmann, 2006), but some use a more modern web 
services-based approach (Deserno, Haak, Samsel, Gehlen, & Kabino, 2013; Haak, Gehlen, 
Jonas, & Deserno, 2014; Tröger, Wilke, Prokofyeva, & Zrenner, 2008). In the context of a 
regulated trial, the complete audit trail and data traceability must be maintained throughout 
the data exchange process. 
The Traceability Problem: Limited Computable Traceability in Clinical Research 
While bioinformatics and other computationally oriented e-science domains have 
embraced computable traceability, clinical research informatics, routine healthcare and other 
domains that rely on distributed, heterogeneous information systems have not yet achieved the 
same level of computable traceability (Curcin, 2016). Within the domain of regulated clinical 
research, submissions to the FDA and Japan’s Pharmaceuticals and Medical Devices Agency 
(PMDA) are required to include the metadata needed to establish traceability for the variables 
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included in the submission datasets. Traceability should provide the means to trace a variable 
in a dataset back to its source by linking to content in each of the previous steps in the clinical 
research data lifecycle. A representation of the clinical data lifecycle is shown in Figure 3. 
Traceability in this example would link content in the analysis results back as far as original 
data captured in an EHR to include any derivations and transformations needed to support the 
transition between each state in the lifecycle. 
 
Figure 3. Clinical research data lifecycle example 
Figure 4 shows an example of the current state-of-the-art for establishing traceability 
within regulated clinical research. The table in Figure 4 provides the metadata definitions for 
the demographics dataset and includes the Origin column to support traceability for each 
demographics variable. 
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Figure 4. Metadata definitions for datasets include Origin for traceability 
 
Origin values shown in Figure 4 represent content originating from the protocol, an 
assigned value, case report form (CRF) variables, and derivations. The CRF Page origin value 
provides a link to an image of an annotated CRF as shown in Figure 5. Referencing an 
annotated CRF in portable document format (PDF) provides traceability that only works one 
step backwards. In this case, it traces a variable in the demographics standardized tabulation 
dataset back to the demographics data collection CRF. There is no capability to show if the 
CRF content originated from an EHR. The annotated CRF is a visual representation of the 
data capture instrument in PDF, but it is not queryable as it is not available in a computable 
format. 
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Figure 5. Variable traceability through a PDF-based annotated CRF 
 
Three key limitations hinder the effectiveness of today’s traceability solution: (1) gaps 
exist in the computable traceability provided by the standard metadata models, for example 
the trace only represents a non-computable description of the previous step in the data 
lifecycle; (2) gaps exist in the semantics and metadata needed to express computable 
traceability in the standard metadata models, for example no mechanism exists to explicitly 
reference the metadata for a CRF variable for traceability purposes; and (3) no traceability 
query capability exists limiting the ability to interrogate the traceability metadata, for example 
a reviewer cannot execute a query to view the entire lifecycle of a variable. These limitations 
are a significant hindrance to the in-depth and thorough analysis of the available evidence in 
the regulatory decision making process (van Valkenhoef, Tervonen, de Brock, & Hillege, 
2012). The missing metadata restricts the possible automation alternatives and limits the 
extent to which automation can be applied (Zozus et al., 2017). Despite considerable existing 
research, determining the appropriate analytic and query mechanisms to answer traceability 
questions remains an open research opportunity (Carata et al., 2014; Davidson & Freire, 
2008). Provenance in healthcare and science is currently receiving substantial attention as a 
research topic (Curcin et al., 2013). 
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Research objectives of the project 
The primary research objective of this design science research (DSR) project is to 
create a clinical research traceability framework that builds on the existing industry data 
standards. The model created within this framework will enable the clinical study metadata to 
be represented as a graph displaying the full, interconnected history of each data element. 
This research project extends the Information Product Map (IP-MAP) research to use 
information products (IP) as the means to establish computable traceability within 
standardized clinical research metadata.  
The specific research objectives addressed by this project include: (1) develop 
metadata models to support computable traceability and traceability visualizations that are 
compatible with industry data standards for the regulated clinical research domain, (2) adapt 
graph traversal algorithms to make them capable of identifying traceability gaps and 
validating traceability across the clinical research data lifecycle, and (3) develop a traceability 
query capability for retrieval and visualization of traceability information. This DSR project 
seeks to demonstrate the feasibility of the traceability framework by implementing and 
evaluating it.  This project will also evaluate the traceability framework’s utility to clinical 
research data experts as a means for determining the integrity of the data based on the 
information manufacturing processes used to create it. The IP-Maps that exist within the 
framework will be extended to enable traceability at the data element level as a dimension of 
data quality. 
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CHAPTER 2 
LITERATURE REVIEW 
Health Information Technology Standards General to CDISC 
“Standards are not only technical questions. They determine the technology that will 
implement the Information Society, and consequently the way in which industry, users, 
consumers and administrations will benefit from it” (Jakobs, 2003). 
Vertical information systems (VIS) standards provide technical specifications that 
promote information exchange and other coordinated activities within an industry vertical 
(Markus, Steinfield, & Wigand, 2006).  VIS standardization consists of (1) standards 
development and (2) standards diffusion. Both are collective action dynamics, and solving the 
first does not guarantee success with the second (Markus et al., 2006). Open standards such as 
the world wide web standards have a significant potential impact on information systems (IS) 
theory and practice (Markus et al., 2006). Technology standards are an essential driver of 
industrial productivity, but their value can only be maximized with broad standards diffusion 
(Zhu, Kraemer, Gurbaxani, & Xu, 2006). In an increasingly global economy with diverse 
value chains, inter-organizational systems provide both operational and strategic benefits to 
the organizations and industries that adopt them (Boh, Xu, & Soh, 2008). From a practitioner 
perspective numerous industries have a standards consortium (Nelson & Shaw, 2003), and 
standardization has significant practical implications for information technology (IT) 
management. From an economic perspective, standardization provides a means for 
organizations to increase the overall size of their market (Nickerson & Muehlen, 2006). 
According to Erickson, Wolcott, Corrigan, and Aspden (2003) data standards are 
“formally accepted or endorsed definitions and rules regarding the format, meaning, and 
transmission of data elements.” Creating standardized data elements involves the 
establishment of standards that: (1) define what to collect, (2) determine how to represent the 
collected data, and (3) delineate how to encode the data for transmission to another party 
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(Erickson et al., 2003). Table 1 lists a sub-set of the standards development organizations 
(SDO) in healthcare and the data standards they develop. 
 
Table 1. Example healthcare data standards 
SDO Example Standards Description 
HL7 (Health Level 7) • HL7 v2.x 
• FHIR (Fast Healthcare 
Interoperability Resources) 
• CDA (Clinical Document 
Architecture) 
• CCD (Continuity of Care 
Document) 
• SPL (Structured Product Labeling) 
HL7 develops healthcare information 
standards for exchange, integration and 
sharing of electronic health data. 
Although HL7 is based in the United 
States and accredited by ANSI 
(American National Standards 
Institute) the HL7 organization and the 
standards it develops are international 
in scope. 
CDISC (Clinical Data 
Interchange Standards 
Consortium) 
• ODM (Operational Data Model) 
• SDTM (Study Data Tabulation 
Model) 
• CDASH (Clinical Data 
Acquisition Standards 
Harmonization) 
• ADaM (Analysis Data Model) 
CDISC develops healthcare 
information standards for clinical 
research, including regulated clinical 
research. 
NEMA (National 
Electronics 
Manufacturers 
Association) 
• DICOM (Digital Imaging and 
Communications in Medicine 
Committee) 
DICOM is a standard for transmitting, 
storing, and viewing medical images. 
WHO (World Health 
Organization) 
• ICD-9 (International Classification 
of Diseases-9) 
• ICD-10 
ICD-9 and ICD-10 provide diagnosis 
and disease codes widely uses for 
billing and claims. 
Regenstrief Institute for 
Health Care 
• LOINC (Logical Observation 
Identifiers Names and Codes) 
Concept-based terminology for 
medical laboratory orders and results. 
IHTSDO (International 
Health Terminology 
Standards Development 
Organization) 
• SNOMED CT (Sytematized 
Nomenclature of Medicine – 
Clinical Terms) 
A standardized, multilingual 
vocabulary of clinical terminology 
widely used for exchanging and storing 
clinical healthcare information. 
MSSO (MedDRA 
Maintenance and Support 
• MedDRA (Medical Dictionary for 
Regulatory Activities) 
MedDRA is a medical terminology 
used to classify adverse events that is 
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SDO Example Standards Description 
Services) and JMO 
(Japanese Maintenance 
Organization) 
commonly used in regulated clinical 
trials. 
 
Common Data Elements, or CDEs, are a common way of standardizing content for 
data collection in clinical trials. A number of healthcare metadata repositories (MDR) have 
been developed to maintain and publish CDEs, many with ties to national governments, as 
can be seen on the US National Institutes of Health (NIH) CDE Resource Portal (NLM, 
2013). CDEs are metadata that can describe any type of measurement or concept. CDEs 
represent the “smallest meaningful data container in a given context” (Sinaci & Erturkmen, 
2013). They provide an informal meaning and usage for the data element, as well as 
synonyms, alternative definitions, valid units of measurement, and code lists (Papatheodorou 
et al., 2009). CDEs, unlike items that derive their meaning from their position in a formal 
taxonomy or ontology, do not rely on context to derive their meaning. Such classification 
systems can be used to organize CDEs, but CDE semantics exist independent of the 
classification hierarchy (Papatheodorou et al., 2009). 
CDEs can be combined by context into groups, such as for use in CRFs or datasets, 
and they can be grouped according to Data Element Concepts. A Data Element Concept links 
associated CDEs that derive their meaning from a common concept, a fundamental tenant of 
ISO/IEC 11179 (ISO/IEC, 2013; Ngouongo, Löbe, & Stausberg, 2013). A number of CDE 
models have been developed. The Health Information Technology Standards Panel (HITSP) 
has specified a set of standard CDEs called C154: Data Dictionary Component to harmonize 
their use across the various HITSP standards. For instance, HITSP C32 annotates the data 
elements in the HL7 CCD with their HITSP C154 CDE counterparts to harmonize the 
meaning of the CCD elements (Sinaci & Erturkmen, 2013). The Federal Health Information 
Model (FHIM) provides another set of CDEs in the form of an information model of 
healthcare data intended to promote interoperable Electronic Health Records (EHRs). The 
Transitions of Care Initiative (ToC) provides the Standards and Interoperability (S&I) Clinical 
Element Data Dictionary (CEDD) for CDEs aimed at improving the exchange of core clinical 
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information among healthcare entities in support of meaningful use and improved quality of 
care (ONC, 2015). 
Although some have classified the CDISC standards as CDEs for clinical research, the 
CDISC approach differs from the typical CDE philosophy. The CDISC standards do not 
follow the CDE approach since they specify the permissible context for each Data Element, 
and do not support the use of CDEs that function as independent units outside of their 
prescribed context (CDISC, 2015). CDISC data elements may be required in a specific 
domain or CRF, and they may support other data elements that function together to provide 
the full meaning of a research concept. CDEs focus on the characteristics of an individual data 
element often at the expense of relationships with other data elements. Many individual data 
elements cannot represent a complete clinical observation on their own, and require the 
context of other data elements to make the CDE meaningful. In other cases, CDEs may 
include content in the CRF question, such as units, that would be better captured by a separate 
data element. 
XML in Healthcare Data Standards 
XML (extensible markup language) has been widely used to create standards or 
models for healthcare data representation and data exchange (Domínguez et al., 2007; Forster 
& Vossen, 2012; Hume et al., 2016; Shabo, Rabinovici-Cohen, & Vortman, 2006; Vergara-
Niedermayr, Wang, Pan, Kurc, & Saltz, 2012). Both CDISC and HL7 have produced XML-
based standards that are mature and broadly implemented. The XML-based CDISC ODM has 
become the standard exchange format for case report form (CRF) data and metadata (Forster 
& Vossen, 2012). ODM has been successfully integrated with EHR-based HL7 CDA, another 
XML-based healthcare standard, to support the use of routine healthcare data in clinical 
research (Bernhard, Axel, Carsten, Fleur, & Martin, 2011; Daniel et al., 2013; El Fadly et al., 
2007; R. Kush et al., 2007).   
HL7 CDA defines the semantics and structure of clinical documents in XML format 
for the exchange of patient data ("Health Level Seven International," 2012). CDA semantics 
are based on the HL7 Reference Information Model (RIM), and referenced healthcare 
terminologies (Hodge, 2008). CDA documents consist of an unstructured textual section and a 
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structured section where standard coding systems, such as LOINC and SNOMED, establish 
machine-readable semantics (Crichton et al., 2009). The HL7/ASTM CCD specification is a 
constraint of the HL7 CDA containing US specific requirements. HITSP has specified HITSP 
C32 describing the HL7/ASTM CCD for interchange purposes (Sinaci & Erturkmen, 2013). 
CCD promotes interoperability of clinical data between healthcare organizations without the 
loss of meaning (Sinaci & Erturkmen, 2013). FHIR is the latest HL7 standard to use XML. 
FHIR’s use of RESTful web services and emphasis on conformance and reference 
implementations has made it a popular with implementers. H. Leroux, Metke-Jimenez, and 
Lawley (2015) made a comparison and mapping between HL7 FHIR and CDISC ODM with 
the goal of achieving semantic interoperability between clinical research and healthcare. Their 
approach to integrating ODM with FHIR involved a mapping of hierarchical ODM 
ClinicalData elements to a set of FHIR resources (H. Leroux et al., 2015). 
XML’s acceptance as a technology for implementing healthcare standards has been 
aided by the broad number of tools and technologies that support it. UML (Unified Modeling 
Language), another well-accepted formalism for healthcare standards and models, can be 
converted into an XML schema, and can be represented in a standard XML format called 
XML Metadata Interchange (XMI) for model interchange (Crichton et al., 2009). Once 
standards or models are available as XML they can be transformed using XSLT or other XML 
processing technologies (Sendall & Kozaczynski, 2003). Other XML technologies that have 
been used to build ODM XML-based solutions include XML databases, XQuery, XForms, 
and schematron (Bruland et al., 2014). 
Introduction to the CDISC Standards for Clinical Research 
CDISC is an SDO and industry consortium creating standards for clinical research, 
including regulated clinical research. CDISC provides standards that intend to cover the 
complete clinical research data lifecycle from protocol through archival. The CDISC 
standards (CDISC, 2016) play a key role in clinical research informatics, including areas such 
as data exchange, archival, regulatory submissions, and interoperability with healthcare data. 
Use of the CDISC data standards has increased over the last several years with increasing 
interest from regulatory authorities such as the US FDA (FDA, 2010, 2013b) and the Japanese 
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PMDA, as well as significant resources being allocated to healthcare data interoperability 
(FDA, 2013a).  In 2012, the fifth reauthorization of the FDA’s Prescription Drug User Fee 
Act (PDUFA V) became law and stated that the “FDA shall develop standardized clinical data 
terminology through open standards development organizations with the goal of completing 
clinical data terminology and detailed implementation guides by FY 2017” (FDA, 2014; 
Vadakin & Kush, 2014). PDUFA V further states that the “FDA will develop guidance for 
industry on the use of the CDISC data standards for the electronic submission of study data” 
(FDA, 2014). 
Both the FDA and PMDA now require that new studies must use the CDISC standards 
if they will be part of a regulatory submission and have a strong preference for the use of 
CDISC standards in studies submitted today. The European Medicines Agency (EMA) has 
stated a preference for the CDISC standards and recommends their use as part of their effort 
to improve transparency and data sharing within clinical research (EMA, 2013). The Chinese 
FDA has also endorsed the CDISC standards. 
Aided by the new regulatory mandates at the FDA and the PMDA, the CDISC 
standards required for submissions have seen very high adoption rates by industry. Standards 
diffusion has been difficult to measure in other industries, but metrics do exist within the 
regulated clinical research industry. The CDISC standards have been downloaded by users 
from over 90 countries, and adoption continues to increase, with the CDISC SDTM adoption 
as of 2014 estimated to be over 80% (Friggle, Li, Labout, & Kush, 2011; Vadakin & Kush, 
2014). Getz (2007) showed that the primary benefit of standards usage was the exchange of 
data with other organizations in the industry with 59% of the respondents (and 78% of the 
CROs) identifying this as a key benefit. The primary reasons delaying the adoption of the 
standards within an organization were (1) the required levels of internal coordination, (2) the 
level of investment required to implement, (3) management resistance, (4) lack of ROI, and 
(5) change management or inertia (Getz, 2007). The 2014 CDISC business case claims that 
using CDISC standards from the beginning of the clinical research data lifecycle can save 
approximately $180 million per submission (CDISC, 2016). With over 420 member 
organizations, the CDISC standards are among the most widely used within regulated clinical 
research. 
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Different CDISC standards exist to address each phase of the clinical research data 
lifecycle, including: (1) Protocol Representation Model (PRM) for the protocol phase, (2) 
Clinical Data Acquisition and Harmonization (CDASH) for the data collection phase, (3) 
Study Data Tabulation Model (SDTM) for standardized data tabulations, and (4) Analysis 
Data Model (ADaM) for data analysis. Although the standards are all part of the CDISC 
portfolio and are intended to work together, each standard has its own pattern of development 
and diffusion dilemmas. Each standard has its own team of volunteers from industry 
participating in standards development. For example, the CDASH team consists primarily of 
those with data management backgrounds, while the ADaM team consists primarily of 
statistical programmers. Each standard has been implemented to varying degrees at different 
organizations within the industry. The regulatory agencies also impact each standard 
differently through their participation in its development or by requiring the standard as part 
of a regulatory submission. For example, SDTM has been more widely adopted than CDASH 
largely because SDTM is required by the regulators for submissions and CDASH is not. 
Overview of the CDISC Foundational Standards 
 
Figure 6. CDISC foundational standards 
Figure 6 highlights the CDISC foundational content standards and identifies the 
corresponding ODM-based data exchange standards. The ODM XML-based standards 
provide the data exchange formats that represent the metadata and data for CDISC content 
standards such as CDASH and SDTM. The Protocol Products primarily include the PRM, a 
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UML-based model representing the main entities in a clinical research protocol, and the Trial 
Design Model (TDM) that has been instantiated as part of SDTM (de Montjoie, 2009). The 
CDASH standard describes the basic data collection fields on a CRF. Development of the 
CDASH standard was triggered by the (FDA)’s 2004 report, Innovation/Stagnation: 
Challenge and Opportunity on the Critical Path to New Medical Products and initially covered 
the common and safety domains (Richesson & Nadkarni, 2011). The Laboratory Data Model 
(LAB) is an XML representation model for laboratory data acquisition and interchange 
(CDISC, 2016; van Valkenhoef et al., 2012). The SDTM standard describes a standard 
structure for study data tabulations. SDTM provides standardized datasets that enable the 
development of software tools and provide the content for subject profiles and data listings 
(CDISC, 2016; Kubick, Ruberg, & Helton, 2007). The Standard for the Exchange of Non-
clinical Data (SEND) standard is based on the SDTM model, but represents data from pre-
clinical toxicology studies (CDISC, 2016; van Valkenhoef et al., 2012).The ADaM standard 
describes metadata models and examples for analysis datasets (CDISC, 2016; Kubick et al., 
2007).  
The CDISC Controlled Terminology (CT) is not referenced as part of the foundational 
standards, but plays a critical role in the effectiveness of the standards. The CDISC CT 
defines the value lists and associated terms, definitions, synonyms, submission values and 
concept codes used by the CDISC content standards. The CDISC CT is developed in 
partnership with the National Cancer Institute’s (NCI) Enterprise Vocabulary Services (EVS).  
The CDISC Operational Data Model (ODM) standard is an XML schema-based 
document and exchange standard created specifically to support the needs of clinical research. 
As shown in Figure 6, the ODM standard (CDISC, 2016) plays an essential role in the 
transmission or exchange of clinical research data and metadata, including FDA submissions 
and interoperability with healthcare data. In general, ODM is considered the most relevant 
format for the exchange of metadata within the clinical research domain (Ngouongo et al., 
2013; Stausberg et al., 2009). ODM is comprised of four major components: (1) Study 
containing the metadata that represents the structural definitions for the study, (2) 
ReferenceData providing information used to interpret the clinical data, (3) ClinicalData 
capturing the clinical data for each subject, and (4) AdminData storing user, location, and 
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electronic signature information (CDISC, 2013c; De Melo, Nagler-Ihlein, & Weber, 2006).  
Figure 7 shows ODM’s hierarchical structure. The hierarchical structure is best suited to 
representing CRF-oriented data (Lefort & Leroux, 2013; Hugo Leroux & Lefort, 2012). ODM 
metadata can be used to generate data collection forms, decision support systems, and other 
applications (Crichton et al., 2009; De Melo et al., 2006; Domínguez et al., 2007; Forster & 
Vossen, 2012). 
 
Figure 7. The ODM metadata and data hierarchies 
In addition to supporting a core set of use cases centered around support for CRF data 
and metadata, ODM also provides an extension mechanism that enables both CDISC and 
vendors to augment the model as needed to support specific interchange scenarios. This 
makes it possible to extend the core ODM standard with the additional information needed to 
support other use cases as was done in Forster and Vossen (2012) and De Melo et al. (2006). 
CDISC has published a number of standardized extensions including: (1) Define-XML for 
dataset metadata (CDISC, 2013b), (2) Dataset-XML for dataset data (CDISC, 2014b), (3) 
SDM-XML for Study Design Model (CDISC, 2011a), (4) CT-XML for Controlled 
Terminology (CDISC, 2011b), and (5) Analysis Results Metadata (CDISC, 2014a) for 
Define-XML v2 (Hume et al., 2016).   
The Define-XML v2.0 standard ODM extension provides the metadata to describe 
tabular datasets and plays a key role in establishing traceability in regulatory submission 
datasets (FDA, 2016a; Hume et al., 2016). When used to represent CDISC content standards 
Define-XML may be used to describe all the SDTM, ADaM, or SEND datasets for a study 
(Kubick et al., 2007; Hugo LEROUX, McBride, Lefort, Kemp, & Gibson, 2012; Lightfoot & 
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Jansen, 2013; Maddox, 2013, 2014; Wheeldon & Burges, 2014). Define-XML was added to 
the FDA’s Study Data Specifications in March of 2005 (FDA, 2010; Kubick et al., 2007), and 
in December 2016 it becomes a requirement for all new studies included in FDA submissions 
(CDISC, 2013b; FDA, 2010). The FDA's March 2017 Study Data Technical Conformance 
Guide (TCG) states that the Define-XML file "describes the metadata of the submitted 
electronic datasets, and is considered arguably the most important part of the electronic 
dataset submission for regulatory review" (FDA, 2017). The TCG further states that "an 
insufficiently documented data definition file is a common deficiency that reviewers have 
noted" (FDA, 2017). Validation of the Define-XML documents beyond mere schema 
validation has become a critical step in the regulatory submission process demanding the 
development of validation rules and validation engines to apply them (Aerts, 2014; Hume et 
al., 2016; "OpenCDISC," 2014). Currently, the FDA requires the use of SAS V5 XPORT 
format for submissions data creating the need to maintain the metadata in a separate Define-
XML document (Kubick et al., 2007).   
The CDISC standards metadata is maintained within the SHARE MDR (Jiang et al., 
2012; Jiang et al., 2010; Sinaci & Erturkmen, 2013). The SHARE ISO/IEC 11179-based 
metamodel provides the foundation for a CDISC standards model and the means of specifying 
the semantics as well as the representation for the standards metadata (Davies, Harris, 
Crichton, Shukla, & Gibbons, 2008). As CDISC expands the scope of the standards to cover 
an increasing percentage of the clinical research data lifecycle (Jiang et al., 2010), the SHARE 
model has been used to explicitly express the relationships between each state in the lifecycle. 
These relationships are used to represent the data flow through the lifecycle (Souza, Kush, & 
Evans, 2007). Standards implementers desire more complete metadata to describe the 
transition, or mapping, from state-to-state within the data lifecycle. Providing metadata 
describing each state in the clinical research data lifecycle, as well as the transition from state-
to-state is referred to as the end-to-end CDISC model.  From a modeling perspective, there 
exists one end-to-end process that spans a number of activities and their associated data states 
(Curbera, Doganata, Martens, Mukhi, & Slominski, 2008). Mapping is the process of 
associating healthcare terms used in one system with the equivalent terms in another system 
(Hebda & Czar, 2013), and mapping metadata is often used to link one specific terminology, 
classification, or nomenclature scheme to another (Imel, Giannangelo, & Levy, 2004). In this 
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case, it maps one state in the clinical research data lifecycle to the next, such as CDASH to 
SDTM or SDTM to ADaM. When the standards are used together in this way the data 
transformations required to support the data lifecycle end-to-end are minimized. Today ODM 
and the other CDISC standards provide limited support for representing data mapping 
information (Richesson & Nadkarni, 2011). Lack of a published end-to-end CDISC standards 
model has limited the ability to represent complete traceability throughout the data lifecycle 
within a study. 
Traceability within Clinical Research Data 
Traceability is a fundamental element of data integrity. It represents both the 
knowledge of the data’s origin and the basis for belief in the data. Traceability indicates the 
preservation of an unbroken chain of data from its source to the point of consumption. Within 
the context of regulated clinical research, traceability indicates that the content of a clinical 
study report (CSR) is explicitly linked back to the source data to include any transformations, 
derivations, and imputations that have occurred in the process. R. D. Kush and Bleicher 
(2003) state that data integrity “means that the content of the submission database matches 
that found in source data.” Study data traceability provides an understanding of the 
relationships between the data in each state within the clinical research data lifecycle (FDA, 
2016a). Traceability plays a critical role in supporting the clinical research analysis results 
since the strength of the study results depend on the source data and the processes used to 
create them (Curcin et al., 2014). Traceability, an essential component of provenance, helps 
other researchers to audit the clinical research process, verify the results, and ultimately can 
help reproduce the research results (Curcin et al., 2014). Traceability also enhances the 
secondary use of clinical research data. The trustworthiness of analysis conducted on 
aggregated data improves when the sources and methods of aggregation are clearly 
understood.  
From a regulatory perspective the FDA has stated that the results presented in the 
analysis results must be traceable back to the original data elements (FDA, 2016a). FDA 
reviewers rely on traceability to: (1) determine the original observations as captured and the 
derivations used to transform them into other variables; (2) understand how the statistical 
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tests, such as confidence intervals or p-values, were determined; and (3) provide an overall 
understanding of the construction of the analysis datasets (FDA, 2016a). Traceability helps 
the reviewer to understand “the relationships between the analysis results, analysis datasets, 
tabulation datasets, and source data” (FDA, 2016a). The FDA has identified a lack of 
traceability as one of the top 7 data standards issues (Chhatre & Malla, 2012), and it has been 
cited as a key to the FDA’s ability to successfully review submission data (Peterson & Izard, 
2010).   “Messy data” that is difficult to understand can delay the FDA’s ability to complete 
the review of a New Drug Application (NDA) (Berkowitz, 2011) potentially costing the 
sponsor company millions of dollars in lost revenue. The PMDA has expressed traceability 
requirements similar to the FDA, and have identified traceability as a key element of an NDA 
submission (Takanami, 2014). The ICH GCP (International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical 
Practice) cites traceability as one its 13 core principles (ICH, 1996b).  
Despite the importance of traceability requirements for regulated clinical research, the 
ability to easily trace data back to its source remains limited. The technology available to 
support the systematic review of submission datasets are limited in functionality when it 
comes to traceability (van Valkenhoef et al., 2012). The current situation precludes efficient 
and fully transparent decision making (van Valkenhoef et al., 2012). Today no tools exist 
capable of tracing a data element from the protocol through to the analysis results tables, 
listings, and figures (Dootson, 2011). Current federal regulations, such as Title 21 of the Code 
of Federal Regulations; Electronic Records; Electronic Signatures (FDA, 2003; Segalstad, 
2008), better known as 21 CFR Part 11, describe traceability needs, but do not prescribe how 
traceability should be assessed. Due to these limitations regulatory decisions are not 
sufficiently based on the available evidence pointing to a lack of traceability and transparency 
(van Valkenhoef et al., 2012). 
In a 2015 Accenture survey 80% of the respondents claimed “consistent data across 
the clinical data lifecycle” as a key reason for implementing the CDISC standards within their 
organizations (Accenture, 2015). The CDISC ODM v1.3.2 and Define-XML v2.0 standards 
provide the metadata models that represent the traceability across the data lifecycle, and 
Define-XML is currently required as part of a standards-compliant regulatory submission 
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(CDISC, 2016). The Define-XML def:Origin element provides metadata explicitly in support 
of traceability, and definitions for the def:Origin Type attributes are listed in Table 2. 
 
Table 2. Define-XML v2.0 def:Origin types taken from (CDISC, 2013a) 
Type Type Description 
CRF Data that was collected as part of a CRF and has an annotated CRF associated with the 
variable. 
Derived Data that is not directly collected on the CRF or received via eDT, but is calculated by an 
algorithm or reproducible rule defined by the sponsor, which is dependent upon other data 
values. 
Assigned Data that is determined by individual judgment (by an evaluator other than the subject or 
investigator), rather than collected as part of the CRF, eDT or derived based on an algorithm. 
This may include third party attributions by an adjudicator. Coded terms that are supplied as 
part of a coding process (as in --DECOD) are considered to have an Origin of "Assigned". 
Values that are set independently of any subject-related data values in order to complete 
SDTM fields such as DOMAIN and --TESTCD are considered to have an Origin of "Assigned". 
Protocol Data that is defined as part of the Trial Design preparation. An example would be VSPOS 
(Vital Signs Position), which may be specified only in the protocol and not appear on a CRF 
or transferred via eDT. 
eDT Data that is received via an electronic Data Transfer (eDT) and usually does not have 
associated annotations. An origin of eDT refers to data collected via data streams such as 
laboratory, ECG, or IVRS. 
Predecessor Data that is copied from a variable in another dataset. For example, predecessor is used to 
link ADaM data back to SDTM variables to establish traceability. 
 
Table 3 describes the metadata traceability rules listed in the Define-XML v2.0 
specification (CDISC, 2013b). 
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Table 3. Define-XML v2.0 traceability rules taken from (CDISC, 2013a) 
# Rule Description 
1 For regulatory submissions, def:Origin metadata must be provided for all SDTM or ADaM variables. 
It is at the sponsor's discretion whether to provide def:Origin at the Variable or Value level. 
2 If the ItemDef corresponding to a SDTM or ADaM variable includes a def:ValueListRef and all of the 
ItemDef elements referenced in the corresponding def:ValueListDef include a def:Origin element, the 
def:Origin is optional with the variable level ItemDef. 
3 If the ItemDef corresponding to an SDTM or ADaM variable includes a def:ValueListRef and the 
def:Origin elements of ItemDef elements referenced in the corresponding def:ValueListDef are 
different, then the def:Origin cannot be provided with the variable level ItemDef. 
4 If the variable or value is derived, the corresponding ItemDef must include a MethodOID attribute that 
references the corresponding MethodDef. 
5 When def:Origin/@Type=”CRF”, there must be a def:DocumentRef child element and 
def:DocumentRef/@leafID must match the ID attribute of the def:leaf element corresponding to the 
def:AnnotatedCRF within the same MetaDataVersion. Otherwise, def:DocumentRef/@leafID must 
match the ID of a defined def:leaf element within the same MetaDataVersion. 
6 If the variable is derived, a MethodDef must be provided. If the variable is assigned, a MethodDef is 
optional. 
 
Where traceability is concerned domain-specific models and semantics are preferred 
(Curcin et al., 2014; Johnson, Kamineni, Fuller, Olmstead, & Wernli, 2014). The CDISC 
standards provide the models for traceability within the context of regulatory submissions. 
FDA regulations on electronic records and signatures, 21 CFR Part 11, came into effect in 
1997 and required a computer generated, time-stamped audit trail (FDA, 2003). The 21 CRF 
Part 11 regulations were established prior to many of the recent advances in provenance and 
traceability.  
Traceability within Information Product Maps 
An Information Product Map (IP-Map) is an analysis model drawn from a top-down 
perspective that represents the data flows and processing that occur during the creation of an 
information product (IP) to support a decision maker’s understand of that IP 
(Shankaranarayanan & Wang, 2007). IP-Maps provide a conceptual visualization of an IP’s 
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manufacturing process that aids decision makers in identifying how data is being captured, 
transformed, stored, and utilized prior to becoming available to the decision maker (Chee, 
Yeoh, & Gao, 2011; Shankaranarayanan, Wang, & Ziad, 2000). IP-Maps provide a 
foundation for analyzing data quality (Shankaranarayanan & Wang, 2007). This research 
focuses on the use of IP-Maps to support traceability, a dimension of data quality, within the 
domain of regulated clinical research. In the context of a clinical trial, and particularly a 
regulatory submission, IPs include the tables, listings, and figures included in the analysis 
results that must be understood by a regulatory reviewer and possibly the analysis datasets 
themselves due to their essential role in traceability. 
An IP-Map uses a set of modeling constructs to represent the process of creating an IP 
in a manner similar to the process for manufacturing a physical product (Shankaranarayanan 
et al., 2000). IPs share many of the same product quality-control processes with traditional 
manufacturing processes (Shankaranarayan, Ziad, & Wang, 2003). IP-Maps allow 
information consumers to visualize, comprehend, and evaluate how the IP is assembled 
(Shankaranarayanan & Wang, 2007).  MDRs have been referenced by IP-Maps as a means of 
providing access to the detailed data element-level metadata as well as information on data 
element mappings and transformations (Shankaranarayanan, 2005; Shankaranarayanan & Cai, 
2006).   
IP-Maps are designed top-down to describe an IP. They specify the raw data (RD) 
inputs that come from outside the IP-Map boundaries and the component data (CD) items that 
are generated as the IP is created. The RD and CD data flow into and out of one of eight 
different types of constructs called blocks. Each stage within the IP-Map is connected to show 
the flow of data through the process. Each stage consists of blocks that contain composition 
attributes, or a reference to those attributes in an MDR, that provide the metadata descriptions 
of the individual data elements. These attributes, or data elements, are necessary to provide 
the detail needed to understand the IP manufacturing process, as well as to measure data 
quality within the process. The top-down development of an IP-Map shows how these data 
elements flow through the process to include any transformations or derivations that alter the 
data as it moves through the process. In this sense, IP-Maps provide high-level support for the 
notion of traceability within the process for creating an IP.  IP-Maps define traceability as the 
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ability to trace a sequence of one or more stages that precede a given block within the IP-Map 
(Shankaranarayanan et al., 2000). Thus, IP-Maps provide a high-level abstraction of the 
detailed data element-level traceability. Providing traceability at multiple levels of granularity 
can be used to improve a decision maker’s understanding of the process that creates the IP. 
Table 4 (Shankaranarayan et al., 2003; Shankaranarayanan et al., 2000) describes the block 
types used to construct an IP-Map. 
Table 4. IP-Map block types 
Block Name (Abbreviation) Description 
Data Source (DS) This block represents the source of the raw input data items as 
they enter into the IP-Map. 
Processing (P) This block represents any processing performed on data items 
including: transformations, calculations, imputations, 
derivations, concatenations, or other manipulations needed to 
produce the information presented in the IP. 
Inspection (I) This block represents pre-determined checks performed to 
test for data quality, appropriate authority, missing values, 
and adherence to other validity rules. Among other things this 
block ensures that the data items are free of defects. 
Data Correction (DC) This block is a specialized form of the process block that 
represents an exception process triggered by quality errors 
that require corrective action to resolve. 
Decision (D) This block represents a branching function that transfers data 
for a specific type of processing based on the values of 
specified data items. 
Data Storage Block (STO) This block represents data items that are stored in files or 
databases to make them available for further processing. 
Information System Boundary (SB) This block represents data items moving from one system to 
another, particularly data transfers from one type of system to 
another. 
Business/Organization Boundary (BB) This block represents data items moving from one business or 
organizational unit to another to highlight changes or quality 
issues that could arise from this transition. 
Data Sink (Consumer) (CB) This block represents the data items in a final IP that will be 
used by the IP consumer. 
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Blocks in an IP-Map are identified by unique, non-null names and are further 
described by a set of attributes (Shankaranarayan et al., 2003). A stage in an IP-Map 
represents a step in the IP manufacturing process. Each stage in the IP-Map is represented by 
one or more blocks. A start stage and an end stage in an IP-Map are represented by two blocks 
directly connected by a data flow (Shankaranarayan et al., 2003). IP-Maps can be used to 
determine reachability and traceability as elements of data quality within the IP 
manufacturing process (Shankaranarayanan & Wang, 2007). Shankaranarayan et al. (2003) 
defines IP-Map reachability as the “ability to identify all production stages of an IP that can 
be reached from a given stage” and traceability as the “ability to identify a sequence of one or 
more stages that precede any stage.” 
Chee, Yeoh, Gao, and Richards (2014) implemented a layered metadata framework 
using IP-Map to support traceability in a Business Intelligence (BI) environment where 
aggregated data often comes from different sources and undergoes various transformations. 
The variety of data sources and transformations made it difficult for decision makers to 
understand the processes that created the data. Decision makers were unable to visualize the 
entire information manufacturing process of a given BI IP (Chee et al., 2011). Many of the 
data traceability needs in clinical research are similar to traceability needs in BI applications. 
The data warehousing view data lineage problem within a BI environment is another vein of 
research that shares many common objectives with the traceability and provenance research 
as covered in (Buneman & Tan, 2007; Cui, Widom, & Wiener, 2000; Missier, Paton, & 
Belhajjame, 2010; Tan, 2007; Woodruff & Stonebraker, 1997). The BI IP-Map solution was 
implemented using a 3-layered architecture: (1) business processes, (2) information processes, 
and (3) a detailed description of the metadata. While this BI framework supports traceability, 
the needs of clinical research data element-level traceability are more detailed and granular 
than those targeted by the BI IP-Map research.  
Granularity and layering are two key concepts influencing the metadata model needed 
to support traceability and provenance within an application. From a granularity perspective, 
the semantics of individual data transformations are needed to ensure that a traceability query 
can determine the specific inputs that impact a derived data element. Such granularity 
decisions impact the types of questions that can be answered with the traceability metadata 
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(Carata et al., 2014). Layering enables the model to represent traceability at multiple levels of 
abstraction, each layer supporting different views. The layered metadata frameworks 
described in (Chee et al., 2011; Chee et al., 2014) and (Shankaranarayanan, 2005) provide 
examples of layering based on IP-Maps.  
Traceability as Dimension of Provenance 
"Data provenance plays a critical role in advancing research data sharing nationally 
and internationally. Without provenance, it is difficult if not impossible for one researcher, 
separated by distance and decades of time from another, to trust the data of the latter" 
(Cheah & Plale, 2015). 
Definition of Provenance. Provenance describes how a data item in a specific state 
was derived from a specified source (Moreau, Groth, et al., 2008). Broadly defined, 
provenance describes the origins of a data item and refers to the documented history of the 
process, including derivations, that the data item took to arrive in a dataset (Buneman, 
Khanna, & Tan, 2000). According to the W3C “provenance is information about the entities, 
activities, and people involved in producing a piece of data or thing, which can be used to 
form assessments about its quality, reliability or trustworthiness” (W3C, 2013). Traceability 
represents a key component of provenance that is essential to data integrity. Traceability 
within a provenance context may be referred to as (1) data provenance, (2) dataflow 
provenance, or (3) data lineage.  
Provenance Taxonomy. The provenance literature has been categorized based on an 
extended Taxonomy of Provenance (Simmhan, Plale, & Gannon, 2005a) shown in Figure 8. 
The original Simmhan et al. (2005a) taxonomy was developed for a survey of provenance 
literature for e-science and is relevant for clinical research. Each of the following sections 
highlight the provenance research as it relates to both the regulated clinical research 
requirements and the current state-of-the-art. 
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Figure 8. Provenance taxonomy (Simmhan et al., 2005a) 
 
Data Quality. Currently, an international consensus on how to assess data quality and 
its usability for research does not exist. Quality is defined by the International Standards 
Organization (ISO) as the "degree to which a set of inherent characteristics of an object 
fulfills requirements" (ISO, 2015). According to De Lusignan et al. (2011) six key concepts 
describe data quality for clinical research: (1) overall data quality which asks if "these data are 
fit for purpose?"; (2) data provenance, defined as how data came to be, that includes data 
lineage; (3) data extraction errors; (4) data processing errors, which includes errors created 
during data mapping and transformations; (5) traceability, the capability to identify the origins 
of any data variable within the final analysis datasets, is required for sound governance and 
nearly impossible without a formal system for managing metadata; and (6) curation, which 
ensures that metadata and data are available for future researchers to use for new research or 
to review previously published findings. 
Dataflow provenance information about data sources and transformations can be used 
to estimate the overall quality and reliability of clinical research data (Jagadish & Olken, 
2004). Elements of data quality such as integrity, trustworthiness, completeness, and identity 
are essential to dataflow provenance. Assessments of data quality build on data 
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trustworthiness, and provenance can aid in the identification of data flows that use metadata 
sources and transformations of unknown or incorrect origin (Bertino, Dai, & Kantarcioglu, 
2009; Jagadish & Olken, 2004). A perceived lack of transparent processing in the generation 
of clinical decision support recommendations has limited their effectiveness. Trust is an 
essential element required for the success of data-driven medicine, and data flow provenance 
is a fundamental aspect of trustworthiness (Curcin, Fairweather, Danger, & Corrigan, 2017). 
Completeness is characteristic of data qualify described in (Mettler, Rohner, & 
Baacke, 2008). Completeness as a dimension of provenance quality is defined as "the extent 
to which provenance is missing or to which provenance is more than the actual amount of 
collectible provenance" (Cheah & Plale, 2015). Completeness in dataflow provenance 
assessments examine metadata gaps including orphan variables that are not traceable back to 
inputs, inputs that are not linked to outputs, and cases where a transformation or derivation 
function should be part of the trace.  
Maintaining identifier integrity throughout the end-to-end data lifecycle is also 
essential to dataflow provenance (R. Y. Wang, Storey, & Firth, 1995). Within clinical 
research, each metadata element must be uniquely identified within the context of a study at a 
minimum. In aggregated data environments where the outputs of one process become the 
inputs to the next, as found with data lakes, a persistent and unique identifier policy may be a 
requirement (Suriarachchi & Plale, 2016). Provenance data is frequently represented in 
graphs, and graph nodes and edges often require unique identifiers within the context of the 
graph (Curcin et al., 2017). 
Audit Trail. The audit trail is an essential element of data provenance (Miles, Groth, 
Branco, & Moreau, 2007), and 21 CFR Part 11 (FDA, 2003) establishes it as a regulatory 
requirement in clinical research. Data provenance within the CDISC standards often focuses 
on ODM’s support for a 21 CFR Part 11 compliant audit trail with electronic signature 
support. The ODM audit trail exists at different levels of granularity within the schema 
hierarchy from Study Events to individual data items. The audit trail covers the W7 model 
(Ram & Liu, 2009) where provenance is captured using the 7 W’s including: (1) what (an 
event or change of state that impacted the data), (2) where, (3) when, (4) who, (5) which 
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(instruments or software that were used in the event), (6) how (an action leading to the 
events), and (7) why. ODM’s coverage of the 7 W’s is shown in Figure 9 below. 
 
Figure 9. CDISC ODM audit trail support (CDISC, 2008) 
 
Replication. The Institute of Medicine defined a clinical study to be reproducible when 
a second study reaches the same conclusions as the first (Davis, Nolan, Woodcock, & 
Estabrook, 1999). There are a number of levels of replication including: (1) replication of a 
study by a different group following the same basic study design and methods; (2) replication 
of a study by the same group; or (3) replication of the analysis of the same data using different 
data management, programming, and statistical analysis (Zozus, Richesson, Walden, 
Tenenbaum, & Hammond, 2016). Replication of data derivations is essential to the validation 
and trustworthiness of the analysis results. Establishing data flow provenance is critical to 
determining the validity of scientific results by assuring they can be reproduced (Curbera et 
al., 2008). Dataflow provenance must include details on the derivations such that a reviewer 
can understand, and ideally could repeat, the process used to create the dataset under 
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examination (Simmhan, Plale, & Gannon, 2005b). This approach to dataflow provenance 
originated in the e-sciences where it was used to represent scientific workflows, and it was 
originally used by the scientific programmers that develop and maintain research workflows 
(Curcin et al., 2017). In regulatory submissions to the FDA or PMDA, the detail needed to 
support dataset replication is maintained in the Define-XML metadata and the documents it 
references.  
As science has become progressively more data-driven and computationally oriented, 
as well as more interdisciplinary, the need for data sharing and transparency to support 
research reproducibility has grown correspondingly (Ludäscher, 2016). Data provenance is 
essential for transparency and computational reproducibility.  Curcin (2016) identifies 4 levels 
of reproducibility that apply within the context of a learning health system: (1) auditability 
provides the additional details required to analyze the state of the data at each step in the 
research process, (2) traceability provides an unbroken chain of data from its source to the 
point of consumption to include any transformations and derivations that impact the data, (3) 
replicability provides the ability to repeat the processes using the original tooling and data, 
and (4) reproducibility provides the ability to independently confirm the results of the 
research using new data. Traceability is the most critical level for establishing trust and 
believability in the research processes as it provides the details establishing precisely what 
occurred at each step in the process (Curcin, 2016). Provenance data plays an important role 
in the reproducibility of the scientific processes necessary for replicating the results of 
published research (Missier, 2016). 
Zozus et al. (2016) state that reproducibility requirements for studies using EHR data 
have not been sufficiently developed, but also identified traceability as an essential 
component of research replication. To establish traceability, research information systems 
must maintain when and from where EHR data was received, the state of the data received, 
any transformations performed to map the data into the research data model, and any 
algorithms used to derive research values.  
Blockchain technology has been identified as a possible means to enhance the 
replication and reproducibility of clinical research in the future. Tracing complex data flows 
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from numerous diverse research participants while documenting each step in the protocol in 
real-time through a timestamping workflow is viewed as an important step towards 
establishing improved traceability as well as data consistency and inviolability (Benchoufi, 
Porcher, & Ravaud, 2017). Future EHR systems may provide researchers easy access to a 
comprehensive, immutable log of a patient's medical information via blockchain technologies 
(Ekblaw, Azaria, Halamka, & Lippman, 2016). Blockchain technology provides an 
unfalsifiable timestamp that provides the proof of existence of any piece of data through the 
application of public key cryptography (Benchoufi et al., 2017). A blockchain healthcare 
record would use this public key cryptography feature to create an append-only, immutable, 
verifiable, timestamped chain of content (Ekblaw et al., 2016). Equally important for 
empowering patients in research, blockchain technology can empower peer-to-peer exchanges 
where patients and researchers work together to establish consent and access to data 
(Benchoufi et al., 2017).  
Attribution. As the scientific community continues to embrace data sharing, open 
science, and the realization that the data itself can represent a significant research contribution 
(Borgman, 2012); data citation becomes an extension of data provenance (Jagadish & Olken, 
2004). Data citation enhances the ability for researchers to collaborate and promotes the 
secondary usage of existing data by making it possible to contact the people that generated a 
piece of data or derivation algorithm (Allen, Brand, Scott, Altman, & Hlava, 2014). Citing 
portions of datasets down to the individual data element level or for a specific derivation 
requires additional metadata as well as specific mechanisms for referencing a slice of a 
dataset (Hoyle et al., 2015). Technologies such as URI/URLs provide a universal locator for 
an electronic document, but citing content within the document can be more challenging, 
especially when traditional paper mechanisms like page numbers are friable in electronic 
documents (Buneman et al., 2000). 
Informational. Provenance data can provide metadata descriptions of datasets that can 
aid in discovery activities, as well as retrieval from a data archive (Simmhan et al., 2005b). In 
the CDISC standards ODM supports the long-term archival of clinical research data where the 
integrity of the data and metadata as captured from the original systems is maintained in a 
system-neutral, open format. ODM represents the information necessary to achieve the 
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technical aspects of regulatory compliance by maintaining the full audit trail and electronic 
signatures for a given study. ODM utilizes an easy to understand “CRF metaphor” for 
organizing the data and metadata (W. Kuchinke, Aerts, Semler, & Ohmann, 2009). ODM 
provides a non-proprietary means to archive data that meets the federal regulations, and does 
not require the archival of proprietary software to support the use of the data (W. Kuchinke et 
al., 2009; Souza et al., 2007). This is a critical characteristic of an effective study data archival 
given that the lifespan of regulated clinical research can extend past 50 years. Many current 
electronic data capture (EDC) and study data management systems directly export to ODM 
facilitating its use as part of an archival solution (CDISC, 2017). ODM can be linked to EHR 
data and SDTM to create an end-to-end study data archival. Define-XML and Dataset-XML 
could be used as part of a dataset archive, and when combined with ODM provide the 
beginnings of an archive that covers the data lifecycle. For datasets, archived Define-XML 
references to external dictionaries or scoring algorithms must understand how those 
references will be maintained over the lifespan of the archived data (Buneman et al., 2000). If 
the maintainers of the external sources referenced cannot ensure their availability over the 
lifespan of the data archive, the external sources may need to be included in the study archive. 
Establishing traceability within an archive further enhances data integrity and makes it easier 
for new users to understand the data. 
Big Data Analytics. Big data analytics will influence traceability within healthcare and 
clinical research. Y. Wang, Kung, and Byrd (2016) conducted a content analysis of 26 big 
data implementation cases in healthcare and identified traceability as one of the five big data 
analytics capabilities for healthcare. The other four capabilities were: (1) analytical capability 
for patterns of care, (2) unstructured data analytical capability, (3) decision support capability, 
and (4) predictive capability. For purposes of this study, Y. Wang et al. (2016) defined 
traceability as the ability to track output data from all information systems throughout the 
organization. The primary purpose for big data traceability is making data consistent, visible 
and easily accessible for analysis.  Ideally systems would be designed from the outset to 
include the metadata necessary to support traceability, simplify maintenance, and simply the 
analytics work (McClatchey, Branson, & Shamdasani, 2016).  Big data systems using a 
description-driven philosophy manage metadata describing each data item separately from the 
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data allowing re-use over time and traceability between data item versions as well as between 
the various states in the information lifecycle (McClatchey et al., 2016). 
Traceability and data provenance may increase in importance in the context of big data 
where the same data maybe analyzed repeatedly to serve a variety of analytical purposes. As 
the datasets are repurposed to support new studies the separation between the original 
producer of the dataset and the data consumer increases, straining the original semantics. The 
lineage for any dataset in a big data context must be preserved to ensure the trustworthiness 
and believability of subsequent analytical uses of the datasets (Toivonen, 2015).  Traceability 
and provenance within big data systems facilitates the reproducibility and verification of 
analysis results, as well as the validation of analyses between researchers (McClatchey et al., 
2016).  
Data lakes employ a schema-on-read approach where data transformations are 
presumed to occur within the lake leading to data items that exist in a range of stages in the 
data lifecycle. The availability of data in a variety of lifecycle stages increases the value of 
traceability and data provenance within the context of the data lake. In this case, data 
provenance "is the information about the activities, entities, and people involved in producing 
a data product" that exists in the data lake (Suriarachchi & Plale, 2016). As science becomes 
increasingly data-driven, as well as more collaborative and interdisciplinary, the importance 
of traceability to establish trust in the data and the analysis results will continue to remain a 
key capability (Ludäscher, 2016). 
Data and Process Provenance. Data provenance, sometimes referred to as data lineage 
(Kifor et al., 2006) or dataflow provenance, is essential to the degree of trust placed in a data 
item, and plays a key role in data integration (Buneman & Tan, 2007).  Data provenance 
requires information describing the creation, attribution, recording, processing, version 
history, and ownership of data items in support of its integrity (Buneman, Chapman, & 
Cheney, 2006).  In data provenance lineage metadata is gathered about the data (Simmhan et 
al., 2005a). The lineage metadata is essential to preserving the scientific value of data. Data, 
or dataflow, provenance can describe the source for each data item as well as including the 
when, where, how, who, which, and why of data changes throughout the data lifecycle (Ram 
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& Liu, 2009).  Data provenance can also be considered retrospective provenance because it 
maintains a log of the changes that were made for inspection after they happen (Clifford, 
Foster, Voeckler, Wilde, & Zhao, 2008). Technologies supporting data provenance seek to 
automatically capture the trace of a specific research task and its resulting data in order to 
facilitate reproducible research (Curcin, 2016). 
Process provenance, often referred to as workflow or course-grained provenance, 
provides a complete description of the process used to generate a dataset to include the 
software programs used, external data capture instruments, and even a description of human-
performed manual tasks (Buneman et al., 2006).  Process provenance can also be considered 
prospective provenance because it captures a specification of a change or derivation before it 
is applied to create data changes (Clifford et al., 2008). 
Moreau and Groth (2013) describe provenance as consisting of three views: (1) the 
data flow view, (2) the process flow view, and (3) the responsibility view. Moreau and Groth 
(2013) recommend starting with the data flow view. The data flow view of provenance is 
“concerned with the data flow within computer systems” and includes the derivations that 
transform the data items (Moreau & Groth, 2013). The data flow view of provenance is also 
referred to as traceability. In a clinical research context, the process flow view would be based 
on the protocol and study design, and the responsibility view would be based on the audit trail 
and electronic signature information. 
Regulations. Data provenance plays an important role in addressing the regulations 
that guide regulated clinical research and their associated data submissions. Maintaining audit 
trails and traceability are established requirements stipulated in 21 CFR Part 11 (FDA, 2003), 
regulatory guidance on traceability (FDA, 2016a), and Good Clinical Practice (ICH, 1996a) in 
the US and in EudraLex Vol. 4 Annex 11: Computerized Systems in the European Union (EC, 
2010). Data provenance can function as an enabling technology supporting conformance with 
the technical controls of 21 CFR Part 11 (Curcin, 2016). The FDA has also published 
guidance documents related to traceability in clinical research, including the 2003 guidance 
on Electronic Records; Electronic Signatures (ERES) Scope and application (FDA, 2003), and 
the 2007 revised Guidance for Industry Computerized Systems Used in Clinical Investigations 
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(FDA, 2007b).  Title 42 CFR 93, while not literally specifying traceability, indirectly points to 
the need for traceability by requiring the capability to address allegations of research 
misconduct for any institution funded by the US Public Health Service (Zozus et al., 2016). 
Regulations with traceability requirements for non-clinical studies include 21 CFR 58.130 (e) 
and 21 CFR 58.35 (b). 
Granularity. The level of granularity needed to support provenance varies among 
domains (Simmhan et al., 2005b).  Provenance data can be collected at many different levels. 
For example, the ODM audit trail exists at different levels of granularity within the schema 
hierarchy from Study Events to individual data items (CDISC, 2013c). The costs associated 
with capturing and maintaining provenance data can be expressed as inversely proportional to 
the level of granularity (Simmhan et al., 2005a). Data provenance is considered fine-grained 
provenance and describes in detail how each data item changes throughout the data lifecycle 
(Ram & Liu, 2009). Data provenance is a fundamental component of data quality (Buneman 
& Davidson, 2010).   
Annotation and Inversion Techniques. Provenance data can either be maintained 
explicitly, as it is in ODM, or deduced indirectly from the available data changes (Cui et al., 
2000). In Simmhan et al. (2005b) these approaches are categorized as annotations for the 
former and inversion for the latter. With annotations derivations are recorded prospectively 
(Clifford et al., 2008), or eagerly (Tan, 2004), as textual descriptions of the source data, 
derivations, and processes impacting the data. These prospective provenance annotations are 
pre-established and available as metadata used referenced in the provenance record. Inversion 
techniques take the available data changes and invert the derivations to find the data needed to 
produce the outputs (Cui et al., 2000). For example, certain queries and user-defined functions 
can be inverted to identify the source data (Simmhan et al., 2005a). The inversion technique is 
more efficient from a storage perspective, but the more complete and accurate annotation 
approach is required for provenance in regulated clinical research. 
For explicitly maintained data provenance there are three common techniques for 
managing provenance data: naïve, transactional, and hierarchical (Buneman et al., 2006). The 
ODM audit trail supports all 3 varieties, and the application generating and managing the 
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provenance data controls the implementation of a provenance technique. Naïve provenance 
represents the most basic technique as it stores one provenance record for each changed data 
item (Buneman et al., 2006). Transactional provenance is more efficient from a space and 
processing perspective than naïve provenance because a logical grouping of change events are 
captured by one audit record (Buneman et al., 2006). Hierarchical provenance can be used in 
combination with transactional provenance and uses a hierarchical structure to inherit 
provenance data from parent nodes to reduce redundancy in the audit trail information 
maintained (Buneman et al., 2006). 
Syntactic and Semantic Information. In order for provenance-aware applications to be 
interoperable, it is critical that the process documentation they produce be structured 
according to a shared data model (Moreau, Groth, et al., 2008). General standards for 
provenance have been published by the W3C called the PROV Data Model (PROV-DM) 
(W3C, 2013), but many disciplines use standards specialized for their own domain. Each 
discipline has diverse provenance requirements (Simmhan et al., 2005a). For example, in 
regulated clinical research regulations such as 21 CFR Part 11 (FDA, 2003), regulatory 
guidance on traceability (FDA, 2016a), and data standards required for regulatory 
submissions (FDA, 2015a) all influence the provenance solution. Established standards for 
data provenance and traceability exist within the regulated clinical research domain.  
A number of current provenance solutions make use of XML, including CDISC ODM, 
W3C PROV-XML, and OPM (Clifford et al., 2008; Miles et al., 2007). XML’s hierarchical 
structure naturally lends itself to provenance requirements such as audit trails and annotations. 
Some solutions use XML to link to ontologies to provide the needed semantics (Zhao, Goble, 
Stevens, & Bechhofer, 2004). Semantic web technologies, such as OWL and RDF, often play 
an important role in establishing the ontologies available for provenance within specific 
domains. The OWL/RDF model flexibility, support from provenance standards, availability of 
open source tools, and scalability have contributed to its broad usage in general-purpose 
provenance solutions (Malaverri, Mota, & Medeiros, 2013). Information models, such as 
Domain Analysis Models (Fridsma, Evans, Hastak, & Mead, 2008), can also support 
semantics within provenance. The difficulty developing and maintaining large ontologies or 
information models can be a barrier to establishing provenance semantics within a given 
38 
domain. In cases such as healthcare where multiple ontologies exist to serve different 
requirements, establishing one standard ontology to serve an entire domain may not be 
feasible. 
Data Provenance Standards. Provenance models, such as the W3C PROV Data Model 
(PROV-DM) (W3C, 2013) and the Open Provenance Model (OPM) (Moreau, Freire, et al., 
2008), provide a useful, general purpose means for tracing derivations from a specific source 
to an item in a particular state. According to the W3C “the goal of PROV is to enable the 
wide publication and interchange of provenance on the Web and other information systems” 
(W3C, 2013). Standards benefit data provenance since interoperability between provenance-
capable applications requires a common structure or shared data model (Moreau, Groth, et al., 
2008).  Provenance models must support references to domain semantics, and existing domain 
models should be used where available (Curcin et al., 2014; Johnson et al., 2014). Within the 
domain of regulated clinical research, the CDISC standards provide the domain models and 
metadata for data element level traceability, and these benefit users since the semantics are 
known within the domain. 
Storage Scalability. The number of datasets and the provenance granularity required 
have a significant impact on the scalability of the provenance solution, and provenance 
requirements vary by domain (Simmhan et al., 2005b). The number of derivations needed to 
create a dataset also impacts scalability. As the number of derivations increases the depth of 
the provenance lineage increases, along with the storage and processing requirements for the 
provenance solution (Simmhan et al., 2005a). The storage technique employed impacts the 
provenance scalability, and provenance storage solutions implement one of three previously 
cited approaches: naïve, transactional, and hierarchical (Buneman et al., 2006). Certain 
reduced provenance representations, such as Social Network Analysis, have demonstrated 
their ability to reduce provenance data volume while maintaining their ability to support the 
analysis of the provenance data (Gungoren & Aktas, 2016). 
Storage Overhead. Process, or workflow, provenance may require manual tasks to 
capture and store key provenance annotations. The burden of capturing these annotations may 
negatively impact the completeness, accuracy, and machine-readability of the provenance 
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records (Zhao et al., 2004).  For example, the CDISC Define-XML metadata standard is 
typically generated post hoc to satisfy the needs of a submission, and it often includes a 
number of manual tasks to record the required metadata (Hume et al., 2016). Some of the 
metadata referenced in Define-XML is maintained in PDF, adding to both the need to 
manually create metadata as well as additional storage overhead. A more progressive 
approach to producing Define-XML involves creating the Define-XML metadata as a 
specification that drives the generation of datasets and service specification documents 
(Lightfoot & Jansen, 2013; Maddox, 2013, 2014; Wheeldon & Burges, 2014). 
Data provenance of clinical research data aids the reviewer in forming an 
interpretation of the integrity and authenticity of the data. Computer generated, time-stamped 
audit trails play a key role in establishing both integrity and authenticity by capturing details 
on every event that impacts the data. Care must be taken during the development of data 
capture software to ensure that the deployed services are capable of capturing events that 
impact the data as they occur such that any adverse impact to application performance is 
mitigated (Moreau, Groth, et al., 2008).  The size of the data increases substantially with the 
addition of a complete audit trail, and adequate storage space must be allocated by data 
capture and archival solutions to maintain this information.  
Exchange formats such as XML and RDF can also add to the size of the data when 
uncompressed (FDA, 2015b). Retrieving audit trail data for analysis requires that the design 
consider both the storage and retrieval tools to ensure performance is adequate for the task. 
Retrieval tasks are made more complex by requirements to query the audit trail for a specific 
data item that is related to a specified event that impacted the data while filtering out other 
related provenance information (Moreau, Groth, et al., 2008).  
Establishing and maintaining data provenance in order to confirm the integrity and 
authenticity of the data requires that the provenance technology has been verified to perform 
the services needed to capture, store, and retrieve this information correctly. Provenance 
technology refers to both the hardware and software components needed to establish and 
maintain a complete provenance record as an end-to-end resource (Cheney, Chong, Foster, 
Seltzer, & Vansummeren, 2009). In regulated clinical research 21 CFR Part 11 requires the 
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validation of software systems that could impact the “reliability, integrity, availability, and 
authenticity of required records and signatures” (FDA, 2003). Computerized systems used in 
regulated clinical research must maintain a record of all changes, and must be re-validated to 
the extent demanded by the change. A software configuration management strategy is 
typically needed to control, audit, and report on the changes to the technology impacting 
electronic records in regulated clinical research environment (Burney, Saleem, Mahmood, & 
Jilani, 2010).  
The quality of the provenance data itself can be assessed to ensure that the data quality 
claims based on provenance data are well-founded. Cheah and Plale (2015) uses the following 
dimensions to assess provenance quality: (1) correctness indicates the extent to which 
provenance data is correct and free of error including the evaluation of quality attributes such 
as provenance data accuracy, unambiguity, consistency, and homogeneity; (2) completeness 
indicates the amount of missing or extra provenance data; and (3) relevancy indicates the 
degree to which the provenance data is relevant to the needs of the reviewer.  
Graph Visualization. Provenance data can typically be represented as a Directed 
Acyclic Graph (DAG), also referred to as causality graphs since the data flow DAG for a 
specific data item represents how it was created and all subsequent changes (Moreau, Groth, 
et al., 2008; Zhao et al., 2004). The DAG nodes represent data items and the edges represent 
the dependency relationships, such as versions, mapping, or derivations. Graph traversal 
algorithms can be used to find directed paths through a graph and test nodes for reachability. 
Reachability means that a directed path can be found from a source node to a specified target 
node within the DAG (Sedgewick & Wayne, 2011). The DAG can be used to present a visual 
representation of provenance data, or as a source to query against. Such visual representations 
can manifest patterns of real-world phenomena (Huynh, Ebden, Ramchurn, Roberts, & 
Moreau, 2014), such as unusually active editing patterns for a specific data point, which might 
initiate further examination into the “who”, “when”, and “why” provenance information. 
Since provenance graphs can become large, mechanisms are needed to cluster and filter the 
graphs in support of specific use cases (Macko, Margo, & Seltzer, 2013).  
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Queries and Service APIs. Datasets and databases can be searched for provenance data 
using standard search and query mechanisms. A significant body of literature exists in the 
area of provenance in database systems. Provenance data should be in a computable form and 
should be provided in a data store that permits querying using commonly available software. 
Provenance Requirements in Healthcare Systems 
"In the era of Big Data, deep learning systems such as IBM Watson, and other 
technologies that often rely on black-box analytical environments, it is of paramount 
importance to support transparency in computerized systems which actions have direct 
consequences on human lives" (Curcin et al., 2017). 
The Standards Development Support Team for the Data Provenance Initiative under 
the Standards and Interoperability Framework for the Office of the National Coordinator 
(ONC) for Health Information Technology (IT) and the Health IT Standards Committee 
(HITSC) Data Provenance Task Force have been asked to provide recommendations for a 
standardized healthcare approach to data provenance as applied to EHRs (Gallagher, 2015). 
To establish a standard for capturing and exchanging EHR provenance information the Data 
Provenance Initiative community will: (1) define a provenance vocabulary and metadata, (2) 
create a technical specification for implementing data provenance, and (3) create guidance 
documents that help implementers understand how to implement provenance and on what 
level it should be applied (Gallagher, 2015). As the trend away from document formats 
towards atomized data continues, the need for data provenance to ensure the authenticity and 
integrity of the data has increased. The data provenance initiative is in the process of 
evaluating a number of candidate standards from the existing healthcare data standards 
including CDISC ODM v1.3.2, HL7 CDA Release 2, HL7 FHIR Release 1.1 Provenance 
Resource, W3C PROV-XML, and others. 
Zozus and Bonner (2017) provide a list of the types of metadata needed to support 
traceability across a broad range of clinical study types, including prospective studies, 
retrospective studies, longitudinal studies based on EHR data, observational studies, and 
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studies supported by institutional data stores. Table 5 lists the sources of metadata described 
in (Zozus & Bonner, 2017). 
Table 5. Clinical study metadata types or sources from (Zozus & Bonner, 2017) 
Metadata Type Description 
Audit trail What, when, where, who, and why for each data change. The attribution and 
date/time for each data change, along with the previous value prior to the change.  
Data element 
definition  
ISO/IEC (2013) defines a data element as a "unit of data that is considered in 
context to be indivisible." An MDR based on the ISO/IEC 11179 standard 
manages the lifecycle of a data element definition. Each data element may have a 
value domain associated with controlled terminology and formal semantics to 
establish its meaning. 
Data origin Identifies the source of the data from the previous step in the lifecycle or from 
the phenomena that was observed, questioned, or measured to produce a data 
value. Contextual information further specifying the origin may also be included. 
Data transfer The specification for data sent to or retrieved from an external information 
system which could include transfer log information. 
Data 
transformation 
The specifications for software that transforms or performs a specified operation 
on the data. All data transformation data changes should be captured in the audit 
trail. 
Data quality 
assessment 
The specifications for conformance rules and other constraints or logic that were 
applied to the data values to identify discrepancies. Any changes to the data 
resulting from the quality assessments should be captured in the audit trail. 
Information 
retrieval 
The specifications or source code for the queries executed to retrieve data values 
and any additional information needed to recreate the data extraction. 
 
Curcin et al. (2014) provides a list of interoperable provenance implementation 
recommendations developed as part of the TRANSFoRm project, a European learning 
healthcare system initiative. This list of 21 recommendations has been reproduced in Table 6. 
Table 6. Interoperable provenance recommendations from (Curcin et al., 2014) 
# Type Recommendation 
1 Syntax Use W3C PROV or the Open Provenance Model for modelling provenance data 
recorded in an electronic healthcare system. When choosing between the two, 
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# Type Recommendation 
consider available tools and libraries in both systems for potential reuse or 
adaptation. 
2 Vocabulary  Institutions involved in a distributed healthcare application should agree to a 
common vocabulary to use in provenance constructs where possible. 
3 Domain models Link provenance models and data with domain knowledge models and data, 
respectively. These may be expressed in the form of templates, similar in form to 
workflows or business processes, and should be shared with the community. 
4 Detail focus Always aim to model the detail of what happens, including each processing step 
and data item involved, rather than summary information that directly answers 
current provenance questions. 
5 Granularity Use the existing biomedical models and ontologies as indicators of the level of 
granularity of process description that users are likely to be interested in the 
future, and validate it against the provenance questions known at design time. 
6 Connectivity Model the provenance with the expectation that, if brought together, it would 
form a single graph describing the full, interconnected history of the system, as 
opposed to being delimited into a set of isolated records. Globally unique IDs 
should be used where feasible to facilitate interlinking. 
7 Human actions Include both salient human activities and automated processes in the model of 
provenance to be captured. 
8 Model elements In designing the provenance model, consider explicitly representing each 
element of the process flows and the data flows, as well as the attributions of 
actions to users. Layering ontologies is a useful approach that maintains logical 
separation between these distinct elements. 
9 Reuse of existing 
data 
Where feasible, integrate the data captured by existing mechanisms (version 
control, audit, logging, etc.) into the provenance record, whether by reference or 
translation, to provide as rich and integrated an account as possible. 
10 Library reuse If not using shared execution middleware with provenance capture support, 
make use of existing OPM/PROV libraries to capture provenance data within 
your application code. 
11 Timely capture Build the runtime provenance capture functionality into each step of the system 
processes, at the appropriate level of granularity, using global identifiers where 
possible and linking to records of preceding steps using the chosen provenance 
model relations. 
12 Performance 
testing 
Test the performance overhead of provenance capture within a small sample part 
of your application to ensure it is acceptable for your application or if the 
technologies used and level of detail of model need to be modified. 
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# Type Recommendation 
13 Database structure Consider whether provenance storage needs to be provided in a relational 
database, if one is the standard solution in the research environment, or would 
an RDF store or a NoSQL graph database be an option. Privacy and data 
regulations will play an important role in deciding whether and how best to 
distribute the data in a multiple site scenario. 
14 Data 
infrastructure 
Reuse existing application infrastructure for provenance transmission if storing 
provenance centrally rather than at each site. Messaging systems may be used to 
transmit data reliably and asynchronously between application sites. 
15 Rate of growth Due to the typically large size of provenance data collected over time, it is 
crucial to establish early on the rate at which provenance storage requirements 
are expected to increase over time. The level of detail in the model may need to 
be adjusted accordingly and some deletion / archiving procedures introduced. 
16 Permissions When implementing provenance access control, consider the differences in 
access permissions between concrete data, and provenance records of that data. 
17 Restrictions When designing an access control mechanism for provenance data, decide 
whether restricted provenance information should be completely hidden or just 
have details abstracted. If the latter is the case, a mechanism is needed for 
answering user queries using graphs restricted to that user's access level. 
18 Sensitive data When provenance is used to capture data about the actions of the security layers, 
separation of functionality needs to be introduced to avoid inadvertently   
exposing sensitive data. One way of doing so is by providing token identifiers 
which can then be used to request detail from the security mechanism. 
19 Extensibility of 
queries 
Introduce mechanisms for dynamically adding new provenance queries to the 
software. 
20 Interactive 
querying 
Provenance data can be used to answer individual queries or create tabular and 
graphical reports, but added value can be obtained by exploiting the graph 
representation of provenance to support open-ended, investigative querying. 
21 Breaking 
abstraction 
When creating provenance queries, whether for atomic questions, or for 
navigating the provenance graph space, try to find queries that can be optimized 
by being directly formulated in the underlying query language and investigate 
whether the performance gain warrants this. 
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Cognitive Load and Visualizing Traceability Information 
It is assumed that traceability data can be represented by a causality graph, or DAG, 
that has been enriched with annotations to provide the complete information needed to trace 
an object back to its origin (Moreau, Freire, et al., 2008; Zhao et al., 2004). A standard 
graphical notation for provenance was introduced by the OPM in part to promote common 
tools and methods for the visual representation of provenance graphs (Moreau et al., 2011). In 
the e-sciences the causality graph is a common method for representing traceability, and 
supports accompanying methods for visualizing and browsing the graph (Simmhan et al., 
2005a). Within a traceability causality graph the nodes represent data items and the edges 
represent the dependency relationships, such as versions, mapping, or derivations (Acar et al., 
2010). The causality graph can also provide a data source to query against.  
Visual representations can manifest patterns of real-world phenomena (Huynh et al., 
2014) which might initiate further examination into the who, when, and why detailed 
provenance information. The ability to easily explore the entire traceability graph makes it 
easier for the users to answer many more interesting questions (Macko & Seltzer, 2011). 
Large causality graphs with many thousands of nodes are too large for users to navigate 
comfortably without mechanisms to simplify the content displayed. The traditional approach 
to traceability visualization shows only the relevant nodes, as specified by a filter, or as 
defined by a view. Graph visualizations have a number of properties that can be exploited 
when rendering a visualization. For example, position, size, color, edge weight, and 
application specific rules for how the properties influence the graph visualization (Collberg, 
Kobourov, Nagra, Pitts, & Wampler, 2003).  
Symbolic representations of data in a tabular representation facilitate the extraction of 
specific data items. Tables work well for representing discrete data values. Graphs provide 
spatial problem representations that topologically convey information about relationships in 
the data. Spatially represented data facilitates viewing at a glance without requiring each data 
point to be addressed independently. Graphs are particularly strong at assessing a problem as 
a whole, and tasks that require understanding relationships or making associations between 
data items (Vessey, 1991). Tabular presentations work well for tasks that require an accurate 
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interpretation of values. Graphs work well for tasks that require assessing time dependent 
patterns (Dickson, DeSanctis, & McBride, 1986).  
Huanga (2009) proposed a cognitive load construct within the context of graph 
visualizations that includes: (1) domain complexity, (2) data complexity, (3) task complexity, 
(4) visual complexity, (5) demographic complexity, (6) an indicator of the complexity of the 
data within the domain, and (7) time complexity. Huanga (2009) noted that higher levels of 
domain knowledge decreased the effort needed to understand the graph visualization of 
biology networks. When mismatches between data representation models and tasks require 
users to perform additional mental translations that increase the user’s cognitive load, task 
performance is expected to degrade. Degraded task performance can be measured by 
increased time to complete the task and increased probability of error. Higher performance 
occurs when the data representation models fit the task requirements (Goodhue, Klein, & 
March, 2000). 
 
 
47 
CHAPTER 3 
RESEARCH METHODOLOGY 
"Design science research is motivated by the desire to improve the environment by the 
introduction of new and innovative artifacts" (Simon, 1996). 
This research utilized the DSR paradigm as described in Simon (1996) and Hevner, 
March, Park, and Ram (2004). This research project applied the seven guidelines established 
for DSR in Hevner et al. (2004). Table 7 briefly describes how this research meets the each of 
the Hevner et al. (2004) DSR guidelines. In DSR the objective is to create and evaluate an IT 
artifact that explicitly addresses an organizational problem or opportunity, as noted in Hevner 
et al. (2004). The implementation of the IT artifact provides “proof by demonstration” 
(Nunamaker Jr & Chen, 1990), and shows the feasibility of both the design process and the 
final designed product (Hevner et al., 2004). 
 
Table 7. Based on Hevner et al. (2004) design science research guidelines (P. 83) 
Guideline Description 
Design as an Artifact The Trace-XML Framework for clinical research metadata traceability is the 
primary artifact created by this DSR project.  
Problem Relevance Trace-XML solves a real-world problem by extending the existing clinical 
research data standards in a way that can be (1) adopted as a future standard, 
(2) used by regulators to improve traceability within submissions, (3) used by 
clinical researchers to enhance data quality, and (3) used by software tool 
vendors seeking to enhance their product's support for the end-to-end clinical 
research data lifecycle. Traceability enhances the strength of clinical research 
analysis results by providing the source data and the processes used to 
determine the stated study results (Curcin et al., 2014). 
Design Evaluation In addition to passing a set of test cases, the Trace-XML framework was 
analytically evaluated using graph theory and traversal algorithms as discussed 
in Chapter 5. A qualitative study that used semi-structured interviews and 
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applied thematic analysis to evaluate the utility generated by Trace-XML is 
discussed in Chapter 6. 
Research Contributions The Trace-XML Framework and its associated IT artifacts are the primary 
research contributions of this DSR project. More specifically, the research 
contributions include the Trace-XML graph model, traceability algorithms, and 
Define-XML extension. 
Research Rigor The application of graph theory and the adaptation of specific graph traversal 
algorithms provide the theoretical foundation for Trace-XML. This theoretical 
foundation enables the development of traceability proofs and represents a 
rigorous mechanism to validate traceability.  
Design as a Search 
Process 
Trace-XML seeks to address current regulatory requirements and extends the 
existing data standards. Trace-XML adapts existing graph theory and traversal 
algorithms to support the requirements of clinical research data traceability. 
The development of Trace-XML evolved during numerous build-evaluate 
design cycles. 
Communication of the 
Research 
In addition to being the subject of this dissertation, this DSR project was 
presented in a paper at the 2017 AMIA Clinical Research Informatics 
conference, and an associated journal article is in progress.  
 
Build and evaluate are the two primary activities in DSR (March & Smith, 1995). 
Hevner (2007) describes that DSR cycles shown in Figure 10 that highlight a central design 
cycle. The design cycle iterates between the build-evaluate activities with the evaluation 
providing the feedback needed to refine the design for the next build iteration. This continues 
until finally a satisfactory design is realized. To more fully leverage the complementary 
nature of the build-evaluate cycle, this research project used a test-driven development (TDD) 
methodology where each iteration’s unit test scripts are developed prior to implementation as 
part of the build cycle. The evaluation cycle conducted a more rigorous system test that 
included testing the integration of all the application components. The formal evaluation will 
include the use of the theoretical foundations to prove that traceability has been established 
within the prototype implementation. It will also include a user evaluation to determine if the 
artifacts developed for this project improve the ability of clinical data experts understand the 
traceability metadata for a clinical trial. Semi-structured interviews from a panel of clinical 
data stakeholders will be conducted to attain the data needed to perform the user evaluation 
analysis. 
49 
 
Figure 10. Design science research cycles (Hevner, 2007) 
Traceability Framework High-level Requirements 
As part of the relevance cycle highlighted in Hevner (2007) and shown in Figure 10, a 
set of high-level requirements were identified for the clinical research data traceability 
environment. These requirements are listed in Table 8, and were provided as input to the 
build-evaluate cycle during the development of the Trace-XML artifacts. Each of the 
requirements listed below were covered by the final Trace-XML artifacts. 
 
Table 8. Traceability framework high-level requirements 
# Requirement 
1 The traceability model must support references to domain semantics, and existing data and domain models 
where available (Curcin et al., 2014; Johnson et al., 2014).  
2 A common vocabulary for expressing the semantics of provenance entities must be used (Curcin et al., 2014). 
3 The metadata traceability model must be layered to represent traceability information at multiple levels of 
abstraction (Curcin et al., 2014; Davidson & Freire, 2008). 
4 Traceability models must be capable of forming a single graph that describes the full history of any specific 
data element through all stages of the clinical research data lifecycle (Curcin et al., 2014). 
5 A query capability must exist to support the retrieval of detailed traceability information. This information 
may include metadata details on a specific data item, a tabular listing of items, or a trace back to the data 
item’s origin (Curcin et al., 2014). 
6 The traceability framework should represent traceability constructs using a common vocabulary to support 
distributed healthcare applications (Curcin et al., 2014). 
7 The traceability framework must provide the means to validate traceability as a means to assess data quality 
(FDA, 2016a). 
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# Requirement 
8 The traceability framework must provide a mechanism for dynamically adding new traceability queries 
(Curcin et al., 2014). 
9 The traceability framework must provide the information needed for a reviewer to understand the 
relationships between the analysis results, analysis datasets, tabulation datasets, and source data (FDA, 
2016a). 
10 The traceability framework must represent relationships between data elements in a standardized way (FDA, 
2016a).  
11 The traceability framework must be capable of identifying traceability gaps (Hume et al., 2016) 
12 The traceability framework must attempt to resolve traceability gaps using the available metadata. 
Artifact Design Table 
To document the Trace-XML high-level design a DSR artifact design table was 
created to (1) map the research objectives to the research gaps identified during the literature 
review, (2) to identify the theories that will be used to address the research objectives, (3) to 
list the high-level features that will apply the theory to address the research objective, and 
finally (4) to list how the features of the artifacts produced will be rigorously evaluated. The 
artifact design table is shown below in Table 9. 
 
Table 9. DSR artifact design table 
Research Gap Research Objectives Theory Artifact Features Evaluation  
Gaps exist in the 
computable 
traceability provided 
by the standard 
metadata models in 
the regulated clinical 
research domain. 
Computable 
traceability is not 
possible. (Davidson 
& Freire, 2008; 
Dootson, 2011; 
Hume et al., 2016; 
Miles et al., 2007; 
“Where is content 
missing?” 
 
Develop a 
traceability 
framework that 
identifies traceability 
gaps within clinical 
research study data. 
Graph theory and 
graph traversal 
algorithms 
(Sedgewick & Wayne, 
2011; 
Shankaranarayan et 
al., 2003) 
 
Causality graphs 
(Acar et al., 2010; 
Curcin et al., 2014; 
Moreau et al., 2011) 
 
IP-Maps (Chee et al., 
2014; 
Algorithm that 
identifies traceability 
gaps. The algorithm 
identifies missing 
edges or the 
relationships between 
metadata elements 
that represent data 
flows. The algorithm 
identifies both 
reachability and 
traceability failures. 
 
 
Develop proofs for 
reachability and 
traceability within the 
Trace-XML 
framework using 
graph theory and 
graph traversal 
algorithms 
(Shankaranarayan et 
al., 2003).  
 
Conduct a qualitative 
assessment of the 
utility of the 
algorithm 
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Research Gap Research Objectives Theory Artifact Features Evaluation  
van Valkenhoef et 
al., 2012) 
 
 
Shankaranarayanan, 
2005; 
Shankaranarayanan et 
al., 2000)  
implementations to 
determine the utility 
added to clinical 
research data experts 
(Guest, MacQueen, & 
Namey, 2011). 
 
Gaps exist in the 
semantics and 
metadata needed to 
express computable 
traceability in the 
standard metadata 
models in the 
regulated clinical 
research domain. 
(Davidson & Freire, 
2008; Dootson, 2011; 
Hume et al., 2016; 
Miles et al., 2007; 
van Valkenhoef et 
al., 2012) 
 
“What content is 
missing?” 
 
Within the 
traceability 
framework develop 
an algorithm that 
recommends the 
metadata content 
needed to resolve the 
traceability gaps, and 
extends the existing 
standards metadata 
sufficiently to 
express computable 
traceability.  
Graph difference 
algorithms 
(Archambault, 2009) 
 
XML schema, XML 
query languages, 
XML databases, and 
graph databases 
(Cheney, 2009; 
Curcin et al., 2014) 
 
IP-Maps 
(Shankaranarayanan, 
2005; 
Shankaranarayanan et 
al., 2000). 
 
 
Algorithm that 
recommends 
resolutions to the 
identified traceability 
gaps. 
 
The Trace-XML 
CDISC Define-XML 
extension to the 
standards metadata 
provides the 
additional semantics 
and metadata needed 
to create a graph 
model that supports 
computable 
traceability. 
 
Develop proofs for 
reachability and  
traceability, and 
completeness within 
the Trace-XML 
framework using 
graph theory and 
graph traversal 
algorithms 
(Shankaranarayan et 
al., 2003).  
 
Conduct a qualitative 
assessment of the 
utility of the 
algorithm 
implementations to 
determine the utility 
added to clinical 
research data experts 
(Guest et al., 2011). 
No capability exists 
to verify traceability 
completeness within 
clinical research 
study data (Davidson 
& Freire, 2008; 
Dootson, 2011; 
Hume et al., 2016; 
Miles et al., 2007; 
van Valkenhoef et 
al., 2012). 
 
“Is the content 
correct and 
complete?” 
 
Within the 
traceability 
framework develop 
algorithms that verify 
the correctness and 
completeness of the 
standards metadata to 
Graph theory and 
graph traversal 
algorithms 
(Sedgewick & Wayne, 
2011; 
Shankaranarayan et 
al., 2003) 
 
XML schema, 
schematron, XML 
query languages 
Algorithm that 
verifies traceability 
completeness after 
validating for 
correctness.  
Constraint rules 
verify correctness. 
Develop a proof for 
completeness within 
the Trace-XML 
framework using 
graph theory and 
graph traversal 
algorithms 
(Shankaranarayan et 
al., 2003).  
Conduct a qualitative 
assessment of the 
utility of the 
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Research Gap Research Objectives Theory Artifact Features Evaluation  
support computable 
traceability. 
(Cheney, 2009; 
Curcin et al., 2014) 
 
IP-Maps 
(Shankaranarayanan, 
2005; 
Shankaranarayanan et 
al., 2000). 
 
algorithm 
implementations to 
determine the utility 
added to clinical 
research data experts 
(Guest et al., 2011). 
 
Trace-XML Development  
Following the DSR methodology build and evaluate cycles (March & Smith, 1995), a 
prototype software application was developed in Java to implement Trace-XML including the 
creation of the traceability graph and the algorithms for querying and validating traceability. 
JDOM 2 was used to process the XML in the Java application. The BaseX 8.5.2 XML 
database engine XQuery 3.1 processor was used to implement the traceability query tool. The 
Define-XML extension was implemented in XML schema. The traceability graph is 
represented using the GraphML v1.0 schema. The final Trace-XML software artifacts 
rendered GraphML for two open-source graph visualization and editing tools: yEd v3.1.6 
(yWorks, 2017) and Gephi v0.9.1 (Bastian, Heymann, & Jacomy, 2009; Gephi, 2017).  
Trace-XML Layered Framework Implementation 
The Trace-XML Framework implementation consists of 3 layers: (1) the Information 
Product Map (IP-Map) model: a high-level view of the manufacturing process for creating an 
information product (IP); (2) the CDISC standards metadata: metadata describing the IPs, data 
elements, and computations at a detailed level of granularity; and (3) a graph model: 
traceability throughout the clinical research data lifecycle that supports traceability 
visualization, validation, and queries. Layer 1 applies the IP-Map research to use IPs to 
represent computable traceability within clinical research data at a higher level of abstraction.   
Layer 2 represents the detailed study metadata provided by the ODM and Define-XML files. 
This detailed study metadata maps into the higher-level IP-Map representation found in Layer 
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1 of the framework. Layer 3 includes the algorithms that generate the graph, identify any 
traceability gaps, and validate the completed graph. Generating the graph for Layer 3 
uncovered traceability gaps in the CDISC standards metadata in Layer 2. Trace-XML 
addresses these traceability gaps through the development of an extension to the Define-XML 
standard.  
Trace-XML Accessibility and License  
The Trace-XML software will be made available as open source under the Apache 
License, version 2.0. The system documentation and instructions on accessing and using the 
software are available on GitHub at https://github.com/swhume, and will also be made 
available at http://www.odm-review.com/ as well as http://www.cdisc.org.  
Evaluation 
The scientific evaluation of artifacts is the essence of information systems as DSR 
(Iivari, 2007).  DSR evaluation schemes can be artificial or naturalistic in nature (Venable, 
2006). Although the artifact will be evaluated in a demonstration environment, and not in a 
live clinical research project, it will use the metadata and data flows from the current industry 
standards as well as content from an actual study. As actual standards and study metadata will 
be used in the testing, the effectiveness will be evaluated using naturalistic test cases, while 
the process of creating and evaluating the traceability established within the Trace-XML 
framework will be performed in an artificial environment. As noted in Iivari (2007), the 
artifacts must be comprehensively tested in laboratory and experimental conditions prior to 
executing case or field studies. The evaluation should assess the artifact for utility and ensure 
it solves an identified problem within an organization’s technical infrastructure (Tremblay, 
Hevner, & Berndt, 2010).   
Hevner et al. (2004) provide five categories of design evaluation methods, including: 
(1) observational, (2) analytical, (3) experimental, (4) testing, and (5) descriptive. In addition 
to testing the artifact, the quality, efficacy, and utility of the artifacts in this DSR project will 
be confirmed by the analytical and observational evaluation methods.  
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Analytical Evaluation 
The analytical evaluation proves that reachability, traceability, and completeness are 
demonstrated within Trace-XML through the application of graph theory and specific 
traversal algorithms. The use of graph theory and graph traversal algorithms within the 
framework contributes significantly to the research rigor and the quality of the artifacts. The 
theoretical foundation of the artifact provides the basis for the claim that traceability has been 
established within the extended Trace-XML Framework, as well as the basis for the extension 
to the CDISC standards created as an artifact of this DSR project. Testing for traceability 
makes use of proofs established in Shankaranarayan et al. (2003), but applies them at the data 
element-level within a clinical study. The same basic algorithms work at multiple levels 
within the traceability framework. The analytical approach to evaluating the theoretical 
framework represents the most significant component of the evaluation plan. Chapter 5 
describes the analytical evaluation in detail and contains the details of the algorithms and their 
theoretical foundations. 
Observational Evaluation 
An observational evaluation was necessary to determine the utility of the Trace-XML 
Framework from a clinical research data expert’s perspective. Causality graphs are commonly 
used for traceability data representation in the e-sciences (Simmhan et al., 2005a, 2005b) as 
well as other domains (Moreau, 2010; Moreau, Groth, et al., 2008). However, no empirical 
evidence exists to support either the graph-based interface or the tabular interface as a better 
fit for the task of assessing the traceability of regulated clinical research data. The optimal 
approach to applying existing knowledge about graph visualizations, or when different 
representations are preferred, remains an open question (Carata et al., 2014). 
The observational evaluation approach consisted of demonstrating the artifact to 
clinical data experts and using semi-structured interviews to gather data to evaluate the utility 
of the artifacts for use in a field environment. Semi-structured interviews facilitated the 
examination of the individual expert’s understanding of traceability within the Trace-XML 
Framework. This provided access to the contextual issues regarding the utility of the 
framework for use in the field that would be otherwise difficult to access (Chee et al., 2014; 
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Yin, 2014). The interview method enabled personal contact with the participants, but 
eliminated the risk that a few participating experts dominate the interaction as can happen in 
focus groups (Chee et al., 2014). The observational utility and usability assessments 
complement the analytical evaluation and help ensure that the artifacts are solving real-world 
problems as experienced by the clinical research data experts. A pre-defined set of open-
ended questions were used for all interviews permitting the interviewer to probe into the 
details as needed to gain insights into themes that could influence future versions of the 
artifacts.  This approach permitted the respondent to share issues that might not have been 
considered during the development and evaluation of Trace-XML. 
The interpretive qualitative study used to assess the utility created by Trace-XML used 
the Applied Thematic Analysis (Guest et al., 2011) method. Thematic analysis was used to 
analyze the interview data. The design and results of the qualitative study are detailed in 
Chapter 6. 
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CHAPTER 4 
THE TRACE-XML FRAMEWORK 
Design Science Research Artifacts 
The primary artifact generated by this research is a clinical research data traceability 
framework named Trace-XML. Within this framework, artifacts contributing to the 
knowledge base include (1) the Trace-XML extension to the CDISC standards metadata that, 
when applied, provides the means to create a model that supports computable traceability; (2) 
the algorithms that identify the traceability gaps and validate that the resulting model supports 
traceability; and (3) a graph representation that provides the means to run traceability queries 
and visualize the traceability metadata. 
This research contributes an extension to the Define-XML CDISC standard that 
addresses the traceability gaps uncovered by the Trace-XML algorithms. It also contributes 
new recommended standards implementation practices that improve traceability 
completeness. IP-Maps have been used to evaluate data quality, and this research extends that 
work to examine traceability as a dimension of data quality at the level of granularity needed 
to support regulated clinical research. This research contributes the algorithms for remedying, 
validating, and querying traceability in the Trace-XML graphs.  
Traceability Framework Overview 
The Trace-XML Framework provides traceability across data from all phases of the 
clinical research data lifecycle, from data collection through analysis datasets. Trace-XML 
provides new full lifecycle, end-to-end traceability features, including (1) the ability to 
validate end-to-end traceability, (2) the ability to run end-to-end traceability queries, and (3) 
the ability to visualize end-to-end traceability. These new features provide a comprehensive 
view of study data traceability that combines existing CDISC standards metadata across files 
from different phases in the clinical research data lifecycle. This replaces today's siloed 
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approach to traceability that provides descriptive metadata within the context of one phase of 
the lifecycle, as shown in Figure 11.  
Each data lifecycle phase in Figure 11 has a CDISC XML file containing the 
metadata that describes the data for that particular state in the clinical research data lifecycle. 
The ADaM metadata exists in a Define-XML file, the SDTM metadata exists in a separate 
Define-XML file, and the CDASH metadata exists in an ODM file. Each XML metadata file 
exists independently of the others. Furthermore, each XML metadata file does not reference 
the metadata available from the other phases in the data lifecycle supporting the notion of a 
siloed approach to metadata traceability within the CDISC standards. Trace-XML creates 
new, full lifecycle traceability capabilities by enabling each of the separate XML metadata 
files to reference metadata in the other files, creating an integrated, full study lifecycle view of 
traceability. 
 
Figure 11. Trace-XML adds cross-lifecycle, study-level metadata traceability 
 
The Trace-XML Framework shown in Figure 12 consists of 3 layers: (1) the IP-Map 
model represents a high-level view of the manufacturing process for creating an IP; (2) the 
CDISC standards metadata models represent the IPs, data elements, and computations at a 
detailed level of granularity; and (3) a graph model represents traceability throughout the 
clinical research data lifecycle that supports traceability visualization, validation, and queries.  
The layers in the framework work together to provide a complete view of study-level 
traceability at increasing levels of detail. Each layer and its associated traceability 
visualizations address a different traceability assessment need.  
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Figure 12. 3-layered Trace-XML Framework conceptual diagram 
 
The purpose of each layer in the framework is summarized in Table 10. Each 
framework layer adapts existing technologies to represent the metadata describing full 
lifecycle traceability in the clinical research domain. Contributions of this research project 
include the specific technology adaptations or extensions developed to represent the metadata 
in the layered Trace-XML Framework, as well as the algorithms developed to work with layer 
3. 
 
Table 10. Trace-XML Framework layers 
Layer Model Purpose References 
1 
IP-Map 
models 
This layer adapts the IP-Map's conceptual 
visualization of an information product 
manufacturing process to aid reviewers in identifying 
how clinical data is being captured, transformed, 
validated, and stored throughout a study. This layer 
is useful for regulatory and other data reviewers to 
acquire a high-level understanding of the data inputs 
and processes used to create a resulting information 
product. By design, this layer does not provide 
enough detail to fully satisfy the traceability 
requirements for regulated clinical research. 
(Chee et al., 2011; Chee 
et al., 2014; 
Shankaranarayan et al., 
2003; 
Shankaranarayanan, 
2005; 
Shankaranarayanan et 
al., 2000) 
2 
CDISC 
metadata 
models 
This layer adapts the Define-XML standard through 
the Trace-XML extension. This layer provides the 
detailed study metadata as described by the CDISC 
ODM and Define-XML models. This metadata 
(CDISC, 2013a, 2013c; 
Hume et al., 2016) 
59 
Layer Model Purpose References 
describes the study artifacts, data elements, 
terminologies, and computational methods used in 
the study. The Define-XML files are required 
elements of a compliant regulatory submission to the 
FDA or PMDA. ODM and Define-XML are mature, 
widely used standards for representing clinical trial 
metadata. 
3 
Directed graph 
model 
This layer implements a digraph based on the ODM 
and Define-XML metadata models and applies the 
Trace-XML extension to generate the graph's 
directed edges. The digraph model is represented 
using the GraphML XML standard. The GraphML 
digraph for an entire study enables traceability 
validation, visualization, and queries. The GraphML 
files can be visualized using multiple open source 
software applications. 
(Sedgewick & Wayne, 
2011; Shankaranarayan 
et al., 2003) 
 
Layer 1 Overview: The IP-Map Layer. Layer 1 applies the IP-Map research to 
represent computable traceability within clinical research data at a higher level of abstraction 
(Shankaranarayan et al., 2003). IP-Map provides a conceptual visualization of an IP’s 
manufacturing process that aids information consumers in identifying how data is being 
captured, transformed, stored, and utilized prior to becoming available to the decision maker 
(Chee et al., 2011; Shankaranarayanan et al., 2000). This research uses IP-Maps as an analysis 
tool to support traceability as a dimension of data quality. In the context of a clinical trial, and 
particularly a regulatory submission, IPs include the analysis datasets and analysis results that 
must be understood by a regulatory reviewer. For example, it is particularly important that 
regulatory reviewers understand the traceability for study endpoints and the efficacy datasets. 
The IP-Map layer provides diagrams depicting the data flow from source data to final IP. The 
FDA has requested diagrams to show the “electronic data flow” when electronic health 
records (EHR) are used as source data in clinical research (FDA, 2016b), and IP-Maps can 
represent this information. IP-Maps were developed as a data quality tool to improve data 
believability and ease of understanding (Chee et al., 2014) by displaying an information 
manufacturing process that includes the transformations and quality checks that precede the 
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creation of an IP. The addition of the data transformations and quality check processes to a 
basic data flow diagram should be of interest to regulatory and other reviewers with a special 
interest in data quality. 
Figure 13 shows a partial IP-Map for the creation of the CDISC ADaM Subject Level 
Analysis Dataset (ADSL) that includes EHR data sources as well as data extraction, cleaning, 
transformation, and validation processes. Figure 13 also represents the flow of the data from 
raw sources to a final ADSL dataset IP. The IP-Map is used to establish reachability and 
traceability as elements of data quality within the IP manufacturing process (Shankaranarayan 
et al., 2003).  
 
Figure 13. Example layer 1 partial IP-Map for ADSL 
 
Layers 1 and 2 of the Trace-XML Framework are integrated in both directions, layer 1 
references layer 2 and layer 2 references layer 1. Each block in the IP-Map contains metadata 
that includes a description of the block and specific metadata that references the layer 2 
metadata XML files. The CDISC specific metadata models provided by layer 2 in the 
framework can explicitly reference the layer 1 IP-Map components using the Alias element, 
as shown in Figure 14. 
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Figure 14. Using Alias to link a Define-XML domain to an IP-Map block 
 
Layer 2 Overview: The CDISC Standards Metadata Layer. Layer 2 represents the 
detailed study metadata provided by the CDISC ODM and Define-XML metadata files 
created as part of a study. These files contain a complete description of the study artifacts, 
such as CRFs and datasets, as well as the detailed data element definitions and the methods 
used for derivations and transformations of the data. Figure 14 shows a Define-XML v2.0 
fragment that represents a partial demographics dataset. The detailed metadata maps into the 
higher-level IP-Map representation found in layer 1 of the framework and provides inputs into 
the graph model in layer 3. In this research, the CDISC standards provide the domain models 
and metadata for the data element level traceability, and this benefits users as these semantics 
are known within the clinical research domain (Curcin et al., 2014; Johnson et al., 2014). 
The current versions of ODM and Define-XML provide descriptive metadata in 
support of traceability, but do not include the metadata needed to provide computable 
traceability across the data lifecycle as shown in Figure 11. For example, Define-XML for 
the SDTM standard provides a link to a PDF-based image of an annotated CRF, but cannot 
<!-- Dataset Definition (DM) --> 
<ItemGroupDef OID="SDTM.IG.DM" 
        Domain="DM" Name="DM" Repeating="No" IsReferenceData="No" 
        SASDatasetName="DM" Purpose="Tabulation"  
 def:Structure="One record per subject" def:Class="SPECIAL PURPOSE" 
        def:CommentOID="COM.DOMAIN.DM" def:ArchiveLocationID="LF.DM"> 
    <Description> 
      <TranslatedText xml:lang="en">Demographics</TranslatedText> 
    </Description> 
    <ItemRef ItemOID="SDTM.IT.STUDYID" OrderNumber="1"  
Mandatory="Yes" KeySequence="1"/> 
    <ItemRef ItemOID="SDTM.IT.DM.DOMAIN" OrderNumber="2" Mandatory="Yes"/> 
    <ItemRef ItemOID="SDTM.IT.USUBJID" OrderNumber="3"  
Mandatory="Yes" KeySequence="2" MethodOID="SDTM.MT.USUBJID"/> 
    <ItemRef ItemOID="SDTM.IT.SUBJID" OrderNumber="4" Mandatory="Yes"/> 
    <ItemRef ItemOID="SDTM.IT.SITEID" OrderNumber="7" Mandatory="Yes"/> 
    <ItemRef ItemOID="SDTM.IT.DM.COUNTRY" OrderNumber="14" Mandatory="Yes"/> 
    <ItemRef ItemOID="SDTM.IT.DM.RFSTDTC" OrderNumber="15"  
Mandatory="No" MethodOID="SDTM.MT.RFSTDTC"/> 
    <Alias Context="ADSL-IP-Map" Name="STO1" /> 
    <def:leaf ID="LF.DM" xlink:href="dm.xpt"> 
        <def:title>dm.xpt</def:title> 
    </def:leaf> 
</ItemGroupDef> 
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display the full lifecycle of a variable. The Trace-XML Define-XML extension created as part 
of this research project extends the existing standards to include explicit references to the 
source data and methods such that a directed graph can be created in layer 3 of the 
framework. The extension augments the metadata definition of each variable to include 
references to its immediate predecessor variables defined elsewhere within the study 
metadata. This source reference metadata is typically located in another Define-XML or 
ODM file that represents the previous stage in the clinical research data lifecycle. The layer 2 
metadata is displayed within the framework using stylesheets to create a data dictionary style 
view, the same view provided as part of a regulatory submission. Layer 2 of the Trace-XML 
Framework integrates views of traceability generated using the layer 3 graph that presents the 
full data lifecycle trace for each variable. Integrating layer 3 views into the style sheet used 
for regulatory submissions of Define-XML promotes the alignment of Trace-XML artifacts 
with the existing standards. 
Layer 3 Overview: The Graph Layer. Layer 3 includes the algorithms that generate 
the directed graph, identify the traceability gaps, and validate the completed graph. The forms, 
datasets, variables, and computational methods metadata provided by the CDISC models in 
layer 2 become the nodes in the layer 3 graph. Each graph node includes the CDISC metadata 
details drawn from layer 2. The flow of the directed graph matches the flow provided in the 
IP-Maps in layer 1. Generating the graph using the Define-XML and ODM metadata 
uncovered gaps in the layer 2 metadata needed to generate the complete set of graph edges. 
These gaps were addressed through the Trace-XML extension to the Define-XML standards 
metadata that added the explicit references to source variables. These source variable 
references were used to generate the directed edges in the full lifecycle graph. Once the 
directed graph has been generated the data flow for a study can be visualized as shown in 
Figure 15.  
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Figure 15. Full lifecycle Trace-XML graph using the tree layout 
 
Validation of CDISC standards metadata beyond mere XML schema validation has 
become a critical step in the regulatory submission process. Using the directed graph and 
depth-first search (DFS) based algorithms provided by Trace-XML, metadata validation can 
be extended to cover traceability across the full clinical research data lifecycle to improve 
data integrity. When Trace-XML identifies an unexpected gap in reachability or traceability a 
report can be generated to show the unexpected gaps. The Unreachable Nodes report fragment 
shown in Figure 16 shows two nodes that are unexpectedly unreachable in a Trace-XML 
graph. When valid traceability exists across the study lifecycle, no unexpected reachability 
gaps should exist.  
 
 
Figure 16. Trace-XML Unreachable Nodes report fragment 
 
Once the software confirms that the graph is valid, a Trace-XML query traces a 
variable back to its original source to include any transformations or derivations that impact 
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the data. The results of a Trace-XML query show the full lifecycle for a variable and include 
metadata retrieved from the layer 2 XML files. For example, the Trace-Query report fragment 
in Figure 17 shows each step of the trace from analysis variable back to the original data 
collection source, including the detailed metadata describing the content in each step. This 
Trace-Query output uses the Trace-XML graph and includes metadata details drawn from 
three separate XML files: (1) the ADaM Define-XML file, (2) the SDTM Define-XML file, 
and (3) the CDASH ODM file. 
 
 
Figure 17. Example Trace-Query output for the ADSL SEX variable 
 
Trace-XML Application Overview. In addition to the Trace-XML Define-XML 
extension, the Trace-XML application consists of the three primary software applications 
listed in Table 11. These applications were developed explicitly for Trace-XML in Java and 
represent a significant part of the overall Trace-XML artifacts developed as part of this 
research project. See Table 15 for a list identifying each software component developed as 
part of the applications summarized in Table 11. 
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Table 11. Main Trace-XML Framework software applications 
Software Application Description 
TraceXML The Trace-XML application uses the metadata files provided in layer 2 with the 
Trace-XML Define-XML extension to generate the full lifecycle graph in the 
GraphML standard. This graph provides computable traceability. Trace-XML 
validates the graph for reachability and traceability and reports any gaps found. The 
GraphML graph can be visualized or analyzed using several open source software 
tools that support the graph standard. 
TraceQuery The Trace-Query application generates trace data or a report for any given node in 
the graph generated by Trace-XML. The query returns the full trace for a node that 
includes every step in the study data lifecycle up to that point. The graph nodes can 
be variables, methods, forms, sub-forms, or datasets. The report can be generated 
for any 1 variable, or a set of variables.  
TraceKB The Trace-KB application creates a knowledge base of edge metadata that can be 
used to generate the source reference metadata included in the Trace-XML Define-
XML extension. This application uses CDISC standards content pulled from the 
SHARE MDR to populate the knowledge base. Not all the required edge metadata 
is available from the CDISC standards, and sponsors interested in generating the 
Trace-XML extension content will need to supplement the knowledge base with 
metadata from their own mapping applications or organizational standards. 
  
Trace-XML: An Integrated Framework 
The 3 layers of the Trace-XML Framework are integrated to provide a comprehensive 
view of traceability at increasing levels of detail as shown in Figure 12 and described in 
Table 10. The data flow within the clinical research lifecycle, from data collection through 
analysis datasets, is represented by directed edges within the graph. Tracing a variable’s 
lineage requires following these edges backwards from analysis content back to the source of 
the collected data. The Trace-XML Framework saves the graph as XML using the standard 
GraphML format. GraphML is supported by several open source software tools for viewing, 
filtering, and analyzing the resulting graph. Figure 18 shows the traceability for the ADaM 
ABLFL (vital signs analysis baseline flag) variable in a predecessor graph fragment created 
using the yEd (yWorks, 2017) software. Figure 18 shows an ADAM.IT.VS.ABLFL variable 
that can be traced back through the method that derives it, ADAM.METHOD.VABLFL, 
66 
through to the original data collection variable, ODM.ITEM.VISIT, on the vital signs CRF, 
ODM.FORM.VS. 
 
Figure 18. Trace-XML predecessor traceability graph generated using yEd 
 
Layering enables the framework to represent traceability at multiple levels of 
abstraction. The hierarchical nature of the framework provides data reviewers with a high-
level, abstract view of the entire information manufacturing process in layer 1 that is 
integrated with increasingly detailed views of traceability in the subsequent layers. Trace-
XML’s hierarchical traceability framework fosters an improved understanding for each IP by 
permitting reviewers to seek additional traceability details as needed to answer specific 
questions about individual data elements (Chee et al., 2011).  Trace-XML provides a more 
comprehensive assessment of traceability by integrating the conceptual layer, the clinical 
study artifact metadata layer, and a data-flow or graph layer (Chee et al., 2014). 
Creating framework layers that integrate metadata generated in each phase of the data 
lifecycle creates a new, integrated view of metadata. Today’s standards provide views of one 
phase of the lifecycle at a time and at one level of detail. By integrating the 3 layers of the 
framework and covering the entire lifecycle for a study, Trace-XML provides additional 
traceability metadata along two different dimensions. Figure 19 shows both dimensions of 
traceability created by the Trace-XML Framework. On the vertical dimension, the Trace-
XML Framework provides increasing levels of detail from the IP-Maps at layer 1 to the 
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study-level digraph at level 3. On the horizontal dimension, the Trace-XML Framework 
connects each phase of the clinical research data lifecycle into a single view. Figure 19 shows 
the horizontal dimension representing 3 phases of the clinical research data lifecycle as 
represented by their CDISC content standards. Integrating these dimensions creates a more 
complete and diverse representation of study metadata traceability.  
 
Figure 19. Trace-XML Framework creates new dimensions of traceability 
 
In Trace-XML the CDISC standards provide the domain models and metadata for the 
data element level traceability, and these benefit users as the semantics are known within the 
regulated clinical research domain. However, computable traceability across the clinical 
research lifecycle is not possible using the current CDISC standards because the traceability 
metadata provided in the Origin element provides only descriptive metadata used to identify 
the prior step in the process. Therefore, a Trace-XML extension to Define-XML was 
developed to include specific references to source variables found in a study’s Define-XML 
and ODM files.  The new Trace and TraceItem elements shown in Figure 20 contain the 
source variable references and use the trc namespace prefix that has been designated to 
identify Trace-XML extension content. The leafID element provides a reference to the ODM 
or Define-XML file containing the reference and the ItemOID element contains the reference 
to the source variable. Optional identifying information can also be provided in TraceItem, 
including ItemGroupOID and FormOID attributes used to further constrain the ItemOID 
68 
source reference. 
 
Figure 20. Example Trace-XML extension shown with the trc namespace prefix 
 
For example, although an ItemOID identifier may reference a unique ItemDef element, 
that same ItemDef may appear in many ItemGroupDefs or FormDefs leading the trace to 
include multiple elements containing the source ItemDef. If the source of an ItemDef was a 
single instance of that variable, then referencing only the containing ItemGroupDef and 
FormDef elements provides a more accurate and simple trace. 
The ability to explicitly reference source variables enables the Trace-XML software to 
generate the edges that connect the variables, computational methods, datasets, sub-forms, 
and forms into a graph representation. These references integrate the study metadata across 
the various stages in the clinical research data lifecycle. The ODM and Define-XML content 
provide the variables, computational methods, datasets, sub-forms, and forms that become the 
nodes in the graph. The source references for each variable provided by the Trace-XML 
extension are added to the Origin element to support the instantiation of a directed edge 
between the source and the target nodes. The data flow within the clinical research lifecycle, 
from data collection through analysis datasets, is represented by directed edges within the 
graph. Any derivation or transformation that impacts the variable is also represented in the 
graph. Tracing a variable’s lineage requires following these edges from analysis content back 
to the data collection metadata.  
Figure 21 shows a hierarchical visualization of a Trace-XML graph fragment for a 
study lifecycle that includes data collection, standardized tabulations, and analysis datasets. 
This example fragment highlights the demographic domain and shows a relatively small 
<ItemDef OID="SDTM.IT.USUBJID" Name="USUBJID" DataType="text" Length="30" SAS> 
    <Description> 
      <TranslatedText xml:lang="en">Unique Subject Identifier</TranslatedText> 
    </Description> 
    <def:Origin Type="Derived"> 
        <trc:Trace> 
            <trc:TraceItem leafID="LF.ODM" ItemOID="ODM.IT.Common.StudyID"/>  
            <trc:TraceItem leafID="LF.ODM" ItemOID="ODM.IT.Common.SubjectID"/> 
        </trc:Trace>              
    </def:Origin> 
</ItemDef> 
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portion of a complete study graph that might typically include over 20 domains. Visualization 
tools, such as the yEd software used to render Figure 21, support the graph navigation and 
partitioning needed to analyze large graphs. This graph fragment shows the directed edges 
that connect nodes within one phase of the lifecycle, say connecting the SEX and RACE 
variables to the demographic sub-form (ODM.IG.DM), as well as connecting nodes across 
different phases of the lifecycle. Figure 21 shows the SEX variable with directed edges 
connecting the CDASH SEX variable to the SDTM SEX variable and the SDTM SEX 
variable to the ADaM SEX variable. Additional directed edges show that the SDTM SEX 
variable exists in the SDTM demographics dataset (SDTM.IG.DM), and the ADaM SEX 
variable exists within the subject-level analysis dataset (ADAM.ADSL).  
 
Figure 21. Full lifecycle Trace-XML graph fragment in a hierarchical layout 
 
Each node on the graph can be opened to reveal the detailed metadata pulled from the 
ODM or Define-XML content, such as a description of an algorithm used to transform the 
variable. For example, Figure 22 shows another predecessor graph generated by the yEd 
software with the metadata details for the selected node displayed on the right in the 
properties window. These details are taken directly from the Define-XML, and the details 
available in the graph are limited by the content provided in the Define-XML file. 
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Figure 22. A predecessor graph showing the metadata details for a node 
 
A subset of the metadata needed to create the edges required to generate an integrated 
digraph was retrieved using the Trace-KB component of the Trace-XML Framework. Trace-
KB generates a knowledge base of the relationships needed to connect the XML metadata 
across the phases of the clinical research data lifecycle. Trace-KB retrieves these metadata 
relationships from the SHARE MDR Application Programming Interface (API) (CDISC, 
2015). When the CDISC CDASH standards are used the SHARE metadata can be applied by 
the Trace-KB software to automatically generate the extended source reference metadata 
required by the Define-XML extension. Figure 23 shows a report of the edges added to a 
Define-XML file using the Trace-XML extension to represent missing edges detected by 
Trace-KB. The edge content was retrieved from SHARE using the API and inserted into the 
Define-XML file the Trace-KB application. The report in Figure 23 lists the status as 
"Unconfirmed" meaning that the automated content generation by Trace-KB should be 
reviewed before published as final. 
 
 
Figure 23. Trace-XML edges added to Define-XML using SHARE content 
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Establishing Traceability Using Trace-XML 
Reachability must be established to prove traceability exists within the graph 
generated from the ODM and Define-XML files. Given the directed graph Ga, any node m is 
reachable from node n in Ga if there exists a directed path from n to m. A DFS algorithm for 
digraphs will identify all and only those nodes reachable from a given node n in the digraph 
Ga (Sedgewick & Wayne, 2011; Shankaranarayan et al., 2003).  Nodes that cannot be reached, 
but are expected to be reachable, are flagged as potential validation issues. Nodes with an 
Origin Type of “CRF”, “Derived”, and “Predecessor” must be reachable to be valid. The 
reachability test proceeds end-to-end across the clinical research lifecycle. The examples and 
tests developed for this research project demonstrate reachability that starts with the data 
collection CRF content in an ODM file, connects to nodes in a standardized tabulation 
Define-XML file, which in turn connects to nodes in an analysis Define-XML file. Once 
reachability has been established, it can be shown that if node m is reachable from node n, 
then node n is traceable from node m. Thus, achieving reachability for the nodes in Ga asserts 
that traceability also exists (Shankaranarayan et al., 2003). 
Once traceability has been confirmed, the full trace of any individual variable or node 
can be shown in a report that returns the basic metadata for each node. The Trace-XML query 
report generated by the Trace-Query application takes as input the unique identifier of the 
variable, or node, of interest and returns every connected node that precedes it. The Trace-
XML digraph with confirmed traceability makes this feasible. Trace-Query uses XQuery to 
return the metadata for each preceding node in the trace. The metadata shown in Table 12 
lists a subset of the information returned from a traceability query of the Pooled Site Group 1 
analysis variable. The actual results include more details, such as a description of the 
computational method listed in row #3, than are shown in Table 12.  
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Table 12. Example Trace-XML query results for the Pooled Site Group 1 variable 
# OID Phase Element Type Description 
1 ADAM.IT.ADSL.SITEGR1 Analysis ItemDef Variable Pooled site group 
1  
2 ADAM.IG.ADSL Analysis ItemGroupDef Dataset Subject level 
analysis dataset 
3 ADAM.MT.ADSL.SITEGR1 Analysis MethodDef Derivation Computation 
method 
4 SDTM.IT.SITEID Tabulation ItemDef Variable Study site 
identifier 
5 SDTM.IG.DM Tabulation ItemGroupDef Dataset Demographics 
dataset 
6 ODM.IT.COMMON.SITEID Data Collection ItemDef Variable Study site 
identifier 
7 ODM.IG.COMMON Data Collection ItemGroupDef Sub-form Common 
variables 
8 ODM.F.DM Data Collection FormDef CRF Demographics 
form 
 
A hyperlink to an HTML rendering of each variable’s Trace-XML query can be 
included in the output generated by the Define-XML stylesheet to make reviewing traceability 
easier for reviewers and decision makers. Figure 24 shows a partial view of an ADaM 
Define-XML that lists the vital signs analysis dataset ADVS with links to the individual 
variable traceability queries shown in the Source/Derivation/Comment column. These links 
provide data reviewers access to the detailed traceability information returned by a Trace-
Query query that reaches back to the original source variable. 
73 
 
Figure 24. Links to trace queries added to the Define-XML Source column 
 
Using the graph and DFS-based algorithms provided by Trace-XML, metadata 
validation can be extended beyond individual Define-XML documents to cover the full 
clinical research data lifecycle as a means to improve data integrity. Using Trace-XML, the 
ODM and multiple Define-XML documents may be validated as one study to ensure end-to-
end validity across the clinical research data lifecycle. Unreachable or untraceable nodes may 
be reported as validation errors so that the Define-XML or ODM files can be corrected to 
more accurately reflect the complete data flow through the lifecycle. Figure 25 shows a 
partial list of unreachable nodes generated by Trace-XML. The SDTM.IT.DM.ETHNIC and 
ADAM.IT.ADSL.ETHNIC variables are flagged as unexpectedly unreachable nodes. With 
Origin values of "CRF" and "Predecessor", respectively, these nodes are expected to be 
reachable within the Trace-XML graph, and these variables represent a validation issue for 
this study. In this case, the Trace-XML extension content for the SDTM.IT.DM.ETHNIC 
variable was removed from the SDTM Define-XML causing the validation issue. 
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Figure 25. Report showing unexpectedly unreachable nodes in a Trace-XML graph 
 
The GraphML standard used by Trace-XML can be rendered or analyzed using a 
number of open-source software tools, and Trace-XML can be configured to include 
GraphML extensions used by specific software packages. Open-source software tools such as 
yEd and Gephi provide alternative ways of conducting exploratory metadata analysis using 
visual analytics to quickly access how all the variables used within a study are related to one 
another. These tools provide another mechanism for assessing traceability within a study. 
They generate a wide variety of visualization layouts based on the same study graph to suit 
specific exploratory analysis preferences. These tools also generate graph metrics useful for 
analyzing and comparing study graphs. The graph shown in Figure 26 was created using the 
yEd software using the directed tree layout. Large, full lifecycle graphs are useful for 
exploring high-level data flows and permit a reviewer to zoom in on a graph fragment for a 
more detailed analysis. 
 
Figure 26. Full lifecycle Trace-XML graph in a directed tree layout 
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Visual Assessment of Traceability using Graph Visualizations 
After the gaps in the IP-Grapha were identified and resolved, and the metadata 
standards were enhanced with the additional metadata, the IP-Map was re-instantiated and 
evaluated for reachability, traceability, and completeness. The evaluation process used the 
same algorithms as previously described with the expectation that the previously identified 
gaps had been resolved. After the algorithms provided the evidence of traceability and 
completeness, the software prototype generated a graph representation from the metadata to 
provide the traceability query capability and the graph visualization. The graph representation 
of the CDISC standards metadata is a contribution of this research.  
The graph traceability queries can be used to test individual variables for traceability. 
The query returns every node in the trace back to its source, and missing or additional nodes 
in the trace can be identified when compared to the expected results. Rendering traceability 
graphs visually provides the means to explore traceability and is another means of identifying 
traceability issues. For example, the graphs in Figure 27 show an organic layout rendered by 
the yEd software for a test study. This layout shows that certain methods, instantiated as blue 
nodes, had outputs without inputs. Although this scenario is possible, in this case it 
highlighted errors in the test study metadata. The graph on the right in Figure 27 shows the 
graph rendered after the corrections to the test study have been applied. 
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Figure 27. Using graph visualization to identify traceability gaps 
Traceability can also be visually assessed using the generated graph by selecting a 
node from the full graph and generating the predecessor sub-graph as was shown in Figure 
22. This view provides a complete view of traceability for the selected variable, in this case 
the vital signs analysis baseline flag. The ODM and Define-XML node identifiers are listed to 
the left of the predecessor graph and the metadata details for the selected node are shown on 
the right. 
Summary of the Trace-XML Traceability Rules 
This chapter has described the Trace-XML Framework and how it achieves 
traceability using CDISC standard metadata. It also described a number of Trace-XML 
specific traceability rules. These rules are summarized in Table 13. These traceability rules 
describe specific detailed requirements implemented in the Trace-XML prototype to generate 
the trace graph. 
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Table 13. Summary of Trace-XML specific traceability rules 
# Rule Definition 
1  OIDs must be unique within a 
study 
The OID, or identifier, for an element referenced by a TraceItem 
must be unique within the context of the study.  
2  Zero or more TraceItem 
elements may be used to 
identify the source variables 
An ItemDef variable may provide 0, 1, or n TraceItem elements as 
sources. Not all Origin Type's support traceability, as is noted in 
subsequent rules, and non-traceable origin type variables will have 0 
TraceItem elements. Many variables take their source from one 
variable, oftentimes as a carry-over from the previous phase in the 
clinical research data lifecycle, and these variables will include one 
TraceItem element. In cases where a variable references a 
MethodDef, that method may take multiple source variables as its 
input. Those input variables become TraceItem elements included in 
the ItemDef that receives the result of the MethodDef element's 
transformation or derivation. 
3  Variables with multiple 
TraceItem sources must 
reference a MethodDef 
When an ItemDef has multiple TraceItem elements, an ItemRef to 
that ItemDef must reference a MethodDef. The TraceItem elements 
become the inputs to the MethodDef. The method either transforms 
the inputs or uses the inputs in a derivation such that the output of 
the method provides the source for the ItemDef. 
4  Origin Type="CRF" variables 
require a TraceItem 
A variable with Origin Type="CRF" must include a TraceItem 
element that references the source variable. This variable must be 
reachable from its source. 
5  Origin Type="Derived" 
variables require a TraceItem 
A variable with Origin Type="Derived" must have an associated 
MethodDef, and must include the TraceItem elements that reference 
the source variables. These source variables become inputs to the 
MethodDef, and the output of the MethodDef becomes the input to 
the "Derived" variable. Alternatively, a MethodDef may take no 
source variable parameters and in this case Origin includes the 
attribute trc:NoTraceItems="Yes". 
6  Origin Type="Predecessor" 
variables require a TraceItem 
A variable with Origin Type="Predecessor" must include a 
TraceItem element that references the source variable. This variable 
must be reachable from its source.  
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# Rule Definition 
7  Origin Types in ["Protocol", 
"Assigned", "eDT"] must not 
include a TraceItem 
No traceability is expected for these variables based on the Origin 
Type. They are tested for traceability only since reachability will not 
exist, and these variables are expected to terminate the trace. 
8  Derived variables referencing a 
MethodDef without input 
parameters must specify 
NoTraceItems 
When a MethodDef referenced by a "Derived" variable does not 
define input parameters, then the Origin must set the attribute 
NoTraceItems="Yes" to indicate that there will be no arguments 
referenced as source variable inputs to the method. This variable is 
tested for traceability only since reachability will not exist beyond 
the MethodDef due to the lack of source argument inputs. 
9  Origin Type="Assigned" 
variables require a comment 
A variable with an "Assigned" Origin Type must have an associated 
CommentDef. This is checked by the conformance rules and is not 
part of the current version of the traceability graph. 
10  MethodDef elements may not 
be reachable 
MethodDef elements may not be reachable.  MethodDef elements 
that are referenced by at least one variable are traceable. 
11  FormDef and ItemGroupDef 
elements are not reachable 
ItemGroupDef and FormDef elements are not reachable. 
ItemGroupDef and FormDef elements are traceable if they reference 
at least one variable.  
12  FormDef, ItemGroupDef, and 
ValueListDef elements 
reference the variable nodes 
included in the graph 
The trace graph is implemented by tracing variables defined as part 
of ItemGroupDef and ValueListDef elements. ItemDef elements not 
referenced by an ItemGroupDef or ValueListDef are not included in 
the trace graph. Within ODM only, ItemGroupDef elements must be 
referenced by a FormDef element to be included in the trace graph. 
13  ValueListDef elements are not 
graph nodes 
ValueListDef elements are processed when referenced by a variable, 
but are not added as nodes on the trace graph. 
14  ItemDef elements referenced by 
a ValueListDef element are 
reachable and traceable 
The ItemDef elements referenced by a ValueListDef should include 
the Origin element, as well as TraceItem elements where appropriate 
based on the value of the Origin Type attribute. In Define-XML, it is 
appropriate to include a traceable Origin Type on the ItemDef that 
references the ValueListDef. However, in Trace-XML it is more 
accurate to include the traceable Origin Type and TraceItem 
elements on the value level ItemDef.  
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# Rule Definition 
15  Variables with ValueLists must 
not include a TraceItem 
ItemDef elements that reference a ValueListDef should not 
themselves include a traceable Origin Type as the traceability should 
be defined by the value list ItemDef elements. ItemDef elements that 
include a ValueListDef may use an Origin Type="Assigned", and the 
assignment will be provided by the value list. 
16  Variables that reference a 
ValueListDef must not 
reference a MethodDef  
Items may include a reference to a MethodDef or to a ValueListDef, 
but not both. MethodDef elements can be referenced from the 
ItemRef elements that are defined within a ValueListDef, and in this 
way methods can be referenced from a variable that has a value list 
as part of its definition. 
17 A variable may reference 
source variables from the same 
lifecycle phase 
Variables in one clinical research lifecycle phase may reference 
other variables in the same phase, as well as variables in previous 
lifecycle phases. For example, an ADaM ItemDef may include a 
TraceItem that references another ADaM ItemDef. The Trace-XML 
algorithms back track to find references to source variables that may 
not have been added to the graph when the original ItemDef is 
processed. 
 
Trace-XML graphs are variable-centric meaning that traceability exists between 
variables, or ItemDef elements, and therefore many graph edges connect one variable to 
another. In the case of value level metadata, the value level ItemDef functions as a virtual 
variable within the graph. Trace-XML graph nodes are created using ItemDef, MethodDef, 
ItemGroupDef, and FormDef elements. MethodDef, FormDef, and ItemGroupDef elements 
may not be reachable in the traceability graph due to the ItemDef-centric nature of the graph. 
However, each of these node types is traceable since they have relationships to variables, such 
as functioning as a collection element to organize variables into a CRF or dataset. 
Trace-Query also adheres to requirements that dictate how the trace query is displayed 
in a tabular report format. Trace-Query executes a recursive DFS search on the Trace-XML 
graph, and this search returns the nodes in an order that matches the matches the graph 
traversal, but may not seem correct when the nodes are listed in a sequential report. The 
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Trace-Query display rules, listed in Table 14, adjust the nodes returned from the query to 
better suit the needs of a traceability report. 
 
Table 14. Summary of Trace-Query display rules 
# Rule Definition 
1  Redundant nodes are removed Redundant nodes are removed so that each node is displayed only 
once. For example, two different variables may be a part of the same 
ItemGroup or two ItemGroup elements may be a part of the same 
form, but in each case the element is displayed only once per report.  
2  Nodes are ordered by lifecycle 
phase 
The nodes in the report are grouped by clinical research lifecycle 
phase. In cases where a variable has multiple inputs from different 
lifecycle phases, content from the different phases may be 
interleaved in the sequential query results. Lifecycle phase grouping 
ensures that analysis content comes before tabulation content which 
comes before data collection content in the query report. However, it 
is important to note that within each lifecycle phase the nodes 
remain in graph traversal order.  
3  Fully qualified TraceItem 
elements filter unwanted 
ItemGroup or FormDef 
elements 
A fully qualified TraceItem element includes the ItemGroupOID 
and, if relevant, the FormOID in addition to the ItemOID. For the 
tabulation and data collection phases, these additional references 
work as a filter and eliminate ItemGroup and FormDef elements that 
are not referenced by a TraceItem. For example, this filter eliminates 
the case where a common ItemGroupDef containing key variables, 
such as SiteID and SubjectID, is referenced in many forms, but the 
trace should only display one specific form. This filter is optional.  
 
Technologies Used in the Prototype Implementation 
The prototype software application was developed in Java to implement Trace-XML 
including the creation of the traceability graph and the algorithms for querying and validating 
traceability while identifying any gaps. JDOM 2 was used to process the XML in the Java 
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application. The BaseX 8.5.2 XML database engine XQuery 3.1 processor was used to 
implement the traceability query tool. The Define-XML extension was implemented in XML 
schema. The CDASH and SDTM standards were retrieved from the CDISC SHARE MDR, as 
were the CDASH to SDTM mapping relationships. The traceability graph is represented using 
the GraphML v1.0 schema. The Trace-XML prototype discussed in this paper rendered 
GraphML for two open-source graph visualization and editing tools: yEd v3.1.6 and Gephi 
v0.9.1. A detailed listing of the source code files created as part of the Trace-XML prototype 
are listed in Table 15. 
 
Table 15.  Prototype implementation source code inventory 
Source File 
(Application) 
Type Description 
Tracexml.java 
(Trace-XML) 
Java 
(main) 
Taking as inputs the CDISC ODM and Define-XML files 
representing the metadata for a full study, Trace-XML uses a 
Define-XML extension to generate a full life-cycle study graph 
that provides computable traceability. In addition to validating 
traceability, the Trace-XML graph can be used to query traces for 
a variable or to visualize traceability with a visual rendering of the 
graph. 
DFS.java 
(Trace-XML) 
Java 
 
Depth-First Search (DFS) class - searches the trace graph to 
establish node reachability. 
CdiscGraphML.java 
(Trace-XML) 
Java CdiscGraphML generates a GraphML version of the internal 
graph built from the ODM and Define-XML files. 
DefineGraph.java 
(Trace-XML) 
Java Generates a graph from the Define-XML metadata. Assumes that 
the XML files are loaded in life-cycle phase order. 
Assumes that OIDs are unique within a study. 
Digraph.java 
(Trace-XML) 
Java The Digraph class represents the directed graph built from the 
ODM and Define-XML files. 
Display.java 
(Trace-XML) 
Java The Display class contains static methods used to generate output 
listings, reports, and console messages. 
ODMGraph.java 
(Trace-XML) 
Java The ODMGraph class generates the directed graph from the ODM 
metadata. 
Origin.java 
(Trace-XML) 
Java The Origin class contains constants for the origin types and the 
tests determining whether or not a specific origin is traceable. 
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Source File 
(Application) 
Type Description 
Phase.java 
(Trace-XML) 
Java The Phase class contains the constants for the life-cycle phase 
text. 
TraceNode.java 
(Trace-XML) 
Java TraceNode shares code with the TraceQuery application to trace a 
graph fragment to its conclusion. 
ValidateXml.java 
(Trace-XML) 
Java The ValidateXml class runs schema validation on the XML files. 
Vertex.java 
(Trace-XML) 
Java The Vertex class represents the node objects that comprise the 
graph generated from the ODM and Define-XML metadata files. 
XsltTrace.java 
(Trace-XML) 
Java The XsltTrace class transforms the XML outputs of Trace-XML. 
TraceQuery.java 
(Trace-Query) 
Java 
(main) 
TraceQuery queries the Trace-XML graph using XQuery to 
produce a full life-cycle trace for any given variable OID. 
XsltTrace.java 
(Trace-Query) 
Java XsltTrace runs style sheets to transform XML output into html 
and other formats. 
ConfigReader.java 
(Trace-Query) 
Java ConfigReader loads the contents of the Trace-XML configuration 
file and provides accessors to retrieve the information. 
TraceKB.java 
(Trace-KB) 
Java 
(main) 
TraceKB generates a CDISC standards metadata knowledge base 
that includes the mappings between standards. These TraceKB 
uses these metadata mappings to add the Trace-XML extension 
content to Define-XML XML files. 
ShareAPIClient.java 
(Trace-KB) 
Java ShareAPIClient uses the SHARE API to build the Trace 
Knowledge Base of links between CDISC standards elements. 
XsltTrace.java 
(Trace-KB) 
Java XsltTrace runs style sheets to transform XML output into html 
and other formats. 
ConfigReader.java 
(Trace-Query) 
Java ConfigReader loads the contents of the Trace-XML configurtion 
file and provides accessors to retrieve the information. 
trace-1-0-0.xsd 
(Define-XML extension) 
XML 
Schema 
Primary schema for the Trace-XML Define-XML extension. 
trace-extension.xsd 
(Define-XML extension) 
XML 
Schema 
The Trace-XML extension to Define-XML imports the define-
extension schema and the trace-ns schema, and redefines the 
define-ns schema. 
trace-ns.xsd 
(Define-XML extension) 
XML 
Schema 
The Trace-XML extension v1.0.0 namespace schema. Trace-XML 
extends Define-XML to explicitly reference source items in 
83 
Source File 
(Application) 
Type Description 
Origin in order to generate a directed graph from the ODM and 
Define-XML metadata for a study. 
trace-get-target.xql 
(Trace-KB) 
XQuery Find the mapping target for generating the Trace-XML extension 
content from the SHARE knowledge base. 
trace-get-source.xql 
(Trace-KB) 
XQuery Find the mapping source for generating the Trace-XML extension 
content from the SHARE knowledge base. 
trace-get-edges.xql 
(Trace-KB) 
XQuery Generates a report of the missing edges added to the Define-XML 
file using the Trace-XML extension. 
trace-node.xql 
(Trace-XML, Trace-
Query) 
XQuery Recursive node traversal query that runs on the GraphML file and 
return the nodes in the trace for a given variable. 
trace-node-unique.xql 
(Trace-XML, Trace-
Query) 
XQuery Returns unique set of nodes returned from a trace. 
trace-node-origin.xql 
(Trace-XML) 
XQuery Returns the Origin value for each node in the trace. 
trace-node-oid.xql 
(Trace-XML, Trace-
Query) 
XQuery Uses the results of the GraphML trace look up the nodes in the 
appropriate XML file including the file name and path. 
trace-node-filters.xql 
(Trace-Query) 
XQuery Returns a listing of nodes that removes ItemGroupDef and 
FormDef nodes that are not referenced in a TraceItem element for 
the tabulation and data collection lifecycle phases. 
trace-kb.xql 
(Trace-KB) 
XQuery Builds initial trace knowledge base using metadata from the 
SHARE API. 
trace-kb-edge.xsl 
(Trace-KB) 
XSLT Transforms the Trace-XML extension edges added to the Define-
XML files into and HTML report of the edges added. 
unreachable.xsl 
(Trace-XML) 
XSLT Transforms the list of unreachable nodes in the graph into HTML. 
unreachable-txt.xsl 
(Trace-XML) 
XSLT Transforms the list of unreachable nodes in the graph into a tab 
delimited text file. 
trace-node.xsl 
(Trace-Query) 
XSLT Transform the list of nodes returned from a trace query and their 
associated detailed metadata into an HTML report that displays 
the full trace for a variable. 
text-trace-node.xsl 
(Trace-Query) 
XSLT Transform the list of nodes returned from a trace query and their 
associated detailed metadata into a tab delimited text file report that 
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Source File 
(Application) 
Type Description 
can be opened using spreadsheet software, such as Microsoft Excel, 
to display the full trace for a variable. 
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CHAPTER 5 
THE ANALYTICAL EVALUATION OF TRACE-XML 
This chapter provides an analytical evaluation of the Trace-XML Framework DSR 
artifact. The analytical evaluation provides the primary means of establishing the artifact's 
efficacy. It uses the Trace-XML graph model and the DFS-based algorithms to demonstrate 
the validity of Trace-XML's claims of establishing traceability within clinical research 
metadata. The analytical approach is a static analysis (Hevner et al., 2004) used to ensure that 
reachability, traceability, and completeness can be accessed using the Trace-XML prototype. 
The analytical evaluation of Trace-XML is complemented by a qualitative assessment of 
utility described in Chapter 6, and a set of test cases created for use during the design-cycle. 
Creating a Simple IP-Map to Evaluate Trace-XML 
To test the Trace-XML Framework several test studies were created with increasing 
complexity.  Each test study consisted of three CDISC standard XML files: (1) a CDASH 
ODM v1.3.2 file, (2) an SDTM Define-XML v2.0 file, and (3) an ADaM Define-XML v2.0 
file. A one domain test study was implemented as the simplest possible study that enabled full 
lifecycle testing of the Trace-XML Framework algorithms as implemented in the Trace-XML 
prototype software. The detailed analysis of the Trace-XML algorithms that follows uses just 
the CDASH ODM and the SDTM Define-XML metadata phases of this simple one domain 
test. This small test is sufficient as it fully covers the Trace-XML algorithms. Extending the 
test to additional phases in the lifecycle simply repeats the same algorithms. The CDISC 
CDASH standard, often represented using ODM, describes the basic data collection fields for 
the data domains used in the study. Both the CDASH and ODM standards are widely 
supported by the EDC systems used to collect patient data during a study. Define-XML 
provides the metadata describing the content of the CDISC SDTM and ADaM tabular 
datasets. 
86 
The simple IP-Map in Figure 28 represents the first two phases of the one domain test 
study used to analyze the Trace-XML functionality. Figure 28 shows the transformation of 
one CDISC domain from the CDASH data collection standard to the SDTM standardized 
tabulation standard. This represents two of the essential phases of the overall clinical research 
data lifecycle using the CDISC standards. The detailed CDISC standard metadata for this test 
study was retrieved from the SHARE MDR formatted as ODM and Define-XML. This test 
stops after creating submission ready SDTM datasets. Additional tests that match the 
regulatory submission requirements, and go beyond the simplified test described here, include 
the ADaM, or analysis, datasets that are created using the SDTM data as an input. ADaM 
metadata is also described using Define-XML. 
 
Figure 28. Simplified IP-MAP for creating a submission-ready dataset 
The simplified standards-based IP-Map for the CDISC demographics (DM) domain is 
shown in Figure 28. The two data sources are DS1 and DS2. DS1 provides the metadata 
describing the CRFs used for data collection, as well as the data collected from patients at the 
research site. DS1 contains CDISC CDASH demographics CRF data and metadata 
represented using the ODM standard and represents the source metadata and data for the 
transformation described in P1. DS2 contains the metadata describing CDISC SDTM dataset 
content represented using the Define-XML standard and represents the target format for the 
subsequent transformation described by P1. 
DS1 and DS2 provide the raw data inputs RD1 and RD2, respectively, to P1. P1 
performs the transformations converting the subject demographics CRF data in DS1 into a 
standardized SDTM dataset described by DS2 metadata. Component Data outputs CD1 and 
CD2 flow from P1 into data stores STO1 for the Define-XML file that contains the updated 
SDTM metadata, and STO2 for the Dataset-XML file that contains the subject demographic 
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dataset. These two files provide the Component Data inputs CD3 and CD4 that flow into 
process P2. Process P2 converts them into the submission-ready SDTM demographics dataset 
information product, IP1, for use by the statistical programmers. This simplified map provides 
a sufficient sample to test the traceability available in the current standards model, as well as 
demonstrating IP-Map’s usefulness as a tool for establishing traceability as a measure of data 
quality. 
Testing Traceability in Trace-XML 
Testing begins at layer 1 within the Trace-XML Framework where traceability must 
be confirmed in the IP-Map. The reachability and traceability algorithms used in this research 
are based on those described in Sedgewick and Wayne (2011) and Shankaranarayan et al. 
(2003). In order to prove that traceability exists within the IP-Map, IP-Map blocks must be 
mapped onto a corresponding IP-Graph. Any IP-Map x can be represented as a unique IP-
Graph G(N, L) where each node 𝑛 ∈ 𝑁 represents a block in x and each flow 𝑒 ∈ 𝐿 represents 
an ordered pair (n, m) where n, m ∈ 𝑁. By definition, each block in the IP-Map has a unique, 
non-null identifier. Thus, each node in the IP-Graph is also unique. Each IP-Map flow is 
represented by a directed edge linking two adjacent nodes in the IP-Graph making G(N, L) a 
directed graph, or digraph. In this case, the digraph is a directed acyclic graph (DAG) because 
none of the directed paths have the same first and last node. Because each node n is unique 
and G(N, L) is a DAG, then each ordered pair (n, m) is also unique. To establish traceability 
within the IP-Map from CB1 back to DS1 in the IP-Map, the IP-Graph must be used to 
demonstrate that the node n representing the CB1 block is reachable from node m representing 
the data source block DS1. Block CB1 is reachable from block DS1 if in G(N, L) there exists a 
path from node m to node n indicating there exists a sequence of stages within the IP-Map that 
constitute a path from block DS1 to block CB1.  
The techniques for establishing reachability within a DAG will be discussed in the 
next section, but for the simplified graph in Figure 28 reachability from data sources DS1 and 
DS2 through to the information product CB1 can easily be established by inspection. Since the 
IP-Map diagram was constructed at the conceptual level to serve as an analysis tool, 
traceability is expected to exist. However, regulatory requirements for clinical research 
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demand a more granular accounting of traceability to include each data element in a 
submission rather than the higher level conceptual flow of data. In order to establish 
traceability as an attribute of data quality for the IP-Map, a more detailed analysis must be 
conducted.  
IP-Maps are developed top-down using blocks and flows and then the detailed 
metadata is added for each block. However, IP-Map traceability must be validated from the 
bottom-up. In order to validate that the flows linking the blocks in the IP-Maps accurately 
represent the data flows, a detailed analysis of the data flows within the attribute-level content 
must be performed. Validating traceability within the attributes follows the same process as 
validating the higher-level IP-Map content, except in graph G(N, L) the nodes are attribute-
level data elements and the edges are the data flows between the data elements. To prove 
traceability exists within the attributes reachability, traceability and completeness must be 
established in the attribute-level IP-Grapha. 
Creating the Attribute-level Graph 
To create the attribute-level graph and test for it reachability the algorithms used at the 
IP-Map level must be applied (Sedgewick & Wayne, 2011; Shankaranarayan et al., 2003) to 
the attributes found within the blocks in the IP-Map.  To prove that reachability exists within 
the set of attributes that comprise the IP-Map blocks we first mapped the attributes in the 
attribute-level IP-Mapa onto the corresponding attribute graph IP-Grapha. Any attribute level 
IP-Mapa can be represented as a unique IP-Grapha Ga(Na, La) where each node 𝑛 ∈ 𝑁𝑎  
represents an attribute a within block b in the IP-Map, and each link 𝑒 ∈ 𝐿𝑎 is defined by the 
ordered pair (n, m) where n, m ∈ 𝑁a.  Each block and each attribute within the block has a 
unique, non-null identifier.  Each flow in the IP-Map is a directed edge that represents the 
flow of the data elements in Ga. Thus, Ga is a DAG that reflects the direction of the higher-
level IP-Map flows. The process of mapping each attribute of a block in the IP-Map to a node 
in Ga generates mapping set M. Each member of M is an ordered pair <a, n> where a ∈ 𝐵 and 
𝑛 ∈ 𝑁a. Because every block and attribute within the IP-Map has a unique, non-null identity 
each corresponding node in graph Ga is unique, as is the mapping set M. 
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Testing for Reachability in the Attribute-level Graph 
After creating the IP-Grapha from the IP-Mapa, establishing reachability is the next 
step in verifying traceability. Given the attribute-level digraph Ga generated previously, node 
m is reachable from node n in Ga if there exists a directed path from n to m. A depth-first 
search (DFS) algorithm for graphs will identify all and only those nodes reachable from a 
given node n in the digraph Ga (Sedgewick & Wayne, 2011; Shankaranarayan et al., 2003). 
Given a start node, DFS marks every node it encounters as reachable. When no more nodes 
are reachable down a particular path, DFS backtracks and proceeds down the next link in the 
DAG. The DFS terminates when no more outbound links are accessible from the start node. 
The DFS marks all reachable nodes from the starting node, and unmarked nodes are 
considered unreachable.  
If Ga node F1 in block DS1 is the start node, Figure 29 shows the reachable nodes 
identified using DFS. Figure 29 shows that the DFS did not find edges reaching outside of 
DS1, and therefore only DS1 nodes were marked. To improve readability, Figure 29 
represents the graph for just the first 3 blocks of the IP-Map shown in Figure 28 (DS1, DS2, 
and P1), and yet immediately it is clear that CB1 is not reachable from DS1 since P1 is not 
reachable from DS1. In other words, no path exists connecting the DS1 attributes to P1. This 
has two important implications: (1) the RD1 flow indicated from DS1 to P1 in the IP-Map is 
not supported by the attribute-level graph, and reachability and traceability do not exist in the 
attribute metadata; and (2) that the standards metadata used to represent the IP-Map attributes 
are incomplete and do not support the reachability or traceability drawn in the IP-Map. The 
DFS algorithm demonstrates that more metadata is needed to represent the complete flow of 
the data elements and establish reachability from DS1 to P1 and beyond. Essentially, this 
reachability test demonstrates that the current metadata standards operate within one phase of 
the clinical research data lifecycle and are missing the metadata needed to establish full 
lifecycle traceability that functions across lifecycle phase boundaries. This test demonstrates 
the siloed nature of the existing metadata standards. 
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Figure 29. DFS marks reachable nodes in the first 3 stages of IP-Mapa 
Identifying the Reachability Gaps 
The outbound flow RD1 from DS1 to P1 in the IP-Map shown in Figure 28 indicates 
the expectation of reachability from DS1 to P1. Executing the DFS algorithm on the graph Ga 
demonstrates that reachability does not exist from DS1 to P1. In order to establish reachability 
at the attribute level, additional metadata is needed. The siloed metadata representing each 
phase of the clinical research data lifecycle cannot be explicitly linked to metadata in the next 
phase of the lifecycle using the current standards. The existing CDISC standards 
specifications do not provide the metadata needed to establish the links between the attributes 
in DS1 and P1. However, during the development of the CDISC SHARE MDR (CDISC, 
2016) these attribute-level links were instantiated as maps-to relationships in the SHARE 
MDR model. As an input to the creation of the additional metadata needed for reachability, 
these relationships were extracted from SHARE in the form of a mapping table. Where the 
relationships were not available in SHARE, they were manually created and added to the 
mapping table. A graph Gs was created from this mapping metadata. The two graphs Ga and 
Gs were then compared to identify the reachability gaps in the existing metadata standards as 
expressed in Ga. The algorithm shown in Figure 30 was used to find the missing edges that 
prevented reachability from being established.  
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Equipped with the hash table generated using the SHARE MDR relationships and the 
algorithm shown in Figure 30, the missing edges must next be inserted into the graph Ga. The 
SHARE relationships do not link the source data in DS1 directly to P1, but instead link DS1 
into the DS2 target metadata. That is, the mapping table shows which DS1 data elements map 
to specific DS2 data elements without representing the process needed to perform the 
transformation or mapping. The IP-Map indicates that every DS1 attribute should flow to P1. 
The P1 transformation processes include data transformations, derivations, and direct mapping 
to the output variables described by DS2. As P1 transforms DS1 into outputs described by DS2 
they flow as component data CD1 and CD2 to create output files STO1 and STO2. In order to 
support the process depicted in the IP-Map, the relationships provided by SHARE must be 
interpreted to accurately represent the processes in P1. The algorithm performing this 
interpretation is shown in Figure 31. 
The algorithm in Figure 31 took the missing metadata identified using the algorithm 
in Figure 30, and used it to create the missing edges and nodes needed to update the graph Ga. 
As a result of this process, an additional gap in the standards metadata was discovered. In a 
separate test case that included the CDISC adverse events (AE) domain, an attribute was 
discovered with no relationship to the outputs described in DS2. This AE attribute also has no 
relationship to the metadata in P1 and therefore appears to be a terminal attribute. In this case, 
data management used this data element as a flag to confirm that no adverse events exist. 
Otherwise, data managers cannot know if a subject experienced no adverse events, or adverse 
events exist but the study site had not yet entered the data for them. In order to more 
completely represent traceability, this data management data element prompted the 
implementation of a new rule that requires every attribute to reach a data sink or be identified 
as an exception. For this case, a new data management IP would be created, and additional 
blocks would be added to the IP-Map.  Once the IP-Map was updated, new graphs would 
Given the IP-Mapa attribute graph Ga(Na, La) 
Given SHARE mapping attribute graph Gs(Ns, Ls) 
For every edge  represented by a directed pair of nodes (n, m) in Gs 
if (  and ) and  then 
insert e into a hash table as the directed pair of nodes (n, m) 
   
Figure 30. Identifying the metadata missing from the attribute graph 
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need to be generated to include the necessary nodes and edges required to support reachability 
to that IP. Alternatively, certain attributes will be flagged as not traceable because they 
represent known exceptions. For example, attributes with certain Origin values, such as 
“Assigned”, will be identified as traceability exceptions since data is assigned to the variable 
rather than flowing from a data source in the previous phase of the data lifecycle. In cases 
where the source variable does not flow to the next phase an additional attribute will be added 
to flag the variable as a known traceability exception. Additionally, variables with an Origin 
Type of "Assigned" are expected to have a CommentDef element associated with them that 
further explains the source of the variable content. 
 
 
Resolving the Traceability Gaps in the CDISC Standards Metadata 
The prototype Trace-XML algorithms revealed metadata missing from the CDISC 
standards needed to establish computable traceability in full lifecycle regulatory submission 
datasets. The current standards address traceability using descriptive metadata. For example, 
an SDTM variable with an Origin Type of "CRF" would include a link to an annotated blank 
CRF in PDF format, and an ADaM variable with an Origin Type of "Predecessor" would 
provide text with the domain and variable name of the source variable. This descriptive 
metadata provides limited traceability information. Computable traceability that supports a 
query capability would provide a solution that more completely addresses the regulatory 
requirements. The gaps in the standards metadata were filled in the attribute-level graph using 
a combination of the model relationships available in the SHARE MDR, a graph difference 
Given the IP-MAPa attribute graph Ga(Na, La) 
Given the missing SHARE edges hash table Te 
For every missing edge in Te represented as ordered pair (n, m) where n  
   if m  then  
      provisionally add node m as an attribute in DS2  
   if m is an attribute in DS2 that gets its value from a node p in P1 then  
      add edge (n, p) 
   else if m is an attribute in DS2 with no link to P1 then 
      if no other node n links to the same DS2 node m then  
         add mapping node p to P1 
      else  
         add derivation node p to P1 
      add edge (m, p) 
      add edge (n, p) 
 
 
 
 
   
Figure 31. Algorithm to create the missing metadata in the attribute graph 
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algorithm that identified the missing edges, and an algorithm that transcribed the relationship 
metadata to determine the nodes and edges needed to support the process shown in the IP-
Map (Archambault, 2009).  
Traceability has been a Define-XML requirement from the beginning and extending 
Define-XML with additional traceability metadata represents a natural enhancement to the 
existing specification and schema. ODM and Define-XML were designed to accommodate 
extensions, and Define-XML is a standardized extension of the ODM standard. Providing a 
Define-XML extension named Trace-XML makes the enhancements available for immediate 
use by the clinical research community. Figure 32 shows a small example of the extension in 
use. The new Trace and TraceItem elements containing the source variable references are 
identified using the trc namespace prefix used to classify Trace-XML extension content. The 
TraceItem element includes only the ItemOID attribute, the minimum required content to 
establish a reference to the source variable. This new Trace-XML content complements the 
existing descriptive metadata that shows the immediate source variable as part of the PDF 
annotated CRF document. 
The ability to explicitly reference source variables enables the Trace-XML software to 
generate the edges that connect the variables, methods, datasets, sub-forms, and forms into a 
graph representation. For example, a variable with an Origin of Type “CRF” now includes the 
ItemOID to explicitly reference that variable’s metadata in addition to maintaining a link to 
the descriptive blank-crf.pdf file, as shown in Figure 32. In another case, a variable with an 
Origin Type of “Derived” must include references to the variables that operate as inputs to the 
derivation or transformation provided by the MethodDef associated with the variable, as 
shown in Figure 20. Using the TraceItem references, the Trace-XML software applies a 
recursive algorithm to link to the sources of all previous steps in the data flow. In addition to 
the Define-XML extension, ODM can use the existing Alias element to add the metadata 
needed to map CRF content into the SDTM datasets.  
94 
 
Figure 32. Example of the Trace-XML Define-XML extension 
Resolving Reachability Gaps using Traceability 
Certain variables will be unreachable because their source variables have an Origin 
Type that indicates that the variable is not traceable, such as "Assigned" or "Protocol". When 
testing for reachability, every variable that uses an "Assigned" variable as a source will be 
unreachable. "Assigned" origins represent known reachability exceptions, but variables that 
reference a source variable that has an Origin Type of "Assigned" are expected to be 
traceable. For example, if an SDTM variable is "Assigned", an ADaM variable should be 
reachable from the SDTM variable. In this way, we expect to trace from the ADaM variable 
back to the "Assigned" SDTM variable, but no further.  
To resolve this dilemma, the Trace-XML algorithm re-tests unreachable nodes using 
traceability. Traceability for unreachable nodes is performed by reversing the graph direction, 
and testing for reachability in the opposite direction. Starting at the last phase of the lifecycle 
and working backward, a variable traces its lineage back to a source. In cases where a source 
variable has an Origin Type of "Assigned", the assigned variable is considered the origin and 
the trace is marked as valid. In this case, the "Assigned" variable represents the original 
source. If tracing the variable in the reverse direction through the lifecycle yields a node that 
should itself have a source, such as when the Origin Type of an SDTM variable is "CRF", 
then the trace should continue until if finds a terminal node or a gap in the expected 
traceability. Thus, Trace-XML tests the graph for reachability in both directions to create an 
accurate traceability assessment. 
<ItemDef OID="SDTM.IT.DM.SEX" Name="SEX" DataType="text" Length="1"> 
  <Description> 
    <TranslatedText xml:lang="en">Sex</TranslatedText> 
  </Description> 
  <CodeListRef CodeListOID="SDTM.CL.SEX"/> 
  <def:Origin Type="CRF"> 
    <def:DocumentRef leafID="LF.blankcrf"> 
      <def:PDFPageRef PageRefs="6" Type="PhysicalRef"/> 
    </def:DocumentRef> 
    <trc:Trace> 
      <trc:TraceItem ItemOID="ODM.IT.DM.SEX"/> 
    </trc:Trace> 
  </def:Origin> 
</ItemDef> 
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Re-testing for Reachability and Traceability in the Attribute-level Graph 
After the gaps in the IP-Grapha were identified and resolved, and the metadata 
standards were augmented with the additional metadata, the IP-Map was re-instantiated and 
the IP-Grapha was again evaluated for reachability, traceability, and completeness. The 
evaluation process used the same algorithms as previously described with the expectation that 
the previously identified gaps had been resolved.  
Using the demographics domain example, the missing edges and nodes were added to 
the graph Ga, and the DFS was executed to re-test for reachability. As shown in Figure 33, 
reachability was achieved for the DS1 to P1 blocks. Expanding the test to include DS2 yields 
all the nodes shown in Figure 34 as reachable. Expanding this process to the entire IP-Grapha 
shows that reachability was established for DS1 and DS2 through to CB1. 
 
 
Figure 33. Re-testing for reachability from DS1 to P1 using the updated graph 
Now that reachability has been achieved, we show that if node n in Na is reachable 
from node m, then node m is traceable from node n. In a DAG traceability is not achievable 
since all the edges are directed. The first step in proving traceability for an attribute-level IP-
graph that demonstrates reachability is to create the transpose of Ga that reverses the direction 
of all links in the graph. We create Ga′(Na, La′) as the transpose of Ga(Na, La). Each node in Ga  
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Figure 34. Testing shows reachability from DS1 and DS2 to P1 in the updated graph 
 
is also a node in the transpose graph Ga′. Each link in Ga has the same endpoints in Ga′, but 
the direction of the link is reversed. Once the transpose graph Ga′ has been created, DFS is 
again used to show reachability. Since the nodes in Ga and Ga′ are identical, and the links are 
identical except the direction is reversed, if a node is reachable in Ga′ it is traceable in Ga 
(Shankaranarayan et al., 2003). Thus, by achieving reachability for the attributes in DS1 to the 
attributes CB1 we can show that the CB1 attributes can be traced back to the DS1 attributes. 
Achieving reachability in IP-Grapha means we have reachability in IP-Mapa which in turn 
confirms the flows drawn between the blocks in the IP-Map. 
Testing the Attribute-level Graph for Completeness 
This research project has defined completeness for the IP-Grapha Ga(Na, La) as the 
state where every node 𝑛 ∈ 𝑁𝑎 is reachable from a data source block data element and 
traceable from a data sink data element, or it has been flagged as an exception. Other 
prerequisites for establishing completeness include: (1) the IP-Grapha has been created by a 
complete mapping of all the IP-Map composite attributes; (2) correctness in the XML 
metadata is confirmed; (3) the IP-Grapha is directed, and every pair of distinct nodes is 
connected by a unique directed edge that is reversible; and (4) coverage exists. Correctness in 
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the XML metadata is confirmed when the XML metadata passes both Trace-XML schema 
validation and the CDISC conformance rules created for compliance with the standards. 
These rules confirm that the resulting graph conforms to the typing, ordering, and 
impossibility constraints, among others. The Apache Xerces 2.11 XML parser was used to run 
schema validation against the trace-1-0-0.xsd XML schema, and the XML4Pharma 
Define.xml checker (aerts, 2017) was used to run the CDISC Define-XML v2.0 conformance 
rules. Coverage exists where all data sources are traceable from at least one IP output, and all 
IP outputs are reachable from at least one data source except for the known traceability 
exceptions that are flagged as such. As noted previously, additional metadata must be added 
to the existing industry standards to achieve completeness. Relevance was another dimension 
of provenance quality asserted by Cheah and Plale (2015) to complement correctness and 
completeness. In Trace-XML, the traceability metadata added to provide computable 
traceability is highly relevant as it extends the existing concept of Origin within Define-XML 
and significantly extends the existing traceability capabilities in clinical research to better 
meet the existing regulations. 
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CHAPTER 6 
THE QUALITATIVE EVALUATION OF TRACE-XML 
The qualitative evaluation of Trace-XML evaluated the utility of Trace-XML as a 
DSR artifact that addresses research objectives related to end-to-end traceability within the 
domain of clinical research.  This study collected data by interviewing clinical research data 
experts that represent a range of stakeholder categories. The interviews followed a semi-
structured format, and the data was analyzed using thematic analysis. This same approach was 
used as the primary means to evaluate a traceability framework for the business intelligence 
domain in a recent journal article (Chee et al., 2014). The Trace-XML project seeks to use this 
approach as a secondary means of evaluation that complements the primary analytical 
evaluation method. The following sections of this chapter cover the essential research design 
elements for the qualitative evaluation project (Myers, 2013), as well as the study results. A 
discussion of the implications of the study results is covered in Chapter 7. 
Research Questions 
In addition to gaining feedback to feed into future design cycles, this applied thematic 
analysis qualitative research project sought to explore the utility of Trace-XML to clinical 
research data experts. To better understand Trace-XML utility as it relates to different aspects 
of traceability, this research sought to address three exploratory research questions.  
1. How does Trace-XML impact the task of assessing end-to-end traceability for 
variables within a clinical research study? 
2. How does Trace-XML impact the task of assessing the validity of end-to-end 
traceability within a clinical research study? 
3. What features of an end-to-end traceability solution are most important for the data 
reviewer tasks of assessing and validating traceability for variables within a clinical 
study? 
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Research Design 
Research method 
This qualitative study used Applied Thematic Analysis (Guest et al., 2011) as the 
research method for the evaluation of Trace-XML utility. This research method was applied 
using an interpretive philosophical approach, and applied inductive reasoning to explore the 
data generated by the interviews. The themes established by the analysis were driven by the 
data, and focused on the primary research questions. As a DSR evaluation tool, applied 
thematic analysis of the semi-structured interview data provided the method to assess the 
utility of the artifacts. This qualitative study represents applied research that seeks to 
understand and improve the solution to a practical problem, traceability within clinical 
research. This evaluation method is secondary to a static, analytical evaluation method used to 
prove the artifacts meet the project research objectives. 
Data collection technique 
Semi-structured interviews with clinical research data experts with a stake in clinical 
research study traceability were used to gather data for this study. These clinical research data 
experts represented 5 different categories of organizations. Each interview began with a 
detailed demonstration of Trace-XML. Eight questions were created in advance of the study 
to direct the interview and ensure the data collected would support an evaluation of the 
primary research questions. The questions were designed to assess the usefulness of Trace-
XML to support traceability from a number of perspectives. The demonstration took 
approximately 15 minutes followed by a 30-40 minute interview.  Most of the 8 questions 
included optional probing questions to further explore the primary questions. As a semi-
structure interview with subjects from 5 different categories of organizations, each 
interviewee was given latitude to pursue relevant topics related to their areas of interest and 
expertise. This ensured a richer and more varied set of data to analyze, and provided 
unanticipated new features to feed into the next Trace-XML development design-cycle.  
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Data analysis approach 
The qualitative data gathered from the interview process was analyzed using thematic 
analysis. Thematic analysis seeks to identify the explicit and implicit ideas and patterns, or 
themes, within the data.  An interpretive philosophy was used during analysis to identity the 
underlying themes. In general, thematic analysis relies more heavily on interpretation than it 
does strict analytical techniques such as word counting and other algorithms for text analysis. 
Thematic analysis excels at capturing the "complexities of meaning" within the data (Guest et 
al., 2011) and builds themes using inductive reasoning. Thematic analysis is the most 
commonly used analysis method in qualitative research (Guest et al., 2011). The thematic 
analysis was performed using the QDA Miner Lite v2.0 qualitative analysis software 
(Provalis-Research, 2017). 
Written record 
The qualitative research methods described in (Myers, 2013) include a step for 
describing the written record. As part of the evaluation of the larger DSR project, this research 
has been documented in this dissertation. A journal article covering the full project including 
the evaluation steps will be authored, as well as a conference article that focuses on the 
qualitative evaluation of the DSR artifacts.  
Sampling and Sample Size 
The subjects for this research were selected from the categories of clinical data experts 
listed in Table 16 below. Each category represents a different type of organization giving the 
associated subjects different perspectives on traceability within the CDISC standards. These 
diverse viewpoints helped evaluate Trace-XML utility from a number of different 
perspectives and provided well-rounded input for new Trace-XML features. The sample size 
was 10 clinical data experts distributed evenly across the different categories. Each participant 
is a well acknowledged expert with at least 15 years of clinical research data experience.  
Randomized selection or assignment will not be used in this study. The subjects that 
participated in the study were recruited using email. 
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Table 16. Clinical data expert subject counts by category 
Category Description and Examples # of Subjects 
Regulatory Works for a government regulator 2 
Standards developers Members of CDISC teams that develop the 
standards. 
2 
Biopharmaceutical / 
Contract Research 
Organizations 
Experts that work for a biopharmaceutical 
company or a contract research organization that 
implement the standards. 
2 
Technology vendors Technology experts that work for an 
organization that develops and markets a 
technology that supports one or more parts of the 
clinical research data lifecycle. 
2 
Academic Academics with experience applying the CDISC 
standards in academic clinical research. 
2 
IRB Approval and Consent 
Institutional Review Board (IRB) approval was granted by the Dakota State University 
(DSU) IRB to conduct this research and work with human subjects. The project was granted 
expedited project approval as described in 45 CFR 46.110 on January 24th, 2017 with 
approval # 2016-2016-114 for a term of 1 year.  The research activity was deemed to be no 
greater than minimal risk as defined in 63 FR 60364-60367. The DSU IRB approval letter is 
available for review in Appendix F. 
A consent form was created for subjects participating in the study, and each subject 
received the form prior to the interview. The highlights of the consent form were covered with 
subjects at the outset of the interview, and each subject was given the opportunity to ask 
questions prior to beginning the demonstration. Each subject retained the right to withdraw 
from the study at any time. Subjects were not required to sign the consent form, and their 
agreement to participate in the study implied consent. Upon receiving IRB approval, a pilot 
interview was conducted to ensure the questions worked in the context of an interview and 
would provide the data needed to answer the research questions. The informed consent form 
is available for review in Appendix E. 
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The Interview Demonstration and Questions 
After reviewing the informed consent, each subject was provided with an overview of 
the Trace-XML Framework followed by a demonstration of the Trace-XML software. This 
detailed information on Trace-XML was intended to educate the subject as well as to provide 
the necessary understanding of the Trace-XML Framework artifacts to answer detailed 
interview questions regarding the utility of Trace-XML to provide a solution to the real-world 
problem of traceability within clinical research. The investigator will also demonstrate the 
current state-of-the-art method for assessing traceability to facilitate a discussion on the 
relative utility of Trace-XML. The state-of-the-art traceability demonstration will be based on 
the current regulatory requirements for CDISC traceability in submissions, and will be 
confirmed by an industry expert. All subjects that participated in the study were familiar with 
the current state-of-the-art in traceability as well as the relevant regulations. 
Traceability Definitions and Background 
The following concepts were defined for each subject during the course of the 
demonstration: 
• Metadata traceability: Trace-XML addresses the need for metadata traceability. 
Metadata traceability facilitates the understanding of the relationship between a 
variable to its source dataset(s) and variable(s), including a description of the 
algorithm used to derive or populate a variable from its predecessor. 
• Regulatory submission context: This project focuses primarily on traceability in the 
context of a CDISC study as would be found in a typical FDA or PMDA submission. 
• End-to-end traceability: End-to-end describes traceability from analysis datasets (or 
even analysis results) back to the original source data and covers the different phases 
of the clinical research data lifecycle. 
Trace-XML Demonstration 
Prior to the demonstration, a brief review of the current standard for assessing 
metadata traceability within a regulatory submission was provided, followed by an overview 
of Trace-XML. The Trace-XML Framework demonstration focused on the main attributes 
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and did not attempt to cover every feature. The features covered in the Trace-XML orientation 
and demonstration included: 
1. Use the Define-XML v2.0 SDTM example to demonstrate how traceability is 
established in the context of a regulatory submission using the current state-of-the-art. 
2. Present brief 7-slide PowerPoint introduction to the problem space and the Trace-
XML Framework 
3. Show the IP-Map overview of traceability 
a. Demonstrate possibility of including EHR as source content 
b. Demonstrate example used for the Trace-XML demonstration 
4. Demonstrate Trace-XML Validation 
a. Show validation and the unreachable report 
b. Remove an item and re-generate the report 
5. Demonstrate Trace-XML Query to show an end-to-end trace for one variable 
a. Generate a query trace for an analysis variable 
b. Show the trace query report added to a Define-XML document 
6. Demonstrate Trace-XML graph visualizations 
a. Show the full study graph as an exploratory tool 
b. Show the predecessor graph 
Questions on Trace-XML as an End-to-end Traceability Solution 
The semi-structured interviews began by the investigator asking the prepared 
questions. However, the subject could direct much of the discussion towards relevant topics 
that most interested them. Not every interview spent the same amount of time on the 8 
questions prepared for the interview, depending on how much the subject directed the 
discussion. Probe questions were also prepared as an aid to the investigator, but may or may 
not have been used depending on the specific interview.  
1. Assuming Trace-XML has been implemented as a study review tool, what impact 
would Trace-XML have on assessing end-to-end traceability?  
a. [Probe] Do you think there are end-to-end traceability benefits that Trace-
XML provides that are not available using the current methods? 
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b. [Probe] Assuming no implementation barriers, what impact would Trace-XML 
have? 
2. Given what you know of regulatory requirements for traceability, what impact would 
Trace-XML have on the ability to meet those requirements? 
3. What impact does the ability to visualize traceability have on assessing end-to-end 
traceability? 
a. [Probe] Do you think there are benefits that Trace-XML provides in support of 
end-to-end visualization that are not available using the current methods?  
b. [Probe] How does the visualizing study metadata using the full graph 
representation or predecessor view impact your understanding of study 
traceability? 
4. What impact of does end-to-end traceability validation have on assessing study 
traceability?  
a. [Probe] Do you think there are benefits that Trace-XML provides in support 
end-to-end validation that are not available using the current validation 
methods? 
b. [Probe] How could Trace-XML impact how the industry thinks about study 
metadata validation? 
5. What impact does an end-to-end traceability query feature have on a reviewer’s ability 
to assess traceability of a variable? 
a. [Probe] Do you think there are benefits that Trace-XML provides in support of 
traceability queries that are not available using the current methods? 
b. [Probe] Does including the query results for each variable in the Define-XML 
output improve the ease of reviewing end-to-end traceability for a variable? 
6. What impact does the IP-Map have on understanding traceability within a study? 
a. [Probe] How does the higher-level view of traceability provided by the IP-Map 
diagram impact your understanding of the detailed traceability outputs such as 
the graph visualization or traceability queries? 
b. [Probe] Would the inclusion of an IP-Map diagram with Define-XML impact a 
data reviewer’s understanding of traceability within the study? 
7. What features of a traceability solution are the most important? 
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a. [Probe] What makes the priority features more important than others? 
b. [Probe] If implementation feasibility, money and time were not issues, 
describe the most important features of an ideal traceability solution. 
8. Given what you have seen during the demonstration, what recommendations do you 
have for improving Trace-XML? 
Analysis 
Methods 
Applied Thematic Analysis (Guest et al., 2011) was used within the context of the 
Trace-XML DSR project as the method for evaluating the utility of the artifacts. This 
qualitative study included 10 subjects with expertise in CDISC standards metadata taken from 
organizations in the 5 different categories described in Table 16. The scripted questions were 
asked during the semi-structured interview, but the subject was given the latitude to respond 
and comment in a manner that allowed them to cover the topics they felt were most relevant. 
The questions were designed to assess the usefulness of Trace-XML to support traceability 
from several perspectives. The questions themselves impacted the themes derived from the 
coded text, but did not alter the main substance of the responses.  
The interviewer took detailed notes during the interview and refined the content just 
after the conclusion of the interview to remove ambiguous pronouns and any proper nouns 
that might identify the subject or the subject's organization. A response template was created 
to guide and structure the investigator's note taking during and immediately after the 
interview session. The detailed interview notes were coded using the QDA Miner Lite v2.0 
software. The code table was developed, refined, and condensed over 4 iterations through the 
10 interview cases loaded into the project. The initial and final coding iteration counts are 
listed in Table 17. 
Table 17. Number of Categories and Codes 
Initial and Final Coding Phase Categories Codes 
Initial Code Book Development 9 49 
Final Code Book 5 24 
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The text and codes related to each research question were isolated to identify themes 
and quotes specific to each of the 3 research questions, as shown in Table 18 in the Results 
section. 
Results 
This qualitative assessment of Trace-XML was completed to assess the usefulness of 
the Trace-XML framework to support full study lifecycle traceability. The variety of roles 
represented by the subject categories ensured a wide range of perspectives, while their shared 
background in clinical research data and the CDISC standards ensured common interests in 
improving traceability within clinical research. 
The key themes and code categories identified during this evaluation were: adds 
utility, adds information, simplifies implementation, verifies data quality, and promotes 
understanding. The adds utility theme indicates that Trace-XML was viewed as adding utility 
to the demonstrated traceability tasks by the clinical research data experts. The adds 
information theme indicates that Trace-XML makes available and utilizes additional 
information not previously available to those assessing traceability. The simplifies 
implementation theme encapsulates those codes that mean that Trace-XML makes 
implementing traceability simpler through such individual codes as building on existing 
technologies such as the ODM and Define-XML standards or instilling a tool focus by 
providing a software tool that automates the traceability tasks under review. The verifies data 
quality theme indicates that Trace-XML provides data quality verification capabilities such as 
validation, a completeness assessment, and produces traceability reports and visualizations. 
The verifies data quality theme produced 12% of the total codes, accounting for the fewest 
codes of the major themes. Finally, the promotes understanding theme indicates that Trace-
XML improves a user's understanding of their data and produced 27.9% of the total codes, the 
most of any major theme. 
After the final coding iteration, the code frequency analysis shown in Table 18 was 
generated. The table shows the codes for each category, the number of times the code appears, 
the percentage of all codes applied represented by the code, the number of cases or interviews 
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where the code was applied, and the percentage of interviews where the code was applied. For 
example, the codes for new information (9.8%) created using Trace-XML and showing how 
things fit together (9.8%) each totaled nearly 10% of the total codes. Other codes, such as 
mapping metadata (0.8%) and information re-use (0.8%) represented less than 1% of the 
codes. 
Table 18. Coding Frequency Analysis 
Code Category Code Count % Codes Cases % Cases 
adds utility useful 21 7.9% 7 70% 
role independent 6 2.3% 5 50% 
regulatory impact 24 9.1% 10 100% 
new capability 8 3.0% 6 60% 
too advanced 3 1.1% 3 30% 
Totals 62 23.4% 6.2avg 62%avg 
 
Code Category Code Count % Codes Cases % Cases 
adds information new information 26 9.8% 9 90% 
missing information 6 2.3% 6 60% 
mapping metadata 2 0.8% 2 20% 
all dataset types 5 1.9% 1 10% 
re-use 2 0.8% 2 20% 
complex 5 1.9% 3 30% 
Totals 46 17.5% 3.8avg 38%avg 
 
Code Category Code Count % Codes Cases % Cases 
simplifies implementation tool focus 6 2.3% 1 10% 
simplify 13 4.9% 7 70% 
embedded 4 1.5% 2 20% 
builds on existing 
technology 
12 4.5% 6 60% 
generate 20 7.5% 8 80% 
Totals 55 20.7% 4.8avg 48%avg 
 
Code Category Code Count % Codes Cases % Cases 
verifies data quality validation 17 6.3% 7 70% 
completeness 5 1.9% 4 40% 
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traceability 10 3.8% 6 60% 
Totals 32 12% 5.7avg 57%avg 
 
Code Category Code Count % Codes Cases % Cases 
promotes understanding comprehension 18 6.8% 8 80% 
visual 19 7.1% 7 70% 
identify differences 5 1.9% 3 30% 
big picture 6 2.3% 5 50% 
how things fit together 26 9.8% 8 80% 
Totals 74 27.9% 6.2avg 62%avg 
 
All the major themes identified can be related to the central theme of adding utility, or 
the concept that Trace-XML provides additional utility not currently available to address full 
lifecycle study traceability. Most of the codes deal directly or indirectly with adding utility. 
Utility may be added by improving comprehension or easing traceability implementation 
issues by building on existing technology. Thus, adding utility represents the primary theme 
in this study with the remaining themes of adds information, simplifies implementation, 
verifies data quality, and promotes understanding supporting the main theme. This 
hierarchical relationship is depicted in Figure 35. 
 
Figure 35. The Trace-XML thematic hierarchy 
 
The adds utility central theme directly supports the primary research objective to 
evaluate if clinical research data experts found that Trace-XML was a useful innovation to 
support the real-world problem of assessing traceability within the context of a clinical study. 
In addition to this overarching objective, this qualitative evaluation sought to explore the three 
research questions listed in the Research Questions section of this chapter. Each research 
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question is listed in Table 19 along with the salient themes and supporting example quotes 
from the interviews. 
 
Table 19. Salient themes for each research question 
Research Question Salient Themes Examples 
How does Trace-XML impact 
the task of assessing end-to-
end traceability for variables 
within a clinical research 
study? 
Presents new information 
 
Shows how things fit 
together 
 
Aids traceability 
comprehension  
 
 
 
"The Define-xml embedded piece is extremely 
useful. This is the most obvious first thing to 
get a quick win from Trace-XML because it's 
in the same format they're already using but 
now they get more information with 1-click." 
 
"The Trace-XML query report provides a 
much clearer description than what is available 
today. The reviewers would definitely want 
this. Putting content into the Define-XML 
style sheet makes it simple to use and 
understand." 
 
"Certainly useful information for regulators. It 
provides a seamless way for FDA reviewers to 
identify a sponsor's complete process. It shows 
the regulators the full picture for any variable." 
 
"Today it's hard to pull traceability 
information together and you need the 
mapping files. Trace-XML is a lot easier. You 
can load the study and generate the content 
needed to understand traceability." 
 
Research Question Salient Themes Examples 
How does Trace-XML impact 
the task of assessing the 
validity of end-to-end 
traceability within a clinical 
research study? 
Provides traceability 
validation 
 
Simplifies generating 
traceability content 
 
"Taking variables and making sure that they're 
traceable. It adds a more sophisticated level of 
validation. Doesn't validate a silo, but an entire 
study." 
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Benefits regulators 
 
"Useful to understand if the traceability is 
complete. Think it would be very useful for 
regulators receiving a submission." 
 
"I think users should be interested in end-to-
end quality. Validation is a good use of this 
technology. I would certainly want this. Makes 
it easy to trace everything. Does it in a simple 
way." 
 
"This highlights dead points in a study in 
which data points are based on assumptions 
that are not documented – not linked into the 
overall study data flow." 
 
Research Question Salient Themes Examples 
What features of an end-to-
end traceability solution are 
most important for the data 
reviewer tasks of assessing 
and validating traceability for 
variables within a clinical 
study? 
Shows how things fit 
together 
 
Traceability validation  
 
Visualize traceability 
 
"Knowing where the inputs to data come from, 
understanding the source." 
 
"Establishing the sources for each variable." 
 
"Understanding the data flow through all their 
data." 
 
"The transparency provided by the end-to-end 
flow of information" 
 
"Validation. Finding the gaps in a study trace." 
 
The most codes were applied (27.9%) under the promotes understanding category 
which covers how Trace-XML improved a subject's ability to understand the flow of data 
through the clinical research data lifecycle, from data collection through analysis.  The most 
frequent code applied in this category was how things fit together (9.8%) followed by visual 
(7.1%) and comprehension (6.8%). Trace-XML's potential use to promote understanding was 
a major theme that emerged from the interviews. A summary of the code category frequency 
totals is shown in Figure 36. 
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Figure 36. Code category frequency percentage totals 
 
As noted earlier, the major themes identified from the interviews all support the 
overarching theme that Trace-XML adds utility to assessing traceability and understanding 
how study data fits together. Within the category of adds utility, the code regulatory impact 
was applied the most frequently (9.1%) and had the highest coverage as it was applied to 
100% of the interviews. This indicates that regulatory impact, by adding utility for regulatory 
reviewers, was a key theme that emerged from the interviews. Every interview subject 
mentioned that Trace-XML should interest the regulators.  
There were a wide range of responses to the question regarding the impact of the IP-
Map layer within the Trace-XML framework on understanding traceability, but the most 
common code was big picture under the promotes understanding category. Other frequent 
codes were visual and how things fit together which also indicate that the IP-Map helps 
promote understanding. One subject summarized the impact of an IP-Map for traceability as: 
It would be useful to give someone the high-level view and to understand what 
CRFs contributed to the ADSL dataset. You may only have 1 or 2 key datasets for your 
primary or secondary endpoints and the IP-Map could help find the key analysis 
datasets and variables and how they were created and what the inputs where.  This 
could be used to direct a search to find more detailed information. 
23.4%
17.5%
20.7%
12.0%
27.9%
Code Category Frequency
adds utility adds information simplifies implementation
verifies data quality promotes understanding
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Another summed up the value of IP-Map this way: 
This could be a useful way to present traceability to business users. This 
information is known to the standards folks, but not explicitly documented for those 
that are less familiar with the information used to generate submission content. 
The question regarding the impact of the graph visualization on understanding 
traceability was similarly varied. The visual code was most frequently applied, but how things 
fit together was also frequently applied and indicates that the visualization can help to 
improve one's understanding of the data. In this instance, there were some cautionary codes as 
well, including complex indicating that the graph was complex for the uninitiated to 
understand and too advanced for immediate use by less knowledgeable users.  
The visualization makes it easy to see where things came from. What 
derivations are done. Reviewers spend a lot of time figuring out what is this stuff how 
do these fit together. 
Another subject identified the benefits as well as the impact of the complexity of the 
graph visualization: 
Useful information for those with a curious mind. Less immediately important 
than the tabular HTML visualization since it takes more work and knowledge to get 
something out of it. 
Subject's also had the opportunity to discuss what ideas or new features might improve 
Trace-XML.  The two most common codes were generate and new information. For generate, 
subjects recommended that the additional information needed to support Trace-XML be 
automatically generated, as it can be done from SHARE. For example, one subject noted 
Trace-XML feels like something that's of interest to folks doing mapping since 
the Trace-XML metadata can be generated. Don't want to add the Trace-XML 
metadata manually. Target those doing mappings. 
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For new information, subjects recommended extending Trace-XML to include 
different types of metadata to augment what can currently be communicated. For example, 
one subject recommended 
Visualizing the standards is useful. Generating the visualizations from the 
standards metadata, would be very useful. Annotate the graphs with hyperlinks that go 
to the SDTM web page or a specification. 
The subjects were not informed that Trace-XML includes the Trace-KB tool to 
generate Trace-XML content using the relationships available in the SHARE MDR as it was 
not demonstrated. Thus, none of the subjects commented on this capability. 
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CHAPTER 7 
DISCUSSION AND CONCLUSION 
Primary Benefits of Trace-XML 
Trace-XML contributes two features that immediately benefit data reviewers: the 
ability to validate traceability across the full study lifecycle, and the ability to query the 
complete trace for a variable. Traceability improves a reviewer’s ability to understand a study, 
and has been identified as essential for a regulatory reviewer’s ability to assess a submission. 
This same task of assessing study data is important to non-regulatory data reviewers as well, 
including cases where (1) a research organization seeks conduct a meta-analysis using data 
from different studies, (2) a research organization seeks to aggregate clinical research data 
from a variety of sources, (3) a researcher seeks to perform a data quality assessment on an 
existing study, (4) a researcher attempts to replicate research findings, or (5) a research 
organization in-licenses a compound and its associated study data. In general, advancing 
traceability improves the quality of the study metadata and increases the efficiency with 
which data reviewers begin to understand the data. Making the data easier to understand 
encourages the secondary use of the data.  
Today, computable traceability does not exist within the clinical research metadata. 
Currently, the standards include a limited set of descriptive metadata that provides 
information on the previous step in the process. Identifying the full trace for a variable in a 
CDISC study today is a manual, labor intensive process. Even when manually assembled the 
data collection metadata is not provided in submissions, and instead a PDF rendering of an 
annotated CRF provides the descriptive metadata. Manually assembling the traceability 
metadata for key analysis variables is inefficient and error-prone. It is effectively infeasible to 
manually perform this task at the scale of an entire clinical research study. Thus, Trace-XML 
provides new traceability features that better enable the assessment of traceability within a 
clinical study, and thus, better address the existing regulatory requirements. 
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The ability to conduct an exploratory analysis of traceability for a study, or to compare 
the end-to-end data lifecycle for similar submissions has not been a common practice. It is 
infeasible to visualize a full study or subsets of a study using the current state-of-the-art. 
Trace-XML's ability to generate full lifecycle study graphs makes this analysis possible. 
Combining Trace-XML graphs with graph visualization software enables new analysis 
capabilities not available in the current standards and supporting tools. 
Implementation Feasibility 
"Good design science research often begins by identifying and representing 
opportunities and problems in an actual application environment" (Hevner, 2007). 
The Hevner (2007) relevance cycle shown in Figure 10 establishes the environment 
from which the solution requirements are drawn as well as implementation constraints and 
acceptance criteria. The environment for the solution domain consists of the existing 
processes, people, information systems, and organizational systems that establish the context 
within which the solution much operate. To achieve success, the design science artifacts must 
be implementable in the existing environment. The relevance cycle provides iterative input 
into the design cycle to constrain the design and to provide the feedback needed to adjust the 
artifacts to meet the contextual requirements. Clinical research represents a complex, global 
environment with significant levels of regulatory oversight. Operating within the constraints 
applied by this environment and maximizing implementation feasibility were important 
objectives for the Trace-XML artifacts. 
Trace-XML provides a repeatable method for creating full lifecycle study traceability 
using the CDISC metadata and supporting the requirements of the regulated clinical research 
environment. The Trace-XML extension to the Define-XML standard is small and builds on 
existing Define-XML concepts. The Trace-XML Framework provides the Trace-KB tool that 
generates some of the extended Define-XML content using metadata available in the SHARE 
MDR eliminating the need to add this content manually. Subjects participating in the 
qualitative assessment study noted that their Extract-Transform-Load style software could use 
the CDISC mapping metadata they maintain to generate Trace-XML content for the Define-
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XML files they produce. The CDISC leadership has agreed to promote Trace-XML as a 
Define-XML extension to its membership, and the Trace-XML extension has been proposed 
for inclusion in the next version of the Define-XML standard. The Trace-XML software will 
be made available as open source accessible from the CDISC web site. The combination of 
the Trace-XML extension and software makes possible a repeatable process for generating the 
Trace-XML graph and subsequently enabling full lifecycle study traceability. 
The feasibility for implementing Trace-XML in practice has been enhanced by 
building on the existing industry data standards. Easing implementation barriers and working 
within the existing data and information system infrastructure is critically important to 
adoption of a traceability solution at the industry level.  Domains such as clinical research and 
routine healthcare make use of a diverse range of existing data and technologies within their 
IT infrastructure that cannot be replaced without incurring significant expense and disruption 
(Curcin, 2016). A traceability solution must minimize the impact to the existing infrastructure 
while maximizing the benefits provided to reviewers to increase the feasibility of adoption in 
the near term.  As a regulatory requirement for data submissions to the FDA and PMDA, the 
use of Define-XML by Trace-XML reduces the barriers to implementation for submissions. 
Leveraging the existing standards to the maximum extent possible, and requiring only a small 
extension to the Define-XML standard, allows potential implementers to take full advantage 
of their existing standards investments. In a regulatory context, any additional information 
required for a submission can be viewed as an additional regulatory burden, despite obvious 
benefits. The expansion of existing tools that generate Define-XML files to include the Trace-
XML content would minimize the impact of requiring the Trace-XML extension while 
providing the additional traceability benefits.  
As an extension to Define-XML, Trace-XML metadata does not require additional 
information technology infrastructure to function which reduces barriers to implementation 
and acceptance. Trace-XML generates a graph in the GraphML standard XML format. 
Because the regulatory authorities, as well as organizations generating data for submissions, 
already work with XML documents such as Define-XML, the Trace-XML graph file does not 
represent a new technology that requires additional investment or training. The Trace-XML 
software is implemented in Java, and the regulatory authorities and CDISC membership have 
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demonstrated the ability to run JVM-based applications, such as the Pinnacle-21 conformance 
tool. If users of Trace-XML become interested in graph visualization, Java-based open source 
software is available to render and analyze the Trace-XML graph, including Gephi (Bastian et 
al., 2009). 
Trace-XML uses ODM to provide the metadata for the data capture phase of the 
clinical research data lifecycle. ODM v1.3.2 is a mature standard and "ODM metadata has 
become the language of choice for describing CRFs" (Hume et al., 2016). Most of the major 
EDC systems support ODM and the ability to export ODM CRF metadata (CDISC, 2017). 
Using EDC systems to export ODM-based CRF metadata eliminates the need for new 
technology implementations to support the use of ODM by Trace-XML and better leverages 
the existing features of widely used data capture platforms. Style sheets exist to generate 
annotated CRF visualizations of ODM-based CRFs. As Define-XML is an ODM extension, 
using the Trace-XML extension to link the metadata across the clinical research data lifecycle 
creates the ability for the CDISC XML metadata standards to represent the metadata for an 
entire study, and breaks down the existing silos caused by each metadata file working in 
isolation to represent only one phase of the lifecycle. 
This research sought to better address the stated requirements for full lifecycle study-
level traceability within the context of a regulatory submission. Trace-XML query results can 
be embedded into the existing Define-XML stylesheet outputs, as shown in Figure 24, to 
eliminate the need for additional training to use the Trace-XML output. Providing simple 
means to access Trace-XML content embedded within an existing standards implementation 
minimizes barriers to implementation and improves the feasibility of Trace-XML as a 
traceability solution that could be used by the regulators. 
Trace-XML as a Validation Tool 
Validation of the Define-XML documents beyond mere XML schema validation has 
become a critical step in the regulatory submission process necessitating the development of 
validation rules and the software to apply them (Hume et al., 2016). The regulatory authorities 
publish additional conformance rules for the CDISC standards used in submissions, and apply 
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these rules to each submission using software tools. The study metadata provided in Define-
XML is among the content checked for standards conformance as part of a regulatory 
submission. Full lifecycle, or end-to-end, study metadata traceability validation is an 
immediate benefit provided by Trace-XML to improve the quality of study metadata. The 
Trace-XML graph generation and validation ensures metadata traceability exists within the 
context of a study, and thus would augment the current conformance rules. Today's validation 
rule checks exist in silos and address one phase of the lifecycle at a time. Trace-XML adds a 
full study lifecycle quality and conformance check that is made possible by the Trace-XML 
extension to Define-XML, as well as the Trace-XML algorithms. Prior to Trace-XML this has 
not been feasible. 
To effectively generate and validate traceability graphs for clinical research, new 
traceability rules must be created to establish end-to-end traceability requirements. Trace-
XML has implemented several of these rules. For example, a variable that has multiple source 
variables should reference a method that describes the derivation or transformation used to 
create one result from multiple sources. This may be as simple as a concatenation to create a 
full date field or a calculation used to derive a result. This research project also added a rule to 
ensure that OIDs are unique within a Define-XML or ODM file, and ideally OIDs would be 
unique across the entire study.  New traceability rules should be considered as additions to the 
existing CDISC standards and applied as conformance rules that verify traceability quality 
within a study. Table 13 lists a summary of the Trace-XML specific traceability rules. 
As Trace-XML verifies traceability within the graph, it reports those variables that are 
not traceable based on its rules and algorithms. Trace-XML uses the variable's Origin Type to 
assess the degree to which traceability should be expected for a variable and whether or not it 
should be traceable back to the data collection phase of the lifecycle. By reporting the 
traceability gaps, those implementing the study metadata can remedy the issues and retest the 
updated files for complete traceability. When traceability gaps are addressed prior to study 
deployment this can ensure that the data needed to support analysis are being collected, and 
that unnecessary variables are not collected. 
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Trace-XML as a Tool to Enhance Data Quality 
Creating Define-XML for use as a specification has been recommended as a best 
practice for improving study data quality (Hume et al., 2016). This practice can be improved 
by including Trace-XML metadata into the Define-XML file. As standards that provide study 
metadata, both ODM and Define-XML can be used to support process automation and aid in 
study setup (Hume et al., 2016). There are three fundamental approaches for creating Define-
XML files: (1) create it post-hoc as a means to document the metadata used to create the final 
study datasets; (2) synchronize the generation of the metadata content with the ongoing 
transformations used to create the study datasets; and (3) create the Define-XML metadata 
before the datasets are created, and use it as a specification that drives the creation of the 
study datasets. This last approach has been extended by Lightfoot and Jansen (Lightfoot & 
Jansen, 2013) to describe how a Define-XML file created by the sponsor can be used as a 
template for study setup, and then applied to create a Define-XML file that describes a study 
to be included in a regulatory submission. Wheeldon and Burgess (Wheeldon & Burges, 
2014) describe how creating Define-XML during study setup promotes reuse and governance 
of study designs, reuse of mapping specifications, and automated dataset validation. When the 
Trace-XML extension is created as part of the study specification, traceability gaps can be 
identified and resolved prior to study start improving data quality and reducing the need for 
re-work or mid-study amendments to resolve data issues.  
IP-Maps were developed as a tool to promote data quality and Trace-XML extends 
that research to examine traceability as a dimension of data quality at the level of granularity 
needed to support regulated clinical research. An IP-Map's ability to communicate traceability 
at a high-level of abstraction is the primary benefit of layer 1 of the framework. The IP-Map 
also highlights the data quality steps applied during the production of the information product, 
including data cleaning, data transformations and imputations, and data standards 
conformance. This helps data reviewers to better understand the steps taken to ensure data 
quality within the study. The IP-Maps are particularly useful to those reviewers interested in 
attaining a high-level understanding of the study data and traceability. They provide another 
way to review the study data flows and the processes that could impact data quality. A high-
level conceptual model has become an increasingly important data quality communication 
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tool as new information sources and new validation mechanisms have been introduced into 
the clinical research lifecycle. For example, FDA draft guidance on the use of Electronic 
Health Record (EHR) data in Clinical Investigations recommends that sponsors include a 
diagram of the data flow between the EHR and the clinical research systems (FDA, 2016b). In 
cases where the reviewer does not need the detailed understanding of variable lineage 
provided by layers 2 and 3 of the framework, the IP-Maps in layer 1 may provide all the 
information needed understand the study data flows across the lifecycle.  The links between 
layers 1 and 2 of the framework are not essential if the IP-Maps are not used to help automate 
the generation of the Trace-XML graph. In these cases, layer 1 can stand alone as an 
informative addition to the detailed traceability features provided by Trace-XML. 
Trace-XML as a Visualization Tool 
Trace-XML provides a more comprehensive understanding of the clinical data for a 
study by integrating the conceptual view, the clinical study artifact and data element view, 
and the graph view of the study metadata (Chee et al., 2014). The integrated, hierarchical 
representation of traceability provided by Trace-XML improves the efficiency with which 
data reviewers come to understand the data and traceability within a study. Reviewers are able 
to drill into more detail as needed to answer specific questions about the data (Chee et al., 
2011). Layer 1 in the framework provides a conceptual visualization of the data flow and 
information manufacturing processes for an information product at a high-level of abstraction. 
However, the primary traceability visualization capability is provided by a rendering of the 
Trace-XML graph produced by layer 3 of the framework. 
Rendering the Trace-XML graph to visualize the data flow for a full study provides a 
unique mechanism for exploratory analysis. Patterns in the graphs can be visually identified 
and reviewed. Graph visualizations can aid in the detection of traceability anomalies and can 
improve a reviewer's understanding of how the data flows throughout the study lifecycle. To 
aid the reviewer, nodes within a visualization can be color coded to convey different 
meanings, the size of the nodes can vary according to an established metric, or the distance 
between nodes can be adjusted to highlight certain relationship metrics. For example, node 
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size can be increased to reflect the number of links a node has to other nodes making it easy to 
identify those parts of a study that reference the most data elements.  
A graph covering the full lifecycle for an entire study can grow too large to easily 
analyze visually. To improve the ability to work with large graphs, filtering or collapsing 
parts of the graph can be a useful way to reduce the number of nodes presented at any one 
time. For example, using the yEd graph editor portions of a graph can be grouped together 
and consolidated. A group can be opened to show each of the member nodes, or closed to 
represent the group as a single node within the graph. Grouped nodes can also be viewed 
independently of the full graph permitting simplified interrogation of the individual nodes 
contained in the group. Such graph organization tactics can be used to improve targeted 
visualization tasks. 
The graph visualization of metadata traceability represents a feature that does not exist 
in today's standards or tools. It also represents an exploratory capability that could provide 
useful insights into the data and help data reviewers better understand a study. Outside of this 
ability to explore data traceability and better understand the data, the tasks to which graph 
visualizations will be applied are not clear. The applications of graph visualization as a 
traceability tool will evolve as reviewers become more comfortable with the tools and better 
understand the questions that can be answered using them. Trace-XML generates the graph 
model, but the visualization features vary with the software used to render and analyze the 
graph. This research project has tested two open-source tools that work with GraphML 
graphs, but others tools are available. Additionally, the GraphML graph can be converted to 
other formats such as JSON where other visualization tools such as D3.js can be used to 
produce different visualizations to support specific analytic needs. 
Trace-XML Framework Utility 
As part of the artifact evaluation, Trace-XML was demonstrated to a panel of clinical 
data experts, including regulators, to establish whether or not this work represents an 
advancement in traceability utility that provides new and useful traceability capabilities. The 
feedback received during the interviews with the clinical research data experts both confirmed 
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the utility of Trace-XML as well as provided instructive feedback to be used in future build 
cycles. The overarching theme resulting from the analysis was adds utility, supported by 
themes that highlight the type of value added including adds information, verifies data 
quality, promotes understanding, and simplifies implementation. The most prominent 
supporting theme was that Trace-XML promotes understanding of traceability and how 
things fit together. Within the adds utility category, the code useful was the most prominent at 
7.9% of the total codes produced during the analysis. 
The interview subjects were unanimous in their confirmation that Trace-XML added 
new, meaningful traceability features. Every interviewee noted that Trace-XML improves a 
data reviewer's understanding of their data by significantly simplifying the work needed to 
trace the inputs to any variable in a study. This conclusion is supported by the fact that the 
promotes understanding theme was the most prominent with the code comprehension 
appearing in 80% of the interviews and the code how things fit together also appearing in 80% 
of the interviews. In response to the question about assessing end-to-end traceability 
validation, two of the salient themes were the top two codes applied in terms of number of 
instances: new information and how things fit together. These codes each accounted for nearly 
10% of the total codes and support the claim that Trace-XML presents new information that 
aids data reviewers in understanding a study. 
Another theme in the findings indicates that Trace-XML should add utility to the 
regulatory data review process where traceability is a requirement. Within the adds utility 
theme which accounted for 23.4% of the total codes, the regulatory impact code was the most 
frequently applied at 9.1%.  The regulatory impact code was applied in 100% of the 
interviews and had the broadest coverage of any code in the study. Several non-regulatory 
study participants explicitly requested that Trace-XML be demonstrated to the FDA with the 
understanding that the Trace-XML benefits would apply directly to regulatory data reviewers, 
and that regulatory agency interest would help accelerate industry acceptance. One subject 
commented "the FDA is quite interested in a capability like this; they really want a tool that 
allows them to trace through things." 
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Regarding the theme to simplify implementation, many subjects identified the need to 
generate the content used as inputs to Trace-XML, along with a general need to have a tool 
focus and hide the details of the XML. As the use of Define-XML v2.0 has increased, 
implementers have increasingly realized the need to automate the process of generating the 
metadata document to the extent possible. This theme was pronounced when interviewing 
those currently involved with generating Define-XML files. Two subjects referenced the 
possibility of using existing mapping metadata to generate the content needed to fulfill the 
Trace-XML Define-XML extension. Define-XML implementers were also particularly 
excited that Trace-XML builds on existing technology. Using just a small extension to Define-
XML to implement Trace-XML, the subjects observed that this reduces barriers to 
implementation while benefiting from the significant industry knowledge base for Define-
XML. One subject expressed this idea in the following quote: 
This builds on ODM which is a big positive. I like that we're just adding a few 
things to existing standards – not starting from scratch. 
The tool focus code complements the generate code by noting that users benefit more 
from tools that make implementation easy and automatic, as one subject noted: 
To maximize its impact users of Trace-XML should be using it with their tools. 
I would not ask users to add information manually as part of a Define-XML 
generation, but would generate it using tools. Not sure how interested end-user 
implementers would be in implementing this, but they would like to take advantage of 
the features through a tool. 
The Trace-KB feature that generates the Trace-XML extension metadata from content 
retrieved using the SHARE API was not demonstrated prior to the interviews so subjects were 
not aware of this feature.  
The verifies data quality theme was the least applied with only 12% of the overall 
codes. Codes for this theme included validation, completeness, and traceability. This outcome 
may have been influenced by the focus of the questions as well as the role of the study 
participants. It also may reflect that case that many organizations look to the regulatory 
124 
authorities to establish the types of data quality assessments that are needed for a study, and 
are not likely to volunteer to apply more rigor to the assessments without external pressure to 
do so. Most subjects felt that the FDA would be interested in both the improved level of 
traceability as well as the additional level of validation offered by Trace-XML. As one subject 
noted, "conformance rules that include traceability validation will be important." 
The primary cautionary feedback received during some interviews are highlighted by 
the codes complex and too advanced. These codes made rare appearances with complex at 
1.9% and too advanced at 1.1% of the overall codes, but should not be overlooked. 
Complexity became a topic to describe the full graph views of a study. These graphs are large 
and contain a significant amount of detail. Furthermore, this is a new way to visualize study 
metadata that provides new information not available today, so it does represent an entirely 
new way of analyzing study metadata when compared to today's processes. Although all 
interviewees saw the graph visualization as useful and a step forward, some noted that it 
might not meet an obvious need for some roles. As one subject noted "not every user will 
understand what problem the graph visualization solves for them."  
The too advanced code indicates that Trace-XML does not merely represent an 
incremental improvement to existing processes, but offers new capabilities not yet available to 
data reviewers. Again, this code was more likely to be applied to the graph visualization than 
other aspects of Trace-XML, but it was also applied to indicate that this represents an 
advancement to the industry state-of-the-art that will take time to adopt. One subject noted 
that "Trace-XML is 3-5 years ahead of the game now." 
A number of recommendations for improving or expanding Trace-XML came from 
the interviews. As previously noted, a number of subjects recommended automatically 
generating Trace-XML content to the extent possible, and focusing on building tools that 
deliver users benefits while isolating them from exposure to the CDISC XML standards. To 
this end, one subject noted that changing the report labels and naming of graph nodes to 
remove content that reflects the CDISC XML standards would improve usability. Another 
recommendation was to make the colors configurable to show different types of 
categorization.  
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A subject also recommended generating the IP-Map content from the Trace-XML 
metadata changing the process from a top-down approach to a middle-out approach. A 
middle-out approach would generate the lower-level Trace-XML graph, but would use this 
same information to generate an analysis level depiction of the data flow similar to an IP-
Map. Essentially, this recommendation calls for the Trace-XML Framework level 2 metadata 
to be used to generate both the level 3 graph, as well as the level 1 IP-Map. In general, 
minimizing manual steps in the process of using Trace-XML was seen as desirable to ensure 
broad usage. Another recommendation was to add the ability to show an annotated CRF 
generated by Trace-XML using a style sheet. This has been demonstrated to be feasible and 
would add another benefit to encourage the inclusion of ODM XML with the Define-XML 
files as part of a study regulatory submission. 
One subject recommended creating traces or reports that focused on the key study 
endpoints and the most relevant study datasets. Highlighting this information would help 
ensure regulatory reviewers had easy access to the information that was of most interest to 
them, without overwhelming them with information of lesser importance. Another subject 
recommended using Trace-XML to show how a standard evolves over time with additions 
and changes being added to the graph to visually depict changes. This would provide a 
visualization of the standards that would help implementers better understand how they are 
organized and the impact of changes. 
The key themes that emerged from the thematic analysis of the interview data affirm 
that Trace-XML adds utility to the task of creating and assessing end-to-end clinical research 
study traceability across several different user roles and perspectives. The interviewees were 
unanimous and unambiguous in their conclusions regarding the utility added via new 
traceability capabilities demonstrated in Trace-XML. The diversity of perspectives provided a 
number of varied alternatives for new features to add value to future Trace-XML builds. 
Subjects also reported that the cautionary notes on complexity and the advanced nature of the 
tool can be addressed by targeting more precise use cases with automated tooling. 
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Impact on Regulatory Submissions 
Trace-XML advances traceability using CDISC metadata and provides capabilities not 
available using the current standards. To fully realize the Trace-XML advances, regulatory 
authorities should request that ODM be included in regulatory submissions to represent CRF 
metadata instead of the current blank CRF in PDF format. ODM generates annotated blank 
CRF visualizations in HTML using style sheets. These visualizations are simpler to create 
than their PDF counterparts. The PDF annotated CRFs are often created manually. Style 
sheets exist today capable of generating annotated CRF visualizations using ODM metadata. 
As noted previously, ODM CRF metadata exports are supported by most commonly used 
EDC systems making it simpler to generate ODM metadata that it is to create Define-XML 
metadata which draws metadata content from a wider variety of sources. Since the ODM 
metadata is machine readable, this enables Trace-XML to function fully and could also enable 
other new features, including traceability links to EHR electronic source data.  
Define-XML v1.0 was published in 2005 to replace define.pdf. While the eventual 
replacement did not happen immediately, machine-readable Define-XML documents are now 
an important part of a regulatory submission (FDA, 2017). Although, as previously noted, 
generating ODM CRF metadata is simpler than creating a Define-XML, and it would be 
simpler to generate an ODM-based annotated CRF, ODM is not currently accepted as part of 
a regulatory submission. Replacing PDF documents for representing CRF metadata not only 
provides the machine-readable metadata used by Trace-XML, but would also make the 
metadata submissions more consistent. The use of ODM-based standards as a consistent 
means of representing study metadata would simplify submissions while providing 
opportunities to leverage more complete machine-readable metadata for each study included 
in a submission. 
ODM could also be used to optionally submit the raw data collected at the site. 
Currently, limited CRF data is submitted in PDF form, but this information is incomplete, 
lacks machine-readability, and is difficult to generate. ODM provides the machine-readable 
metadata and data for CRFs. It also provides audit trail information which would enable 
regulators to implement standard tools for detecting fraud. The FDA has stated that PDF is an 
inadequate format for submitting EDC CRFs and in 2007 proposed to pilot ODM for 
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submitting CRFs. In the pilot notice the FDA noted that they were interested in ODM as a 
standard that could "reliably provide all three components of the CRF in an electronic format: 
data, metadata, and audit trail" (FDA, 2007a). Combining Trace-XML with ODM metadata 
and data would significantly enhance the provenance information included with each 
submitted study. 
Future Work 
The study data lifecycle used for this research covers from data collection to final 
analysis datasets. Future research will extend this lifecycle to include electronic source data 
from EHR systems as well as analysis results metadata. Pre-populating CRF content with 
EHR data is an area of active research, and including EHR sources in Trace-XML would 
improve a reviewer's understanding of study traceability (Erturkmen, Bain, & Sinaci, 2014). 
The FDA's recent final guidance on the use of eSource within clinical investigations (FDA, 
2016b) notes that eSource has the potential to improve the integrity, traceability, provenance, 
quality, and reliability of data included in electronic submissions (Curcin, 2016). Extending 
ODM to capture references to the eSource content used to pre-populated CRFs would provide 
the additional metadata needed to add EHR content to Trace-XML study traceability. Without 
such an ODM extension to support this addition to Trace-XML, no existing infrastructure 
includes the eSource information as part of the traceability metadata provided in a regulatory 
submission.   
Analysis results metadata represents the study findings produced using the analysis 
datasets. Currently, the Analysis Results Metadata (ARM) extension to Define-XML provides 
the additional metadata needed to represent the study analysis results, and extending ARM to 
support Trace-XML would enable the analysis results to be included in the full lifecycle study 
traceability graph. Regulatory reviewers may be particularly interested in tracing key study 
endpoints and efficacy variables. Although ARM is not yet a regulatory requirement, it is 
strongly recommended for submissions to the PMDA. Extending Trace-XML to include both 
eSource and analysis results fits into the Trace-XML Framework model and significantly 
enhances the value of traceability metadata within the context of a regulatory submission. 
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Graph representation of clinical research studies can be used to compare studies and 
identify differences. A future investigation will generate graphs using standard metadata for a 
CDISC therapeutic area standard and compare it to actual study metadata. The comparison of 
the study graph against the standard graph using graph difference algorithms will highlight 
where novel additions have been added to the study or where the study deviates from the 
standards. Highlighting such differences will greatly aid the review process by focusing a 
reviewer's attention on novel aspects of the study or highlighting deviations from the standard. 
As the standards are better known to reviewers than the novel aspects of a study, such a graph 
difference, would limit the review space significantly.  
This initial version of Trace-XML does not implement the W3C PROV or Open 
Provenance Model because these standards are not currently used in the CDISC standards or 
by regulators, but future versions will support these standards (Curcin et al., 2014). The use of 
PROV would add complexity to Trace-XML with correspondingly limited benefits in the near 
term. However, as more healthcare systems provide data for use in research a more general 
provenance capability may be useful. As more EHR applications and other healthcare systems 
implement standards like PROV, there will be increased utility in supporting these standards 
in Trace-XML. 
Trace-XML generates a GraphML XML representation of the traceability graph. This 
aligns well with the existing ODM and Define-XML standards, and minimizes the new tools 
and training needed to work with the graph. Alternative JSON and RDF representations of the 
Trace-XML may interest users working with alternative data formats and should be supported 
in the future. This has the benefit of supporting a broader set of software tools for working 
with the Trace-XML graph. 
Future work will include expansion of the current example studies to include more 
domains and data to enable larger graphs and a broader range of traceability scenarios to 
evaluate. Larger Trace-XML graphs will require additional work to establish the optimal 
means to visualize traceability content. 
The metadata gaps discovered in this research and referenced in Chapter 5 represent 
the current siloed nature of the standards metadata and subsequently an inability to explicitly 
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reference metadata in adjacent phases of the lifecycle. As an outcome of this research project, 
the metadata needed to establish the missing graph edges has been implemented as the Trace-
XML extension to the Define-XML standard. To expand traceability to include EHR 
electronic source data, ODM might also benefit from the Trace-XML extension in a future 
version.  The Trace-XML extension has been submitted to the CDISC XML Technologies 
Team for consideration. Future work could include incorporating the Trace-XML extension 
into an upcoming version of the ODM or Define-XML standards. 
As Trace-XML becomes more broadly used additional traceability rules should be 
added to the CDISC standards to improve traceability completeness. Certain variables, such 
as those included in CRFs for data management purposes, might not be used in later phases of 
the lifecycle, but these nodes should link to a terminal node in the graph. This improves the 
ability to verify traceability accuracy and helps reviewers identify sets of variables where 
reachability into the next phase of the lifecycle is not expected. Another example of a new 
traceability rule involves methods that can exist at the variable and value-level. Trace-XML 
assumes that an Item does not reference a MethodDef both at the variable level and at the 
value level. Methods should be placed on the value level metadata ItemRef in this instance. 
This improves the accuracy of the Define-XML as well as traceability and should be 
considered as a future rule for Define-XML. This rule has been implemented in the current 
version of the Trace-XML prototype. The development of new rules that address the full 
clinical research data lifecycle should improve both traceability as well as overall data quality. 
A summary of the traceability rules implemented to support Trace-XML can be found in 
Table 13. 
As the Trace-XML graph visualization usage increases, additional flexibility in 
configuring the trace graphs should be considered. For example, setting node sizes, colors, 
and shapes in the configuration file would provide a useful way to tailor the graph 
visualizations produced to address specific analysis interests. Additional features may also be 
added to generate graphs that implement the features of specific graphing packages beyond 
the yEd software.  
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A new version of Define-XML, version 2.1, is currently in the final stages of 
development and future work includes enhancing Trace-XML to support this new version of 
Define-XML. Define-XML v2.1 updates the Origin element and will require updated 
traceability rules. 
Research Contributions 
This research contributes the Trace-XML Framework for creating computable 
traceability using the CDISC metadata standards within the domain of clinical research. This 
framework contributes a new Trace-XML extension to the Define-XML standard that 
addresses traceability gaps uncovered during the development of the Trace-XML software. 
The Trace-XML software contributes the algorithms needed to remedy and validate 
traceability in the Trace-XML graphs, in addition to adding support for traceability queries. 
These DFS-based algorithms make use of contextual rules that adapt the algorithms to the 
CDISC standards and make it possible to effectively add full lifecycle traceability to CDISC 
standard metadata. These rules, summarized in Table 13, adapt the DFS-based algorithms to 
support traceability within the Trace-XML graphs and are a contribution of this research. 
Trace-XML also contributes the graph model generated using the extended CDISC metadata 
to represent full study lifecycle traceability. In addition to the layered traceability perspective, 
the primary benefits of the Trace-XML Framework are (1) to identify and resolve traceability 
gaps in clinical study metadata, (2) validate metadata traceability in a clinical study, and (3) 
query and visualize traceability metadata. The Trace-XML Framework maximizes the use of 
the existing standards models and technology to minimize barriers to implementation. 
Conclusion 
The artifacts presented in this research provide the means to advance traceability 
within clinical research. The artifacts extend the existing standards and provide a bridge 
between the previous traceability solutions and a new more advanced traceability solution. 
These artifacts also make implementation in a real-world environment feasible. The 
evaluation of the artifacts supports the claim that Trace-XML provides new and useful 
functionality that improves a reviewer's ability to assess traceability and understand the data. 
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The Trace-XML extension to Define-XML and the software implementation of the 
framework will be published as open source. The Trace-XML software and documentation 
are available on GitHub at https://github.com/swhume in the trace-xml and trace-query 
repositories. Trace-XML content will also be made available on the CDISC web site 
(http://www.cdisc.org), as well as on the ODM Review web site (http://www.odm-
review.com). 
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APPENDICES 
APPENDIX A: GLOSSARY OF TERMS 
Table 20. Glossary of Terms / Acronyms 
Term / Acronym Definition 
ADaM Analysis Dataset Model 
API Application Programming Interface 
ARM Analysis Results Metadata 
BI Business Intelligence 
CCD Continuity of Care Document 
CDA Clinical Document Architecture 
CDASH Clinical Data Acquisition Standards Harmonization 
CDE Common Data Element 
CDISC Clinical Data Interchange Standards Consortium – a standards development 
organization for clinical research data standards. 
CFR Code of Federal Regulations 
CRF Case Report Form 
CRO Contract Research Organization 
eCRF Electronic Case Report Form 
Define-XML CDISC standard for specifying the tabulation data definitions in XML format. 
A required standard for CDISC standard dataset metadata (e.g. SDTM, 
ADaM, SEND) submissions to regulatory authorities such as the FDA and 
PMDA.  
DSR Design Sciences Research 
DAG Directed Acyclic Graph 
DSU Dakota State University 
EDC Electronic Data Capture 
EHR Electronic Health Record 
EMA European Medicines Agency 
EVS Enterprise Vocabulary Services (NCI EVS) 
ePRO Electronic Patient Reported Outcomes. 
FDA US Food and Drug Administration 
FHIM Federal Health Information Model 
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FHIR Fast Healthcare Interoperability Resources – an HL7 data exchange standard 
GCP Good Clinical Practice 
GraphML Graph Markup Language – an XML standard for representing graphs 
HITSP Health Information Technology Standards Panel 
HTML Hypertext Markup Language – used to represent web pages and forms for 
rendering in browsers. 
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
IP-Map Information Product Map 
IRB Institutional Review Board 
IS Information Systems 
ISO International Standards Organization 
IT Information Technology 
IVRS Interactive Voice Response System 
JSON Java Script Object Notation 
LOINC Logical Observation Identifiers Names and Codes  
MDR Metadata Repository 
NCI National Cancer Institute (US) 
NIH National Institutes of Health (US) 
ODM Operational Data Model 
ONC Office of the National Coordinator for health information technology (US) 
PDF Portable Document Format 
PMDA Japan Pharmaceuticals and Medical Devices Agency 
PRM Protocol Representation Model (CDISC) 
RDF Resource Description Format 
RIM Reference Information Model (HL 7) 
SDO Standards Development Organization 
SDTM Study Data Tabulation Model. 
SEND Standard for Exchange of Nonclinical Data. SEND is a CDISC standard based 
on the SDTM model. 
SHARE Shared Health and Research Electronic library. The metadata repository for 
creating, maintaining, and publishing the CDISC standards. 
TCG Technical Conformance Guide 
TDD Test-Driven Development 
ToC Transitions of Care initiative 
W3C World Wide Web Consortium – community developing Web standards 
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XMI XML Metadata Interchange 
XML eXtensible Markup Language – developed by the W3C 
XQuery XQuery is a query language that provides the means to extract information 
from an XML file or XML database. 
XSL eXtensible Stylesheet Language – a language used for expressing stylesheets 
used to display XML content 
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APPENDIX B: TRACE-XML USER DOCUMENTATION 
Trace-XML 
Trace-XML generates a GraphML graph model that implements full lifecycle study 
traceability. This version of Trace-XML requires an ADaM Define-XML file, an SDTM 
Define-XML file and an ODM file. The Trace-XML extension to Define-XML must also be 
implemented to represent the relationships that reference the source variables for each of the 
Define-XML files. Please reference the Trace-XML extension documentation for details. 
Running a Java Program 
Make sure that the Java Runtime Environment (JRE) is listed in the PATH 
environment variable or set the PATH environment variable to include the JRE. For example, 
on Windows you could run: 
 
> set path=%path%;C:\Program Files\Java\jdk1.8.0_65\bin 
 
Trace-XML was developed using Java version 1.8.0_65. 
Installing Trace-XML 
Copy and unzip the Tracexml.zip file in the directory from which you would like to 
run the application. 
Configuration File 
Prior to running Trace-XML the configuration file must be created. An example 
configuration file is listed below: 
trace-node-unique=trace-nodes-unique.xml 
trace-node=trace-nodes.xml 
define-xsd-file=/Users/shume/Documents/Temp/schema/trace1-0-0/trace-1-0-0.xsd 
trace-node-details=trace-node-details.xml 
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trace-xsl=trace-node.xsl 
unreachable-html=unreachable-nodes.htm 
unreachable-xml=unreachable-nodes.xml 
unreachable-text=unreachable-nodes.txt 
unreachable-xsl=unreachable.xsl 
xml-path=/Users/shume/Documents/Temp/ 
L1-graph=L1-safety-ip-graph.graphml 
trace-node-oid=trace-node-oid.xml 
unreachable-text-xsl=unreachable-txt.xsl 
xquery-path=/Users/shume/Documents/xml/trace-xml/ 
data-collection-file=/Users/shume/Documents/Temp/cdash-odm-test.xml 
data-analysis-file=/Users/shume/Documents/Temp/adam-define-test.xml 
trace-html=trace-node-detail.htm 
odm-xsd-file=/Users/shume/Documents/Temp/schema/odm1-3-2/ODM1-3-2.xsd 
L3-graph=Trace-test-graph.graphml 
data-tabulation-file=/Users/shume/Documents/Temp/sdtm-define-test.xml 
fix-invalid-byte-1=No 
 
The table below provides a brief explanation of each item in the configuration file. 
Those rows with the "Change?" column set to "Yes" are the settings that most typically need 
to be set to run Trace-XML and Trace-Query. 
 
Config. Name Configuration Value Change? 
data-collection-file Path and file name of the ODM file used to represent the 
metadata in the data collection phase of the clinical research data 
life cycle. 
Yes 
data-tabulation-file Path and file name of the Define-XML file used to represent the 
SDTM metadata in the data tabulations phase of the clinical 
research data lifecycle. 
Yes 
data-analysis-file Path and file name of the Define-XML file used to represent the 
ADaM metadata in the data analysis phase of the clinical 
research data lifecycle. 
Yes 
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Config. Name Configuration Value Change? 
xml-path File path to the XML files used and created by Trace-XML. Yes 
xquery-path File path to the XQuery files used by Trace-XML Yes 
L3-graph File name of the GraphML graph produced by Trace-XML. Yes 
define-xsd-file The Define-XML schema with the Trace-XML extension - 
trace-1-0-0.xsd 
Yes 
odm-xsd-file File and path to the ODM v1.3.2 schema file - ODM1-3-2.xsd. Yes 
trace-node-unique List of unique nodes returned from a query.  
trace-node List of nodes returned from a query.  
trace-node-details Metadata details for each node returned from a trace query.  
trace-xsl Creates HTML output from the results of a query.  
unreachable-html Output file for the HTML rendering of the results of the test for 
unreachable nodes in the graph. 
 
unreachable-xml List of unreachable nodes produced by the Trace-XML 
algorithms and queries. 
 
unreachable-text Tab delimited text file listing the unreachable nodes.  
unreachable-xsl Style sheet that generates the HTML report for unreachable 
nodes. 
 
trace-node-oid XML file name containing nodes returned from the GraphML 
graph with reference information from the appropriate ODM or 
Define-XML file such as the node id, OID, lifecycle phase, and 
XML file name and path. 
 
unreachable-text-xsl Style sheet used to generate the tab delimited text content for the 
list of unreachable nodes. 
 
trace-html Trace-Query HTML output report containing the results of a 
query. 
 
fix-invalid-byte-1 A value of "Yes" forces Trace-XML to eliminate an UTF-8 
generation bug - Invalid byte 1 of 1-byte UTF-8 sequence. 
 
 
Running Trace-XML 
Trace-XML was developed using Java version 1.8.0_65. It can be built to package the 
JRE with the application to ease deployment to those environments running older versions of 
Java. The following example shows a command-line that runs the Trace-XML jar file: 
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> java -jar Tracexml.jar cfg=d:/temp/config/trace-xml.cfg yed 
 
Specifying the location of the configuration file is required unless a configuration 
named trace-xml.cfg is located in the same directory as the Tracexml.jar file. The yed 
command-line argument is required to use the GraphML output in the yEd editor software. 
The Trace-XML command-line arguments are listed in the following table: 
 
Cmd-line Argument Description 
cfg= Path and file name of the Trace-XML configuration file. Trace-XML will 
attempt to find a trace-xml.cfg file in the jar directory if this command-line 
argument is not set. The configuration file is required to run Trace-XML. 
yed Include the minimum extensions required to generate a GraphML file that can be 
loaded into the yEd graph editor software. 
reachable Print the reachable nodes to the console. 
unreachable Print the unreachable nodes to the console. 
verbose Turn on verbose mode to get more feedback to the console on Trace-XML 
execution. 
display Attempt to automatically load the HTML Unreachable report and Query results 
in the default browser. 
validate Run Trace-XML, Define-XML, and ODM schema validation on the XML files 
prior to generating the graph. 
help Print the Trace-XML usage information to the console. 
 
 
 
Trace-Query 
Trace-Query generates a trace report using the GraphML study graph given a variable 
OID. You must run Trace-XML prior to Trace-Query to ensure the study graph has been 
generated. Trace-Query uses the Trace-XML configuration file.  
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Running Trace-Query 
Running Trace-Query is similar to running Trace-XML, but with different command-
line arguments. The following example shows a command-line that runs the Trace-Query jar 
file: 
 
> java -jar TraceQuery.jar cfg=d:/temp/config/trace-xml.cfg oid=ADAM.IT.VS.ADY 
 
The oid argument is required, and the configuration file must be accessible either by 
specifying it on the command-line or by placing trace-xml.cfg in the same location as the 
Trace-Query jar file. 
 
Cmd-line Argument Description 
cfg= Path and file name of the Trace-XML configuration file. Trace-XML will attempt 
to find a trace-xml.cfg file in the jar directory if this command-line argument is not 
set. The configuration file is required to run Trace-XML. 
oid= The oid of the variable for which the trace will be executed. The oid must exactly 
match an oid in the graph. 
help Print the Trace-XML usage information to the console. 
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APPENDIX C: TRACE-XML DEFINE-XML EXTENSION  
The Trace-XML schema documentation has been automatically generated using the 
Oxygen XML editor version 18.0 and the Trace-XML extension schema files. The complete 
documentation can be found on-line at: 
https://github.com/swhume/trace-xml 
 
 Trace-XML is a small Define-XML extension adding the minimal elements and 
attributes needed to support traceability. The extension schema files include: trace-1-0-0.xsd, 
trace-extension.xsd, and trace-ns.xsd. The following schema code blocks display the Trace-
XML extension content without the core Define-XML schemas. 
 
 
trace-1-0-0.xsd 
  
<?xml version="1.0" encoding="UTF-8"?> 
<xs:schema targetNamespace="http://www.cdisc.org/ns/def/v2.0" 
    xmlns="http://www.cdisc.org/ns/def/v2.0" 
           xmlns:xs="http://www.w3.org/2001/XMLSchema" 
           xmlns:trc="http://www.cdisc.org/ns/trace/v1.0" 
           elementFormDefault="qualified" attributeFormDefault="unqualified"> 
  <xs:include schemaLocation="trace-extension.xsd"/> 
  <!-- 
      Trace-XML 1.0.0 trace-1-0-0 schema 
  --> 
</xs:schema> 
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trace-extension.xsd 
  
<?xml version="1.0" encoding="UTF-8"?> 
<xs:schema targetNamespace="http://www.cdisc.org/ns/def/v2.0" 
  xmlns="http://www.cdisc.org/ns/def/v2.0" 
  xmlns:xs="http://www.w3.org/2001/XMLSchema" 
  xmlns:odm="http://www.cdisc.org/ns/odm/v1.3" 
  xmlns:def="http://www.cdisc.org/ns/def/v2.0" 
  xmlns:trc="http://www.cdisc.org/ns/trace/v1.0" 
  elementFormDefault="qualified" 
  attributeFormDefault="unqualified"> 
  <!-- 
      Trace-XML 1.0.0 adds the trace-ns to Define-XML 2.0.0 
  --> 
  <xs:import  
namespace="http://www.cdisc.org/ns/odm/v1.3"  
schemaLocation="../define2-0-0/define-extension.xsd"/>  
  <xs:import  
namespace="http://www.cdisc.org/ns/trace/v1.0"  
schemaLocation="trace-ns.xsd"/> 
   
  <xs:redefine schemaLocation="../define2-0-0/define-ns.xsd">         
   
    <xs:attributeGroup name="OriginAttributeExtension"> 
      <xs:attributeGroup ref="def:OriginAttributeExtension"/> 
      <xs:attribute ref="trc:NoTraceItems" use="optional"/> 
    </xs:attributeGroup> 
   
    <xs:group name="OriginElementPostExtension"> 
      <xs:sequence> 
        <xs:group ref="def:OriginElementPostExtension"/> 
        <xs:element ref="trc:Trace" minOccurs="0" maxOccurs="1" /> 
      </xs:sequence> 
    </xs:group> 
     
  </xs:redefine> 
</xs:schema> 
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trace-ns.xsd (page 1) 
  
<?xml version="1.0" encoding="UTF-8"?> 
<xs:schema targetNamespace="http://www.cdisc.org/ns/trace/v1.0" 
  xmlns:xs="http://www.w3.org/2001/XMLSchema" 
  xmlns:odm="http://www.cdisc.org/ns/odm/v1.3" 
  xmlns:def="http://www.cdisc.org/ns/def/v2.0" 
  xmlns:trc="http://www.cdisc.org/ns/trace/v1.0" 
  xmlns:xlink="http://www.w3.org/1999/xlink" 
  elementFormDefault="qualified" attributeFormDefault="unqualified"> 
  <!-- 
      Trace-XML 1.0.0 share-ns schema 
  --> 
  <xs:annotation> 
    <xs:documentation>Trace-XML 1.0.0 trace-ns schema</xs:documentation> 
  </xs:annotation> 
 
  <xs:annotation> 
    <xs:documentation> 
      Trace-XML 1.0.0 trace-ns schema developed by Sam Hume swhume@gmail.com. 
Trace-XML extends Define-XML to explicitly reference source items in Origin in 
order to generate a directed graph from the ODM and Define-XML metadata for a 
study. 
    </xs:documentation> 
  </xs:annotation> 
   
  <xs:import namespace=http://www.cdisc.org/ns/odm/v1.3 
schemaLocation="../odm1-3-2/ODM1-3-2-foundation.xsd"/> 
   
  <xs:attribute name="NoTraceItems" type="odm:YesOnly"> 
    <xs:annotation><xs:documentation> 
      NoSourceItems indicates that there are no source items for an ItemDef 
Origin that would normally have source items, but in this instance does not. For 
example,an Origin type of Derived where the derivation takes no source Items as 
inputs. 
    </xs:documentation></xs:annotation> 
  </xs:attribute> 
   
  <xs:element name="Trace" type="trc:Trace"/> 
  <xs:complexType name="Trace"> 
    <xs:annotation><xs:documentation> 
      The Trace element is intended to define the TraceItems that reference the 
sources for an Item. The TraceItems are child elements of the Trace parent 
element. 
    </xs:documentation></xs:annotation> 
    <xs:sequence> 
      <xs:element ref="trc:TraceItem" minOccurs="1" maxOccurs="unbounded"/> 
    </xs:sequence> 
  </xs:complexType> 
 
Continued on the next page… 
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trace-ns.xsd (page 2) 
 
<xs:element name="TraceItem" type="trc:TraceItem"/> 
  <xs:complexType name="TraceItem"> 
    <xs:annotation><xs:documentation> 
      The TraceItem elements are intended to reference the source ItemDefs that 
function as the explicit Origin of a given ItemDef. If the Origin type is Derived 
the TraceItem elements reference the ItemDefs that represent the inputs to the 
MethodDef performing the derivation. 
    </xs:documentation></xs:annotation> 
    <xs:attribute name="leafID"  type="xs:IDREF" use="optional"> 
      <xs:annotation> 
  <xs:documentation>leafID references the document containing the 
TraceItem ItemDef. 
  </xs:documentation> 
</xs:annotation> 
    </xs:attribute> 
    <xs:attribute name="ItemOID" type="odm:oidref" use="required"> 
      <xs:annotation> 
  <xs:documentation>ItemOID references the OID of the ItemDef that 
represents the source item. ItemOIDs should be unique per study in Trace-XML. 
  </xs:documentation> 
</xs:annotation>         
    </xs:attribute> 
    <xs:attribute name="FormOID" type="odm:oidref" use="optional"> 
      <xs:annotation> 
<xs:documentation> 
          FormOID references the OID of the FormDef containing the source item 
(via an ItemGroup). This is primarily used when a source item is referenced in 
multiple forms, but only one instance of this item in one form provides the input 
for this ItemDef. 
        </xs:documentation> 
</xs:annotation> 
    </xs:attribute> 
    <xs:attribute name="ItemGroupOID" type="odm:oidref" use="optional"> 
      <xs:annotation> 
<xs:documentation> 
          ItemGroupOID references the OID of the ItemGroupDef containing the 
source item. This is primarily used when a source item is referenced in multiple 
ItemGroups, but only one instance of this item in one ItemGroup provides the 
input for this ItemDef. 
        </xs:documentation> 
</xs:annotation>         
      </xs:attribute> 
  </xs:complexType>   
</xs:schema> 
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APPENDIX D: TRACE-XML SOURCE CODE 
DOCUMENTATION 
The Trace-XML applications include three distinct programs: Tracexml, TraceQuery, 
and TraceKb. The source code for these applications include comments that comply with the 
Javadoc format for generating standardized documentation. Due to the volume and format of 
this documentation, it has not been embedded in this dissertation. Instead,  the Trace-XML 
source code and documentation have been released under the Apache 2.0 open source license 
and are accessible via GitHub: 
• https://github.com/swhume/trace-xml 
• https://github.com/swhume/trace-query 
A trace-kb repository will be created at a later date, once access to the SHARE API 
becomes more widely available. 
Links to the Trace-XML documentation will also be made available on the CDISC 
web site (http://www.cdisc.org) as well as on the ODM Review web site (http://www.odm-
review.com). 
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APPENDIX E: TRACE-XML QUALITATIVE 
ASSESSMENT INFORMED CONSENT 
DSU Institutional Review Board 
 
Date: 2/7/2017 
 
Dear Subject: 
 
I am conducting a research project entitled "Enhancing Traceability in Clinical Research Data 
Through an Information Product Framework" as part of a dissertation at Dakota State 
University. 
 
The purpose of the study is to evaluate the utility of Trace-XML, a framework for end-to-end 
metadata traceability within the domain of clinical research.   
 
You as a clinical research metadata expert are invited to participate in the study by 
participating in a traceability demonstration and interview. We realize that your time is 
valuable and have attempted to keep the requested information as brief and concise as 
possible. It will take you approximately 30 minutes of your time. Your participation in this 
project is voluntary. You may withdraw from the study at any time without consequence. 
 
There are no known risks to you for participating in this study. There are no direct benefits to 
you from participation in this study. 
 
Your responses are strictly confidential. When the data and analysis are presented, you 
will not be linked to the data by your name, title or any other identifying item. 
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Your consent is implied by agreeing to participate in the demonstration and interview. Please 
keep this letter for your information.  If you have any questions, now or later, you may 
contact me at the number below.  Thank you very much for your time and assistance.  
 
If you have any questions about the research study or content, please feel free to contact me at 
swhume@gmail.com or 484-354-0873. If you have any questions regarding your rights as a 
research participant in this study, you may contact the DSU Office of Sponsored Programs at 
605-256-5100 or at irb@dsu.edu. 
 
Sincerely, 
Sam Hume 
swhume@gmail.com 
 
This project has been approved by the DSU Institutional Review Board, Approval No.: 
#2016-2017-114 
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APPENDIX F: TRACE-XML QUALITATIVE 
ASSESSMENT IRB APPROVAL LETTER 
DSU  Institutional Review Board 
Expedited Project Approval 
 
To:   Sam Hume 
 
Date:  January 24, 2017 
 
Project Title:  Enhancing Traceability in Clinical Research Data Through an Information 
Product Framework 
 
Approval #: 2016-2017-114 
 
Dear Sam Hume, 
 
The IRB approved your project using expedited procedures as described in 45 CFR 
46.110.  The activity was deemed to be no greater than minimal risk, and the following 
expedited category from 63 FR 60364-60367 was found to be applicable to your activity: 
(7) Research on individual or group characteristics or behavior (including, but not 
limited to, research on perception, cognition, motivation, identity, language, communication, 
cultural beliefs or practices, and social behavior) or research employing survey, interview, 
oral history, focus group, program evaluation, human factors evaluation, or quality 
assurance methodologies. 
One-year approval of your project will be dated starting January 24, 2017. If you 
require additional time to complete your project or wish to extend the activity, please submit a 
request for extension before December 24, 2017. The request can be submitted by email to 
IRB@dsu.edu. If there are any unanticipated problems involving risks to subjects or others, or 
if there are changes in the procedures during the study, please contact the Sponsored 
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Programs Office at IRB@dsu.edu .  Any protocol changes must be approved by the IRB prior 
to implementation.  At the end of the project please inform the committee that your project is 
complete. 
 
As a university operating within the United States, our faculty, staff and students are 
required to follow U.S. law. As a researcher affiliated with Dakota State University, you are 
required to comply with all regulations as outlined in the U.S. Office of Human Research 
Protections (OHRP)/ Health and Human Services (HHS) Code of Federal Regulations, Title 
45, Part 46 (45 CFR 46): Protection of Human Subjects. 
 
Protections for international human subjects should be equal to those in 45 CFR 46. It 
is your responsibility, as the Principal Investigator of research protocol #2016-2017-114, to 
ensure that human subjects research conducted internationally adheres to all applicable U.S. 
law and university policy.  If you have questions or concerns about these rules, please work 
with the Director of Sponsored Programs to resolve them before beginning any phase of your 
research that requires contact of any kind with human subjects. 
 
If I can be of further assistance, please don’t hesitate to let me know. 
 
Yours truly, 
 
 
 
 
Jack H. Walters, Ph.D. 
Chair, DSU Institutional Review Board 
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